Frailty assessment: clinical application in the hospital setting

DOI: 10.12809/hkmj187572
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
MEDICAL PRACTICE
Frailty assessment: clinical application in the hospital setting
CW Wong, FHKAM (Medicine), FHKCP
Department of Medicine and Geriatrics, Caritas Medical Centre, Hong Kong
 
Corresponding author: Dr CW Wong (wong.chitwai@gmail.com)
 
 Full paper in PDF
 
Abstract
Because of their heterogeneous health status, older people’s health care needs differ. The concept of frailty, characterised by a decline in physiological reserve with increased vulnerability to stress, is emerging in clinical practice. Characterising older people by frailty could help to predict their prognosis and health outcomes. Further, consideration of frailty in clinical practice could facilitate the determination of patient-centred goals for effective care delivery. In the hospital setting, identification of frailty could guide management plans for older patients upon disposal from emergency departments; risk stratification by frailty allows appropriate decision making about surgical or invasive interventions; selection of frail people to acute geriatric wards for integrated care improves outcomes; end-of-life care for people at advanced stages of frailty improves the quality of their last days of life; and pre-discharge comprehensive geriatric assessment for frail people helps arrangement of post-discharge programmes according to individual needs. Although the emphasis on frailty is growing in clinical practice, there are challenges regarding implementation that need to be addressed.
 
 
 
Introduction
Age-related cumulative decline in multiple body systems that increases the vulnerability to stress and adverse health outcomes brought about the concept of frailty. Frailty is defined as “a medical syndrome with multiple causes and contributors that is characterised by diminished strength, endurance, and reduced physiologic function that increases an individual’s vulnerability for developing increased dependency and/or death”.1 Although physical frailty has received the most attention, frailty is a multidimensional state that also comprises cognitive and psychosocial components. These components interact with each other and with the external environment to determine the frailty state of an older person in a given setting. Frailty is distinct from co-morbidities and disability, despite the fact that they often coexist and are interrelated.2 Co-morbidity is the concurrent presence of two or more medical diseases, whereas disability is difficulty performing activities of daily living and indicates dependency. Frail people are likely to have co-morbidities, and frailty may limit their performance of daily activities. Further, co-morbidities increase the likelihood of being frail and disabled, and disability may exacerbate both frailty and co-morbidities. All of these factors add complexity to the incorporation of frailty into clinical practice.
 
The prevalence of frailty varies among studies and depends on the working definition of frailty. Using a well-known approach, the frailty phenotype model,3 a systematic review reported a weighted average prevalence of 9.9% for frailty and 44.2% for pre-frailty in community-dwelling older people aged ≥65 years.4 One study in Hong Kong based on the same criteria found similar prevalence levels of 7.9% and 50.6% for frailty and pre-frailty, respectively.5 The prevalence of frailty increases with age, rising markedly from 4% in people aged 65 to 69 years to 16% in those aged 80 to 84 years and 26% in those aged >85 years; the prevalence of frailty was also higher in women (9.6%) than in men (5.2%).4
 
There is increasing emphasis of frailty from literature to clinical practice because of its clinical implications. Frailty is associated with a range of adverse outcomes such as falls, disability, hospitalisation, institutionalisation, and death,3 which significantly impact both patients and society. Even though the prevalence of frailty among older people has been constant over time, with the ageing of the population, the number of older people with frailty is expected to continuously increase in the future. In turn, this will pose an increasing burden on the health care system. However, detection of frailty allows risk stratification to predict individual outcomes of interventions or medication treatment. This facilitates better-informed decision making for clinicians, patients, and caregivers while formulating appropriate management plans. As frailty is a dynamic process and is reversible,6 there are targeted interventions to revert frailty, to reduce the level of frailty, or to slow its progression. Overall, consideration of frailty within the health care system is beneficial at both the patient level, as it allows patient-centred and goal-oriented care, and at the societal level, as it facilitates better health care planning and resource allocation in the community. This article focuses on the clinical application of frailty assessment in the hospital setting.
 
Screening and assessment for frailty
Despite the conceptual definition of frailty, a working definition is required to identify and quantify frailty in both research and clinical practice. The two most common approaches are the frailty phenotype model and the frailty index of cumulative deficit model. The frailty phenotype model was described using data from the Cardiovascular Health Study.3 It defines frailty as the manifestation of three or more of the five physical indicators: unintentional weight loss (10 lbs in the past year), self-reported exhaustion, weakness (in terms of grip strength), slow walking speed, and low physical activity. People who have one or two of the indicators are pre-frail, while those who have none of the indicators are non-frail. The frailty index of cumulative deficits model was developed using data from the Canadian Study of Health and Aging.7 It construes frailty as the accumulation of a variety of health deficits including co-morbidities, physical and cognitive impairment, psychosocial risk factors, and geriatric syndrome. It is a quantitative measure that calculates the proportion of deficits present out of the total number of parameters considered. A higher proportion of deficits present is associated with a higher level of frailty, which is represented on a continuum from fitness to mild, moderate, and severe frailty. The numbers of deficits measured ranged from 92 in the initial list to around 30 to 40 in subsequent studies.7 8
 
The frailty phenotype model and the frailty index require measurement, retrieval of patient clinical data, and calculation, all of which are time-consuming and may be unfeasible in routine practice. A variety of more “user-friendly” and validated methods have emerged for practical use. The simplest ones that require the shortest time are single-item measurements of gait speed or a Timed Up and Go test.9 Some measures are derived from the above models, such as the FRAIL scale, which is based on the phenotype model and takes the form of a questionnaire without measurement.10 In addition, the Edmonton Frail Scale, which includes multidimensional questions about the patient’s general health, functional performance, nutrition, medication use, and social support, in addition to clock drawing and a Timed Up and Go test, is quick to administer.11 The Clinical Frailty Scale is based on clinical judgement of an individual’s dependency level and health state to describe a nine-point clinical scale with pictographs from very fit (Category 1) to terminally ill (Category 9).12 13
 
The choice of instruments depends on the purpose and clinical setting. Gait speed and Timed Up and Go testing are simple for routine assessment. The frailty phenotype model allows detection of pre-frailty so that preventive measures can be taken.14 The frailty index is better for prediction of long-term mortality.15 The FRAIL scale is a screening test that is easy to perform in the community setting. The Edmonton Frail Scale can identify modifiable factors for preoperative optimisation. Nevertheless, upon identification of people with frailty, they should undergo comprehensive geriatric assessment (CGA), which is a multidimensional, interdisciplinary diagnostic process to determine a frail older person’s medical, psychological, and functional capacity to develop a coordinated and integrated plan for treatment and long-term follow-up.16 Currently, CGA is regarded as the gold standard for detection and management of frailty.17 18
 
Application of the concept of frailty in hospitals
Older people account for the majority of health care utilisation. According to a Hospital Authority statistical report, patients aged ≥65 years accounted for 53% of the approximately 8 000 000 patient-days in hospitals in Hong Kong during 2016 to 2017.19 A large proportion of these older patients are expected to have frailty. Accordingly, incorporation of the concept of frailty into care is reasonable. The following subsections illustrate how the concept of frailty facilitates patient management in the hospital setting.
 
Emergency department
Utilisation of hospital care services often begins with emergency department (ED) attendance. Risk stratification of older patients in EDs can facilitate allocation of optimal care to patients with different needs and improve outcomes. Various frailty assessment tools, such as the Clinical Frailty Scale and the frailty index, have been studied in the ED setting to identify older people with frailty and the associated adverse outcomes upon ED discharge.20 Studies have shown that compared with those without frailty, patients assessed as frail had a higher risk of revisiting the ED within 6 months of discharge (odds ratio [OR]=2.48; 95% confidence interval [95% CI]=1.25-4.91)21; a higher risk of hospitalisation, nursing home admission, and higher mortality within 30 days of the index ED visit (hazard ratio [HR]=1.98; 95% CI=1.29-3.05)22; 16 times the risk of functional decline at 3 months23; and significantly higher risk of mortality at 6 months (HR=8.68; 95% CI=2.6-28.94).21 In addition, the risk of adverse outcomes increased with higher levels of frailty: 27.4% of the most frail patients had adverse outcomes within 30 days of ED discharge, compared with 16.2% of the least frail patients.22 Understanding which individual patients have an additional risk of adverse outcomes could facilitate treatment plan formulation upon disposal of patients from EDs—whether the patients need hospital admission or are fit to go home and whether they need further assessment, additional community service, or rehabilitation. For patients in EDs with non-acute conditions that do not require hospital admission, those with frailty might benefit from follow-up community-based care, such as community nursing, community outreach teams, phone follow-up, or referral to geriatric day hospitals for CGA and rehabilitation. For those with less acute conditions that demonstrate an equivocal need for hospital admission, non-frail or less frail patients might be discharged for home treatment and subsequent follow-up, but hospital admission for management may be considered for frail patients.
 
Surgical and invasive interventions
Older people with frailty have a limited physiologic reserve to endure surgical operations and are at risk of poorer surgical outcomes. It has been recognised that frailty independently predicts postoperative complications, length of stay, discharge to an institution, and 30-day mortality.24 25 This has led to increasing concern about frailty in surgical practice. Accordingly, a recommendation to incorporate the concept of frailty into preoperative assessment has been made.24 Frailty has been shown to increase the predictability of conventional risk models for adverse surgical outcomes.25 Incorporation of the concept of frailty improves risk stratification and prediction of surgical outcomes to determine who may benefit or be harmed by surgery or whether or not surgery is appropriate or necessary. The anticipated outcomes could facilitate decision making for surgeons and patients and help surgeons to consider less invasive options for those at high operative risk. In addition, frailty assessment enhances preoperative risk management, including medication review, nutritional augmentation, and physiotherapy to minimise postoperative complications. It can also improve postoperative care arrangements, such as close monitoring in an Intensive Care Unit for early complications during the immediate postoperative period, preventive measures against delirium, and attention to hydration, nutrition, and early mobilisation.
 
Acute geriatric wards
For older people with frailty who need in-hospital care for their medical conditions, admission to an acute geriatric ward (AGW) is likely to be more advantageous than that to a general medical ward. General medical wards focusing on treatment of medical problems are insufficient to address older people’s complex needs. Apart from acute medical problems, interactions with underlying co-morbidities and coexisting functional, psychological, and social problems can complicate health outcomes and the independence of older people during and after the acute illness. Acute geriatric wards are designed to provide patient-centred care, including medical care reviews, early rehabilitation, and discharge planning. This is more appropriate for prevention of hospital-related complications such as delirium, falls, pressure sores, and functional decline and for maximisation of recovery, return to the patient’s previous level of functioning, and discharging the patient to his/her home in the community.26 Central to the operation of AGWs is the application of CGA. In a meta-analysis of 22 randomised controlled trials involving nearly 10 315 patients, when compared with patients receiving general medical care, those who received CGA in AGWs were more likely to be alive and in the community at the end of follow-up (median 12 months) [OR=1.22; 95% CI=1.1-1.35], less likely to be institutionalised at the end of follow-up (OR=0.73; 95% CI=0.64-0.84), and less likely to experience outcomes of death or functional decline (OR=0.76; 95% CI=0.64-0.9).18 Targeting acute geriatric care for frail patients with geriatric syndrome, at perceived risk of institutionalisation and functional or cognitive impairment is even more beneficial than targeting based on age alone. Compared with treatment at a general medical ward, every 13 frail patients admitted to AGW would allow one more patient to be alive and in the community at 1 year (OR=1.36; 95% CI=1.16-1.6), whereas age-only recruitment criteria for AGW admission had no significant benefit. In addition, for frail patients, management in an AGW was associated with lower mortality at 3 months (HR=0.55; 95% CI=0.32-0.96), lower risk of an increasing degree of frailty (OR=0.23; 95% CI=0.13-0.4), and lower risk of decline in activities of daily living (OR=0.093; 95% CI=0.052-0.164).27 28
 
End-of-life care
Frailty is independently associated with mortality. Using the frailty phenotype model, older people with frailty were at increased risk of death compared with a non-frail group over 3 years (HR=2.24; 95% CI=1.51-3.33).3 Worsening of frailty status during the previous 2 years also predicted higher mortality over the next 2 years: non-frail to frail (HR=8.1; 95% CI=2-32.5), pre-frail to frail (HR=3.6; 95% CI=1.4-9.1).29 Categorising frailty into different levels allows better characterisation of its correlation with mortality.30 In a large-scale longitudinal study of 13 717 Chinese people aged ≥65 years, using a frailty index of 39 variables and division into four levels of frailty showed that the mortality rate increased with higher levels of frailty.31 The mortality rates at 3 years were 14.4%, 28.7%, 49.9%, and 73.1% for those in 1st quartile (least frail), 2nd quartile, 3rd quartile, and 4th quartile (most frail), respectively. Further, in another study, a 52-item frailty index based on the CGA illustrated that mortality approached 100% for those with frailty index ≥0.5 by about 20 months.32 Frailty measured by the Clinical Frailty Scale has been shown to be an independent predictor of in-hospital mortality.33 Following emergency admission of patients aged ≥75 years, in-hospital death increased from around 2% for those at Clinical Frailty Scale categories 1 to 3 (fit and well) to 24% for those at category 8 (very severely frail) and 31% for those at category 9 (terminally ill).
 
In light of the above, increasing frailty implies that people are at the last phase of life, and it should be considered as an indication for end-of-life care. The prognosis of patients with severe frailty is expected to be even worse when they experience an acute illness or continuous deterioration of a chronic medical illness. In-hospital end-of-life care to avoid futile interventions but promote symptomatic relief, provide psychological or spiritual support to enhance quality of life before death, and foster death with dignity is a more meaningful and proper therapeutic option.34 Even if such patients survive the index admission, end-of-life care or advance care planning could be continued in the community by “community geriatric assessment teams” who support people in residential care homes and “integrated community care services” for patients living in their own homes in the community.
 
Discharge planning
Because of increasing vulnerability to stress with advancing age, not only pre-frail and frail people but also robust older people are likely to experience a decline in physical and mental well-being after hospitalisation for an acute illness.17 35 36 The resultant increase in frailty is associated with increasing risk of subsequent hospitalisation,36 which in turn predisposes patients to become more frail with repeated admission, forming a vicious cycle that ultimately terminates in death. Given that frailty is a dynamic, modifiable process,5 6 early intervention during the post-discharge period may revert patients back to their premorbid state and prevent hospitalisation.
 
Frailty assessment before discharge and comparison with the pre-admission state facilitate recognition of change in physical activity and function in individual patients. Then, targeted interventions for frailty can be planned. Exercise training and nutritional supplementation are the main components of such interventions. Exercise programmes with emphasis on resistance training have been shown to improve physical functioning and reduce frailty,37 38 39 40 and the effects are more prominent for moderately frail patients than for severely frail patients.37 Exercise with concomitant nutritional supplementation to augment caloric intake can further improve muscle strength.38 Cognitive training has also been shown to be effective.39 40 Further, combined interventions (comprising exercise, nutrition, and cognitive training) have additional advantages over individual therapies in reducing frailty.39 40
 
There has been a paucity of study to determine which level of frailty can derive the most benefits from targeted interventions. However, considering that most studies were performed in frail people who were ambulatory and without severe cognitive impairment, patients at less severe levels of frailty are more likely to benefit from such interventions. Nevertheless, performing a pre-discharge CGA to guide post-discharge management plans is justified. For patients with less severe frailty, especially those who had good premorbid functional states, referral to geriatric day hospitals for targeted intervention is warranted. For severely frail people with limited ambulation, therapy to prevent complications resulting from the functional decline, such as supporting their nutritional state and preventing pressure sores or contractures, is more appropriate. For very severely frail patients with limited life expectancy, end-of-life programmes should be continued after discharge. As an integrated part of management, patients’ health states and care plans should be re-evaluated at regular intervals.
 
Present challenges
International guidelines have recommended assessment for frailty during management of older people to facilitate the provision of integrated goal-oriented care.1 9 However, frailty has not yet been formally introduced into clinical practice guidelines in Hong Kong. A standardised approach for frailty is essential, which should start with identification of people with frailty. Selection of an easy-to-use screening tool is required. The FRAIL scale, which only requires answers to five simple questions and has been studied in the Hong Kong population, seems to be a promising screening tool.41 Similarly, single-item measurements of walking speed or grip strength have also been shown to be suitable.42 In the United Kingdom, an electronic frailty index that uses electronic health record data was developed for use in clinical practice to identify and stratify frailty in older patients.43 In Hong Kong, a similar concept was used by the Hospital Authority to generate HARRPE (Hospital Admission Risk Reduction Programme for the Elderly) scores that identify patients at high risk of readmission.44 Thus, it is possible to generate frailty scores by using existing electronic health record data to alert us to people who are frail, so that targeted interventions and appropriate management plans can be offered. The subsequent pathway (which should differ according to frailty level) and setting (in hospital or community) for care upon detection of frailty also needs to be determined.
 
Frailty involves multiple organ systems and affects health outcomes. Its management is complicated by underlying co-morbidities and functional and cognitive decline. Therefore, the management approach should shift from the conventional disease-based approach towards an integrated goal-oriented approach, guided by multidisciplinary CGA. Frailty is an issue for not only geriatricians but also all health care workers who provide care to older people. Thus, consideration of frailty throughout the health care sector is required. Finally, studies showing the cost-effectiveness of the implementation of frailty assessments into care for older people are expected, as they might convince the policy maker to incorporate frailty assessment into health care system in the long run.
 
Conclusion
Frailty is associated with a range of adverse health outcomes. Incorporating the concept of frailty into clinical practice, which should involve multidisciplinary CGA, could enable better risk stratification and prediction of health outcomes. This would also facilitate a change from the conventional disease-based approach to a “whole patient” goal-oriented approach. Further, it is possible to revert or reduce frailty through targeted intervention, so that early identification with appropriate management could maintain older people’s independence in the community. Although there are challenges regarding the implementation of frailty assessments into the Hong Kong health care system, it is time to take the initiative to consider frailty during daily practice and to accumulate experience so that a full-blown care pathway for frailty management can be developed.
 
Author contributions
The author has contributed to the concept or design, acquisition of data, analysis or interpretation of data, drafting of the article, and critical revision for important intellectual content.
 
Declaration
The author has disclosed no conflicts of interest. The author had full access to the data, contributed to the study, approved the final version for publication, and takes responsibility for its accuracy and integrity.
 
References
1. Morley JE, Vellas B, van Kan GA, et al. Frailty consensus: a call to action. J Am Med Dir Assoc 2013;14:392-7. Crossref
2. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 2004;59:255-63. Crossref
3. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146-56. Crossref
4. Collard RM, Boter H, Schoevers RA, Oude Voshaar RC. Prevalence of frailty in community-dwelling older persons: a systematic review. J Am Geriatr Soc 2012;60:1487-92. Crossref
5. Lee JS, Auyeung TW, Leung J, Kwok T, Woo J. Transitions in frailty states among community-living older adults and their associated factors. J Am Med Dir Assoc 2014;15:281-6. Crossref
6. Gill TM, Gahbauer EA, Allore HG, Han L. Transitions between frailty states among community-living older persons. Arch Intern Med 2006;166:418-23. Crossref
7. Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy measure of aging. Scientific World Journal 2001;1:323-36. Crossref
8. Song X, Mitnitski A, Rockwood K. Prevalence and 10-year outcomes of frailty in older adults in relation to deficit accumulation. J Am Geriatr Soc 2010;58:681-7. Crossref
9. Turner G, Clegg A, British Geriatrics Society, Age UK, Royal College of General Practitioners. Best practice guidelines for management of frailty: a British Geriatric Society, Age UK and Royal College of General Practitioners report. Age Ageing 2014;43:744-7. Crossref
10. Morley JE, Malmstrom TK, Miller DK. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. J Nutr Health Aging 2012;16:601-8. Crossref
11. Rolfson DB, Majumdar SR, Tsuyuki RT, Tahir A, Rockwood K. Validity and reliability of the Edmonton Frail Scale. Age Aging 2006;35:526-9. Crossref
12. Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ 2005;173:489-95. Crossref
13. Geriatric Medicine Research, Faculty of Medicine, Dalhousie University. Research / projects, Clinical Frailty Scale©. Available from: http://geriatricresearch.medicine.dal.ca/clinical_frailty_scale.htm. Accessed 27 Oct 2018.
14. Woo J, Leung J, Morley JE. Comparison of frailty indicators based on clinical phenotype and the multiple deficit approach in predicting mortality and physical limitation. J Am Geriatr Soc 2012;60:1478-86. Crossref
15. Malmstrom TK, Miller DK, Morley JE. A comparison of four frailty models. J Am Geriatr Soc 2014;62:721-6. Crossref
16. Rubenstein LZ, Struck AE, Siu AL, Wieland D. Impacts of geriatric evaluation and management programs on defined outcomes: overview of the evidence. J Am Geriatr Soc 1991;39(9 Pt 2):8S-16S. Crossref
17. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet 2013;381:752-62. Crossref
18. Ellis G, Whitehead MA, O’Neill D, Langhorne P, Robinson D. Comprehensive geriatric assessment for older adults admitted to hospital. Cochrane Database Syst Rev 2011(7):CD006211. Crossref
19. Hospital Authority, Hong Kong SAR Government. Hospital Authority Statistical Report 2016-2017. Available from: http://www.ha.org.hk/haho/ho/stat/HASR16_17. pdf. Accessed 27 Oct 2018.
20. Jørgensen R, Brabrand M. Screening of the frail patient in the emergency department : a systematic review. Eur J Intern Med 2017;45:71-3. Crossref
21. Salvi F, Morichi V, Grilli A, et al. Screening for frailty in elderly emergency department patients by using the Identification of Seniors At Risk (ISAR). J Nutr Health Aging 2012;16:313-8. Crossref
22. Hastings SN, Purser JL, Johnson KS, Sloane RJ, Whitson HE. Frailty predicts some but not all adverse outcomes in older adults discharged from the emergency department. J Am Geriatr Soc 2008;56:1651-7. Crossref
23. Sirois MJ, Griffith L, Perry J, et al. Measuring frailty can help emergency departments identify independent seniors at risk of functional decline after minor injuries. J Gerontol A Biol Sci Med Sci 2017;72:68-74. Crossref
24. Robinson TN, Walston JD, Brummel NE, et al. Frailty for surgeons: review of a National Institute on Aging Conference on frailty for specialists. J Am Coll Surg 2015;221:1083-92. Crossref
25. Makary MA, Segev DL, Pronovost PJ, et al. Frailty as a predictor of surgical outcomes in older patients. J Am Coll Surg 2010;210:901-8. Crossref
26. Baztán JJ, Suárez-García FM, López-Arrieta J, Rodríguez-Mañas L, Rodríuez-Artalejo F. Effectiveness of acute geriatric units on functional decline, living at home, and case fatality among older patients admitted to hospital for acute medical disorders: meta-analysis. BMJ 2009;338:b50. Crossref
27. Ekerstad N, Karlson BW, Dahlin Ivanoff S, et al. Is the acute care of frail elderly patients in a comprehensive geriatric assessment unit superior to conventional acute medical care? Clin Intev Aging 2016;12:1-9. Crossref
28. Ekerstad N, Dahlin Ivanoff S, Landahl S, et al. Acute care of severely frail elderly patients in a CGA-unit is associated with less functional decline than conventional acute care. Clin Interv Aging 2017;12:1239-49. Crossref
29. Kulmala J, NyKänen I, Hartikainen S. Frailty as a predictor of all-cause mortality in older men and women. Geriatr Gerontol Int 2014;14:899-905. Crossref
30. Kulminski AM, Ukraintseva SV, Kulminskaya IV, Arbeev KG, Land K, Yashin AI. Cumulative deficits better characterize susceptibility to death in elderly people than phenotypic frailty: lessons from the Cardiovascular Healthy Study. J Am Geriatr Soc 2008;56:898-903. Crossref
31. Dupre ME, Gu D, Warner D, Yi Z. Frailty and type of death among older adults in China: prospective cohort study. BMJ 2009;338:b1175. Crossref
32. Rockwood K, Rockwood MR, Mitnitski A. Physiological redundancy in older adults in relation to the change with age in the slope of a frailty index. J Am Geriatr Soc 2010;58:318-23. Crossref
33. Wallis SJ, Wall J, Biram RW, Romero-Ortuno R. Associations of the clinical frailty scale with hospital outcomes. QJM 2015;108:943-9. Crossref
34. Luk JK. End-of-life services for older people in residential care homes in Hong Kong. Hong Kong Med J 2018;24;63-7. Crossref
35. Gill TM, Gahbauer EA, Han L, Allore HG. The relationship between intervening hospitalizations and transitions between frailty states. J Gerontol A Biol Sci Med Sci 2011;66:1238-43. Crossref
36. Kahlon S, Pederson J, Majumdar SR, et al. Association between frailty and 30-day outcomes after discharge from hospital. CMAJ 2015;187:799-804. Crossref
37. Gill TM, Baker DI, Gottschalk M, Peduzzi PN, Allore H, Byers A. A program to prevent functional decline in physically frail, elderly persons who live at home. N Engl J Med 2002;347:1068-74. Crossref
38. Fiatarone MA, O’Neill EF, Ryan ND, et al. Exercise training and nutritional supplementation for physical frailty in very elderly people. N Engl J Med 1994;330:1769-75. Crossref
39. Puts MT, Toubasi S, Andrew MK, et al. Interventions to prevent or reduce the level of frailty in community-dwelling older adults: a scoping review of the literature and international policies. Age Ageing 2017;46:383-92. Crossref
40. Ng TP, Feng L, Nyunt MS, et al. Nutritional, physical, cognitive, and combination interventions and frailty reversal among older adults: a randomized controlled trial. Am J Med 2015;128:1225-36. Crossref
41. Woo J, Yu R, Wong M, Yeung F, Wong M, Lum C. Frailty screening in the community using FRAIL scale. J Am Med Dir Assoc 2015;16:412-9. Crossref
42. Auyeung TW, Lee JS, Leung J, Kwok T, Woo J. The selection of a screening test for frailty identification in community-dwelling older adults. J Nutr Health Aging 2014;18:199-203. Crossref
43. Clegg A, Bates C, Young J, et al. Development and validation of an electronic frailty index using routine primary care electronic health record data. Age Ageing 2016;45:353-60. Crossref
44. Chan S, Kwong P, Kong B, et al. Improving health of high risk elderly in the community—the HARRPE. Available from: www.healthyhkec.org/SCE/SCE3/abstracts/p37.pdf. Accessed 27 Oct 2018.

Medication overuse headache: strategies for prevention and treatment using a multidisciplinary approach

DOI: 10.12809/hkmj177024
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
MEDICAL PRACTICE  CME
Medication overuse headache: strategies for prevention and treatment using a multidisciplinary approach
M van Driel, MD, PhD1; E Anderson, MSc, PhD2; T McGuire, BPharm, PhD3,4,5; R Stark, MB, BS, FRACP6
1 Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia
2 In Vivo Academy Ltd, In Vivo Communications, Sydney, New South Wales, Australia
3 Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Queensland, Australia
4 School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia
5 Mater Pharmacy Services, Mater Health Services, South Brisbane, Queensland, Australia
6 Neurology Department, Alfred Hospital, Melbourne, Victoria, Australia
 
Corresponding author: Prof M van Driel (m.vandriel@uq.edu.au)
 
 Full paper in PDF
 
Abstract
Medication overuse headache, which affects patients who have migraines and frequent headaches, is prevalent worldwide and can severely impact daily functioning. Medication overuse headache is often not recognised by primary care physicians or general practitioners, as patients may overuse medications that are freely available without a prescription. Overuse of codeine-containing analgesics is particularly problematic and contributes to ongoing morbidity and opioid-related mortality. This article aims to provide an overview of the detection, prevention, and management of medication overuse headache. The definition of medication overuse headache and the risk levels of commonly used symptomatic headache medications are presented. An algorithm consisting of a number of simple questions can assist general practitioners with identifying at-risk patients. Treatment strategies are discussed in the context of a multidisciplinary approach.
 
 
 
The estimated prevalence of medication overuse headache (MOH) in the general population ranges from 0.6% to 7%.1 2 3 4 5 6 7 8 A number of acute headache treatments may cause MOH,7 and the medications that are predominantly associated with MOH vary from country to country.1 7 9 10 Opioids such as codeine are particularly problematic, as they are consistently associated with increasingly severe headaches11 (Table12) and poor outcomes after withdrawal.13 In a number of regions, including Hong Kong and Japan, codeine-containing medication is only available by prescription.14 In Australia, beginning in 2018, codeine (and its combinations with simple analgesics) will only be available by prescription, following a 2015 decision by the Australian Therapeutic Goods Administration (TGA).15 This policy change is supported by evidence demonstrating an increase in unintentional codeine-related deaths in Australia.16
 

Table. Risk of MOH from symptomatic headache medications12
 
A systematic analysis of the global, regional, and national burden of neurological disorders from 1990 to 2015 (using data from the Global Burden of Disease Study 2015) found that neurological disorders were the leading cause of disability-adjusted life years (DALYs) in 2015, with the most prevalent neurological disorders being tension-type headache (1505.9 million DALYs), migraine (958.8 million DALYs), and MOH (58.5 million DALYs).17 As large numbers of people are potentially at risk of MOH, including anyone with frequent primary episodic headaches, strategies for primary prevention, treatment, and prevention of relapse may have substantial public health benefits.
 
Definition of medication overuse headache
The definition of MOH is headache occurring on ≥15 days per month as a consequence of regular overuse of acute or symptomatic headache medication (≥10 days per month for triptans, ergotamines, or opioids; ≥15 days per month for simple or combined analgesics) for more than 3 months. It usually, but not invariably, resolves after the overuse is stopped.18
 
Problems with detection and treatment of medication overuse headache
Patients’ lack of awareness of medication overuse as a cause of headaches, reluctance to acknowledge how much medication they take, and poor adherence to recommended treatment have been identified as barriers to detection and management of MOH. A survey of Australian general practitioners (GPs)19 showed that GPs’ awareness of MOH is low, although the awareness of codeine overuse in general may have increased following the TGA’s decision, which was widely discussed in the media. In Singapore, a general practice survey of patients and their attending physicians in a primary care setting found that 22.6% of the patient population reported taking acute pain medication for headaches at least 4 days per week. However, the physicians only identified this in 5.3% of the study population, indicating that physicians did not recognise a large percentage of patients at risk of MOH.20 Khu et al20 commented that overuse of analgesic medications may lead to ‘doctor-hopping’ by patients in search of increasingly elusive headache relief. There may be a need to provide greater awareness of MOH during medical training, as a survey of final year medical students in Singapore found that 47% were unfamiliar with MOH as a disease entity, and 96% were unfamiliar with local clinical practice guidelines about headaches.21
 
Patients with frequent episodic migraines (headaches on 8-15 days per month) or chronic migraines (headaches on >15 days per month) are at particular risk of developing MOH. General practitioners play a crucial role in identifying these patients, assessing their medication intake, and offering strategies to minimise the risk of MOH (Box 14 22).
 

Box 1. Practical strategies for avoiding MOH
 
Patients may be reluctant to reveal how many analgesics they take or may be unaware or unwilling to accept that the medication they use to treat their headaches is actually contributing to the continuation of their headaches. They may also be reluctant to discontinue medication that they have found to provide some relief for their headaches in the past. Patients who are anxious about their headaches interfering with essential activities, such as work, may use medication routinely as a preventive measure. In addition, a common misperception among consumers is that medication that can be purchased without a prescription (‘over the counter’) is harmless.23 Unfortunately, once established, MOH (particularly that caused by opioids) has a high relapse rate after treatment.24 Adherence to recommended treatment is generally suboptimal in patients with MOH, but the majority of relapses occur in the first year after withdrawal.25 It is therefore important to educate patients about the pathophysiology and treatment of MOH and to continue supporting them beyond the immediate period of withdrawal.
 
Some patients who report “excessive” medication use and very frequent headache do not respond to medication withdrawal. Patients who develop MOH are usually those with intrinsically high-frequency headaches, and withdrawal tends to lead to reversion to their natural background headache pattern, which may range from infrequent episodic migraines to higher-frequency patterns. Scher et al26 questioned the benefit of withdrawal or restriction of medication on the grounds that the patient may not benefit from it. However, withdrawal allows the underlying headache pattern to be determined and a reappraisal of headache control to be conducted. Study results have demonstrated that withdrawal of headache medication benefits many patients with MOH. For example, in a recent study, patients diagnosed with MOH were randomised to 2 months’ detoxification with either complete withdrawal of medication or acute medication restricted to 2 days/week. The number of migraine-days/ month was significantly reduced after 6 months with both treatments, with a greater reduction of migraine-days/month in the complete withdrawal group, indicating that complete withdrawal is generally more effective than medication restriction and that medication overuse was a major factor in the patients’ headache pathology.27
 
A multidisciplinary approach
As patients with MOH often do not present to their GPs in response to the first instance, pharmacists can play a role in educating patients who self-medicate with analgesics when analgesics are purchased without a prescription.28 They could encourage patients who may be overusing pain relief medication to consult their GPs to discuss other treatment options. However, it may not be easy to identify at-risk patients, as some obtain large quantities of headache medications by shopping at different pharmacies. Identification of these patients could be facilitated by using a tracking system to detect patients who buy headache medication at multiple pharmacies.
 
Conditions associated with self-medication, such as MOH, could be prevented by community pharmacists. Community pharmacists have overviews of both prescriptions and non-prescription medications that patients are taking (provided that patients are not visiting several different pharmacies) and are easily accessible to patients.29 30 Thus, the sale of headache medications is an opportunity to discuss their potential adverse effects and their role in MOH. A survey in Japan on the role of community pharmacists in self-medication of patients with headache found that 32% of the surveyed doctors were concerned about the increase of patients who overuse headache medication. Both doctors and pharmacists thought that pharmacists should not only provide patients with “instruction on the use of drugs” but also suggest “when to consult a hospital or clinic”.31 However, strategies may need to be devised to motivate patients to do this, as another Japanese survey of pharmacists and doctors found that 22% of pharmacists had experienced refusal by patients with headache to consult a clinic, despite the pharmacist’s recommendation.32
 
Community pharmacists have an important role in supporting patients with headache. This can be fostered by all key stakeholders—pharmacists, doctors, and patients—being provided with multidisciplinary opportunities to improve their MOH health literacy and to maintain an open and collaborative relationship.
 
Although MOH often develops outside of GPs’ immediate view through patients’ self-medication, GPs are important in its prevention, detection, and treatment. The first step is educating patients, and when they do not understand the cause of and treatment for MOH, taking time to inform them and clarify their misunderstandings.29 The next step is to develop a plan with the patient and provide clear and continuing support for what is often a challenging journey. General practitioners also need to be aware of situations in which patients should be referred to a neurologist, preferably one who specialises in headache management.
 
Discussions between GPs or pharmacists and patients who overuse headache medication are often delicate. The patient may perceive an accusation of ‘recreational use’ of (particularly codeine-containing) drugs. It is vital for productive communication that the health care professional clarify that there is no suspicion of this type and that the medications are recognised as being used to deal with genuinely troublesome symptoms. It is vital to subsequently emphasise that ongoing use of particular headache medications may contribute to perpetuation of headaches and that better strategies are available.
 
Management and prevention strategies
Prevention of headaches is better than curing them. Pharmacists and GPs who are aware of MOH can detect patients with increasing frequencies of headaches and medication use. Strategies to assist such patients before they progress into frank MOH include lifestyle adjustments and appropriate prophylaxis, as discussed below as part of MOH treatment (Box 2).
 

Box 2. Treatment strategies for patients with MOH (abrupt withdrawal with immediate initiation of prophylactic medication)
 
Complete withdrawal from overused headache medications is a key component of the management strategy, along with education, counselling, and support. Abrupt withdrawal is usually preferred, but tapered withdrawal may be more appropriate when codeine is implicated.25 Coexisting psychiatric conditions should also be assessed and managed. As medication discontinuation results in withdrawal headaches—often associated with nausea, vomiting, and sleep disturbance—patients frequently need assistance coping with withdrawal symptoms and persevering with discontinuation.4 12 33 34 Symptoms usually last between 2 and 10 days, with withdrawal from triptans lasting approximately 4 days and that from nonsteroidal anti-inflammatory drugs lasting about 10 days. Withdrawal can be managed through primary care; however, opioid discontinuation may require hospitalisation.34 35
 
Accurate diagnosis based on the third edition of the International Classification of Headache Disorders17 and referral of complex cases to a neurologist/headache specialist is recommended for individualised treatments. Psychiatric assessment may also be indicated in some cases. However, in many countries, limited specialist availability means that referrals need to be selective. Psychologists and physical therapists have a role, as psychotherapy, relaxation techniques, physical exercise, and cognitive behaviour therapy may be useful adjuncts to supervised pharmacotherapy.4 12 23 28 34 36 37 The combination of behavioural treatment and prophylactic medication may significantly reduce the risk of relapse.37 Preventive medications for chronic migraines include antiepileptic drugs (particularly topiramate), antidepressants (eg, amitriptyline), onabotulinum toxin A, and drugs used for episodic migraines (eg, beta blockers). For example, topiramate (oral) and onabotulinum toxin A (by local injection) are recommended by the Taiwan Headache Society 2017 medical treatment guidelines as first-line treatments for prophylaxis of chronic migraines.38 Education about acute and prophylactic treatment may improve adherence to both pharmacological and non-pharmacological therapies.28
 
In some circumstances, withdrawal may require hospital admission. Patients with MOH who have been detoxified as in-patients should be followed up by their GPs. Support by a headache nurse (available in some neurological practices) can improve adherence to detoxification.39
 
Multidisciplinary treatment of patients with MOH, including pharmacological prophylaxis, relaxation therapy, and aerobic sports, is associated with reduction in headaches, as long as patients adhere to the recommended therapies.28 Motivational telephone interviewing may also help to promote adherence.40 To supplement regular GP support, practice nurses could be involved in patient support, and they could liaise with pharmacists to monitor medication use.
 
Conclusion
There is an urgent need for increased awareness of MOH among both patients and health care professionals.41 Medication overuse headache causes considerable morbidity but is preventable. Headache frequency (and the associated disability, depression, and anxiety) can be considerably reduced in patients with MOH through withdrawal from the overused medication and appropriate supportive treatment. A multidisciplinary approach involving primary care physicians (GPs), community pharmacists, nurses, and allied health providers,36 with referral to neurologists/headache specialists (where available) for complex cases, is recommended.
 
Author contributions
All authors contributed to the concept of the paper, acquisition and interpretation of data and critical revision of the manuscript for important intellectual content. EA and MVD drafted the article. All authors approved the final version.
 
Declaration
M van Driel, T McGuire, and R Stark have received consulting fees from In Vivo Academy Ltd for development of education materials for a multidisciplinary programme about MOH. In Vivo Academy Ltd received an unrestricted educational grant from Pfizer to develop educational material about MOH. R Stark has also received lecture and/or consulting fees from Allergan, Novartis, TEVA, MSD, Abbvie and SciGen (Australia) and from In Vivo Academy Ltd relating to a Pfizer-sponsored project, and has undertaken clinical trials for Allergan. E Anderson is an employee of In Vivo Academy Ltd.
 
References
1. Cha MJ, Moon HS, Sohn JH, et al. Chronic daily headache and medication overuse headache in first-visit headache patients in Korea: a multicenter clinic-based study. J Clin Neurol 2016;12:316-22. Crossref
2. Cheung V, Amoozegar F, Dilli E. Medication overuse headache. Curr Neurol Neurosci Rep 2015;15:509. Crossref
3. Herekar AA, Ahmad A, Uqaili UL, et al. Primary headache disorders in the adult general population of Pakistan—a cross sectional nationwide prevalence survey. J Headache Pain 2017;18:28. Crossref
4. Kristoffersen ES, Lundqvist C. Medication-overuse headache: epidemiology, diagnosis and treatment. Ther Adv Drug Saf 2014;5:87-99. Crossref
5. Steiner TJ, Stovner LJ, Katsarava Z, et al. The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain 2014;15:31. Crossref
6. Yu S, Liu R, Zhao G, et al. The prevalence and burden of primary headaches in China: a population-based door-to-door survey. Headache 2012;52:582-91. Crossref
7. Westergaard ML, Munksgaard SB, Bendtsen L, Jensen RH. Medication-overuse headache: a perspective review. Ther Adv Drug Saf 2016;7:147-58. Crossref
8. Zebenholzer K, Andree C, Lechner A, et al. Prevalence, management and burden of episodic and chronic headaches—a cross-sectional multicentre study in eight Austrian headache centres. J Headache Pain 2015;16:531. Crossref
9. Dong Z, Chen X, Steiner TJ, et al. Medication-overuse headache in China: clinical profile, and an evaluation of the ICHD-3 beta diagnostic criteria. Cephalalgia 2015;35:644-51. Crossref
10. Manandhar K, Risal A, Steiner TJ, Holen A, Linde M. The prevalence of primary headache disorders in Nepal: a nationwide population-based study. J Headache Pain 2015;16:95. Crossref
11. Johnson JL, Hutchinson MR, Williams DB, Rolan P. Medication-overuse headache and opioid-induced hyperalgesia: A review of mechanisms, a neuroimmune hypothesis and a novel approach to treatment. Cephalalgia 2013;33:52-64. Crossref
12. Smith TR, Stoneman J. Medication overuse headache from antimigraine therapy: clinical features, pathogenesis and management. Drugs 2004;64:2503-14. Crossref
13. Bøe MG, Salvesen R, Mygland A. Chronic daily headache with medication overuse: predictors of outcome 1 year after withdrawal therapy. Eur J Neurol 2009;16:705-12. Crossref
14. Butler J. You won’t be able to buy codeine over the counter anymore. Huffington Post 2016 Dec 20. Available from: http://www.huffingtonpost.com.au/2016/12/19/you-wont-be-able-to-buy-codeine-over-the-counteranymore_a_21631170/. Accessed 25 Oct 2018.
15. Therapeutic Goods Administration, Department of Health, Australian Government. Proposal for the re-scheduling of codeine products. 2015. Available from: https://www.tga.gov.au/media-release/proposal-re-scheduling-codeineproducts. Accessed 2 Mar 2017.
16. Roxburgh A, Hall WD, Burns L, et al. Trends and characteristics of accidental and intentional codeine overdose deaths in Australia. Med J Aust 2015;203:299. Crossref
17. GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol 2017;16:877-97. Crossref
18. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33:629-808. Crossref
19. van Driel ML, McGuire TM, Stark R, Lazure P, Garcia T, Sullivan L. Learnings and challenges to deploy an interprofessional and independent medical education programme to a new audience. J Eur CME 2017;6:1400857. Crossref
20. Khu JV, Siow HC, Ho KH. Headache diagnosis, management and morbidity in the Singapore primary care setting: findings from a general practice survey. Singapore Med J 2008;49:774-9.
21. Ong JJ, Chan YC. Medical undergraduate survey on headache education in Singapore: knowledge, perceptions, and assessment of unmet needs. Headache 2017;57:967-78. Crossref
22. Lipton RB, Dodick D, Sadovsky R, et al. A self-administered screener for migraine in primary care: The ID MigraineTM validation study. Neurology 2003;61:375-82. Crossref
23. Frich JC, Kristoffersen ES, Lundqvist C. GPs’ experiences with brief intervention for medication-overuse headache: a qualitative study in general practice. Br J Gen Pract 2014;64:e525-31. Crossref
24. Katsarava Z, Muessig M, Dzagnidze A, Fritsche G, Diener HC, Limmroth V. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia 2005;25:12-5. Crossref
25. Evers S, Marziniak M. Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol 2010;9:391-401. Crossref
26. Scher AI, Rizzoli PB, Loder EW. Medication overuse headache: an entrenched idea in need of scrutiny. Neurology 2017;89:1296-304. Crossref
27. Carlsen LN, Munksgaard SB, Jensen RH, Bendtsen L. Complete detoxification is the most effective treatment of medication-overuse headache: a randomized controlled open-label trial. Cephalalgia 2018;38:225-36. Crossref
28. Gaul C, Brömstrup J, Fritsche G, Diener HC, Katsarava Z. Evaluating integrated headache care: a one-year follow-up observational study in patients treated at the Essen headache centre. BMC Neurol 2011;11:124. Crossref
29. Giaccone M, Baratta F, Allais G, Brusa P. Prevention, education and information: the role of the community pharmacist in the management of headaches. Neurol Sci 2014;35(1 Suppl):1-4. Crossref
30. O’Sullivan EM, Sweeney B, Mitten E, Ryan C. Headache management in community pharmacies. Ir Med J 2016;109:373.
31. Naito Y, Ishii M, Kawana K, Sakairi Y, Shimizu S, Kiuchi Y. Role of pharmacists in a community pharmacy for self-medication of patients with headache [in Japanese]. Yakugaku Zasshi 2009;129:735-40. Crossref
32. Naito Y, Ishii M, Sakairi Y, Kawana K, Shimizu S, Kiuchi Y. Need for collaboration between community pharmacies and hospitals or clinics in providing medical treatment for patients with headache [in Japanese]. Yakugaku Zasshi 2009;129:741-8. Crossref
33. Stark R, Hutton E. Chronic migraine and other types of chronic daily headache. Medicine Today 2013;14:29-35.
34. Kristoffersen ES, Lundqvist C. Medication-overuse headache: a review. J Pain Res 2014;26:367-78. Crossref
35. Williams D. Medication overuse headache. Aust Prescr 2005;28:59-62. Crossref
36. Bendtsen L, Munksgaard S, Tassorelli C, et al. Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project). Cephalalgia 2014;34:426-33. Crossref
37. Lake AE 3rd. Medication overuse headache: biobehavioral issues and solutions. Headache 2006;46(3 Suppl):S88-97. Crossref
38. Huang TC, Lai TH, Taiwan Headache Society TGSOTHS. Medical treatment guidelines for preventive treatment of migraine. Acta Neurol Taiwan 2017;26:33-53.
39. Pijpers JA, Louter MA, de Bruin ME, et al. Detoxification in medication-overuse headache, a retrospective controlled follow-up study: does care by a headache nurse lead to cure? Cephalalgia 2016;36:122-30. Crossref
40. Stevens J, Hayes J, Pakalnis A. A randomized trial of telephone-based motivational interviewing for adolescent chronic headache with medication overuse. Cephalalgia 2014;34:446-54. Crossref
41. Stark R, McGuire T, van Driel M. Medication overuse headache in Australia: a call for multidisciplinary efforts at prevention and treatment. Med J Aust 2016;205:283. Crossref

Hong Kong Institute of Allergy and Hong Kong Society for Paediatric Immunology Allergy & Infectious Diseases joint consensus statement 2018 on vaccination in egg-allergic patients

DOI: 10.12809/hkmj177137
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
MEDICAL PRACTICE
Hong Kong Institute of Allergy and Hong Kong Society for Paediatric Immunology Allergy & Infectious Diseases joint consensus statement 2018 on vaccination in egg-allergic patients
Gilbert T Chua, MB, BS, MRCPCH1; Philip H Li, MRes (Med), MRCP2; Marco HK Ho, MD, FRCPCH1; Ellen Lai, BPharm, MClinPharm3; Vivian Ngai, BPharm, MClinPharm; Felix YS Yau, MRCP, FHKAM (Paediatrics)4; Mike YW Kwan, FHKAM (Paediatrics), FHKCPaed5; TF Leung, MD, FRCPCH6; TH Lee, ScD, FRCP7
1 Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, Pokfulam, Hong Kong
2 Division of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, Pokfulam, Hong Kong
3 Department of Pharmacy, Queen Mary Hospital, Pokfulam, Hong Kong
4 Department of Paediatrics and Adolescent Medicine, Queen Elizabeth Hospital, Jordan, Hong Kong
5 Department of Paediatrics and Adolescent Medicine, Princess Margaret Hospital, Laichikok, Hong Kong
6 Department of Paediatrics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
7 Allergy Centre, Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong
 
Corresponding author: Dr TH Lee (takhong.lee@hksh.com)
 
 Full paper in PDF
 
Abstract
Vaccination of egg-allergic individuals has been a historical concern, particularly for influenza and measles-mumps-rubella-varicella vaccines that are developed in chicken egg embryos or chicken cell fibroblasts. The egg proteins in these vaccines were believed to trigger an immediate allergic reaction in egg-allergic individuals. However, recently published international guidelines have updated their recommendations and now state that these vaccines can be safely administered to egg-allergic individuals. This joint consensus statement by the Hong Kong Institute of Allergy and the Hong Kong Society for Paediatric Immunology Allergy & Infectious Diseases summarises the updates and provides recommendations for local general practitioners and paediatricians.
 
 
 
Background
Vaccination is an important and effective method to develop active immunity against certain pathogens. It helps to prevent or reduce the risks of developing certain infectious diseases as well as moderating disease severity. However, the administration of certain vaccines, including influenza, measles-mumps- rubella (MMR), measles-mumps-rubellavaricella (MMR-V) and yellow fever vaccines, has historically been relatively, if not absolutely, contra-indicated in egg-allergic individuals. This is because these vaccines are developed in chicken egg embryos or chicken cell fibroblasts, raising the concern that egg proteins (notably ovalbumin) in these vaccines may trigger an immediate allergic reaction in egg-allergic individuals. As a result, previous vaccination guidelines and vaccine product information have recommended avoidance of influenza and MMR or MMR-V vaccines in individuals with a history of anaphylactic reaction to egg exposure.
 
Local epidemiological studies have shown that 0.4%-0.7% of Hong Kong children were reported by their parents to have had an adverse reaction to intake of a hen’s egg.1 2 No local data for the adult population are available. However, it is important to differentiate between adverse reactions and genuine egg allergy, especially when deciding the need for vaccine avoidance. A recent United Kingdom multi-centre study found that more than a third of patients with suspected egg allergy who were referred to a tertiary allergy centre for vaccination were not actually egg allergic, and all were vaccinated successfully.3
 
Despite the paucity of evidence, there remains some concern that administration of vaccines that could contain egg proteins, notably ovalbumin, might cause allergic reactions in egg-allergic subjects. The Centre for Health Protection recommends that mildly egg-allergic individuals can safely receive inactivated influenza vaccine in a primary care setting. However, those with confirmed or suspected egg allergy who have experienced severe reactions should be seen by an allergist/immunologist for evaluation of their egg allergy prior to administration of inactivated influenza vaccine.4
 
Recently published international guidelines have updated their recommendations regarding the administration of vaccines to egg-allergic individuals. This joint consensus statement by the Hong Kong Institute of Allergy and the Hong Kong Society for Paediatric Immunology Allergy & Infectious Diseases summarises recent updates and provides recommendations for local general practitioners and paediatricians. For practical reasons, this guideline will only cover influenza and MMR/MMR-V vaccines.
 
Yellow fever vaccine is less commonly administered and is commonly propagated in hens’ eggs. Specialist evaluation is recommended prior to vaccination for evaluation of suspected egg allergies with vaccine skin testing or consideration for desensitisation.3 An egg-free yellow fever formulation is available as an alternative.
 
The Q fever vaccine is not available in Hong Kong and therefore is not covered in this guideline.
 
Influenza vaccine
Influenza vaccination is well known to be effective in preventing infections caused by influenza viruses and in reducing the risk of developing complications. We reviewed the product information recommendations of Vaxigrip (Sanofi Pasteur SA, Lyon, France), Fluarix Tetra (GlaxoSmithKline Biologicals, Dresden, Germany), and FluQuadri (Sanofi Pasteur SA, Lyon, France). All recommended that patients with egg or chicken protein hypersensitivity are contra-indicated to receive their vaccines. However, upon direct communication with the respective pharmaceutical companies, all of them were reported to contain <0.1 ug/mL of ovalbumin in their vaccines. Therefore, we disagree with their recommendations.
 
Moneret-Vautrin et al5 reported that only 1% of egg-allergic patients would develop allergic reactions at a threshold as low as 1 mg. As the quantity of ovalbumin in influenza vaccines is ≤1 μg/dose, such a level of egg protein in influenza vaccines is very unlikely to trigger an allergic response in this group of patients. Thus, despite the product information recommendations and the trace amounts of ovalbumin present in these influenza vaccines, they should be safe for egg-allergic individuals, including those with a history of anaphylaxis to egg proteins.
 
Our view is supported by numerous international guidelines on administration of influenza vaccines to egg-allergic individuals, summarised in the Table.6 7 8 9 10 11 12
 

Table. Summary of international recommendations on administrating vaccines to egg-allergic individuals
 
Measles-mumps-rubella and measles-mumps-rubella-varicella vaccines
The MMR and MMR-V vaccines are safe and effective in preventing mumps, measles, rubella, and varicella. The vaccination schedule in Hong Kong recommends that the first dose be administered at age 1 year and the second dose at Primary 1 (age 5-6 years).13 We reviewed the product information recommendations of two MMR-V vaccines available in Hong Kong: Priorix-Tetra (GlaxoSmithKline plc [GSK], Brentford, UK) and ProQuad (Merck & Co, Inc, Kenilworth [NJ], US). The manufacturers of both of these products recommend that patients with severe allergic reactions after egg ingestion should take extra precaution when receiving the vaccines. However, in direct communication with the manufacturers, GSK replied that Priorix-Tetra may contain traces of egg protein but the amount is not measured in the final product. In contrast, Merck replied that internal analysis was done for ProQuad for its egg protein content; however, they refused to disclose the information as they consider it proprietary. We disagree with their recommendations. The Table summarises international recommendations for administration of MMR/MMR-V vaccines to egg-allergic individuals.6 11 14 15 16 It is recommended that all patients, including those with suspected or confirmed egg allergy, should receive the MMR/MMR-V vaccination as a matter of routine in primary care, as the vaccine does not contain egg allergen.
 
Recommendations of the Hong Kong Institute of Allergy and the Hong Kong Society for Paediatric Immunology Allergy & Infectious Diseases
1. All patients with suspected or confirmed egg allergy should receive the MMR/MMR-V vaccination as a matter of routine in primary care.
2. Influenza vaccines can be safely administered, and are recommended, for disease prevention in egg-allergic individuals. They are recommended to be administered in an out-patient or ambulatory setting.
3. Only those patients who have previously required admission to an intensive care unit for severe anaphylaxis to egg should be referred to an allergist for further evaluation prior to influenza vaccination.
4. Should there be any significant concerns from patients, parents or health care professionals, health care professionals who are capable of recognising signs and symptoms of an allergic reaction can provide 15 to 30 minutes of monitoring following vaccination.
5. Specialist evaluation is recommended prior to yellow fever vaccination in egg-allergic individuals (Fig).
6. Individuals who have developed or are suspected to have developed an allergic reaction to the vaccine or other vaccine components (such as gelatine or neomycin) should not undergo further vaccination with these products. Referral to an allergy specialist for further evaluation can be considered (Fig).
7. A significant number of suspected egg-allergic patients may be misdiagnosed, so referral to an allergist for evaluation may be considered.
 

Figure. Proposed workflow for vaccinating patients with suspected egg allergy
 
Author contributions
GT Chua and PH Li drafted the main text of the article, including the tables and figures. E Lai and V Ngai offered their expert opinion as clinical pharmacists and contacted pharmaceutical companies regarding the contents of the vaccines. MHK Ho, MYW Kwan, FYS Yau, TF Leung, and TH Lee contributed to the concept, analysis, and critical revision of the article.
 
Funding/support
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
 
Declaration
All authors have disclosed no conflicts of interest. All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
 
References
1. Leung TF, Yung E, Wong YS, Lam CW, Wong GW. Parent-reported adverse food reactions in Hong Kong Chinese pre-schoolers: epidemiology, clinical spectrum and risk factors. Pediatr Allergy Immunol 2009;20:339-46. Crossref
2. Ho MH, Lee SL, Wong WH, Ip P, Lau YL. Prevalence of self-reported food allergy in Hong Kong children and teens—a population survey. Asian Pac J Allergy Immunol 2012;30:275-84.
3. Li PH, Wagner A, Rutkowski R, Rutkowski K. Vaccine allergy: a decade of experience from 2 large UK allergy centers. Ann Allergy Asthma Immunol 2017;118:729-31. Crossref
4. Centre for Health Protection, Department of Health, Hong Kong SAR Government. Frequently asked question on seasonal influenza vaccine 2015/16. Q14. Who should not receive inactivated seasonal influenza vaccination? Available from: http://www.chp.gov.hk/en/view_content/26837.html. Accessed 20 Nov 2017.
5. Moneret-Vautrin DA, Kanny G. Update on threshold doses of food allergens: implications for patients and the food industry. Curr Opin Allergy Clin Immunol 2004;4:215-9. Crossref
6. ASCIA Guidelines—Vaccination of the Egg-allergic Individual. Australian Society of Clinical Immunology and Allergy; 2017. Crossref
7. Centers for Disease Control and Prevention, Department of Health & Human Service, USA Government. Flu vaccine and people with egg allergies. Available from: https://www.cdc.gov/flu/protect/vaccine/egg-allergies.htm. Accessed 20 Nov 2017.
8. Greenhawt M, Turner PJ, Kelso JM. Administration of influenza vaccines to egg-allergic recipients: a practice parameter update 2017. Ann Allergy Asthma Immunol 2018;120:49-52. Crossref
9. Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2017-2018. Pediatrics 2017;140:e20172550. Crossref
10. British Society for Allergy & Clinical Immunology Paediatric Committee. 2015/16 Influenza vaccine recommendations for children with egg allergy. Available from: http://www.bsaci.org/Guidelines/Flu%20jab%20egg%20allergic%20kids.pdf. Accessed 20 Nov 2017.
11. Dreskin SC, Halsey NA, Kelso JM, et al. International Consensus (ICON): allergic reactions to vaccines. World Allergy Organ J 2016;9:32. Crossref
12. United Kingdom government. The Green Book. 2014. Available from: https://www.gov.uk/government/collections/immunisation-against-infectious-disease-thegreen-book. Accessed 20 Nov 2017.
13. Family Health Service. Department of Health. Hong Kong SAR Government. Hong Kong childhood immunization programme. Available from: http://www.fhs.gov.hk/english/main_ser/child_health/child_health_recommend.html. Accessed 20 Nov 2017.
14. Centers for Disease Control and Prevention. Vaccine safety—measles, mumps, rubella, and varicella vaccine. Available from: https://www.cdc.gov/vaccinesafety/vaccines/mmrv-vaccine.html. Accessed 20 Nov 2017.
15. American Academy of Pediatrics. Measles. In: Kimberlin DW, Brady MY, Hackson MA, editors. Red Books: 2015 Report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.
16. British Society for Allergy & Clinical Immunology. BSACI recommendations for combined measles, mumps and rubella (MMR) vaccination in egg-allergic children. 2007. Available from: http://www.bsaci.org/guidelines/mmreggrecommendations.pdf. Accessed 20 Nov 2017.

Recommendations on prevention and screening for colorectal cancer in Hong Kong

DOI: 10.12809/hkmj177095
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
MEDICAL PRACTICE  CME
Recommendations on prevention and screening for colorectal cancer in Hong Kong
Cancer Expert Working Group on Cancer Prevention and Screening (August 2016 to July 2018)
TH Lam, MD1; KH Wong, MB, BS, FHKAM (Medicine)2; Karen KL Chan, MBBChir, FHKAM (Obstetrics and Gynaecology)3; Miranda CM Chan, MB, BS, FHKAM (Surgery)4; David VK Chao, FRCGP, FHKAM (Family Medicine)5; Annie NY Cheung, MD, FHKAM (Pathology)6; Cecilia YM Fan, MB, BS, FHKAM (Family Medicine)7; Judy Ho, MB, BS, FHKAM (Surgery)8; EP Hui, MD (CUHK), FHKAM (Medicine)9; KO Lam, MB, BS, FHKAM (Radiology)10; CK Law, FHKCR, FHKAM (Radiology)11; WL Law, MS, FHKAM (Surgery)12; Herbert HF Loong, MB, BS, FHKAM (Medicine)13; Roger KC Ngan, FRCR, FHKAM (Radiology)14; Thomas HF Tsang, MB, BS, FHKAM (Community Medicine)15; Martin CS Wong, MD, FHKAM (Family Medicine)16; Rebecca MW Yeung, MD, FHKAM (Radiology)17; Anthony CH Ying, MB, BS, FHKAM (Radiology)18; Regina Ching, MB, BS, FHKAM (Community Medicine)19
1 School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong
2 Department of Health, Hong Kong
3 The Hong Kong College of Obstetricians and Gynaecologists, Hong Kong
4 Hospital Authority (Surgical), Hong Kong
5 The Hong Kong College of Family Physicians, Hong Kong
6 The Hong Kong College of Pathologists, Hong Kong
7 Professional Development and Quality Assurance, Department of Health, Hong Kong
8 World Cancer Research Fund Hong Kong, Hong Kong
9 Hong Kong College of Physicians, Hong Kong
10 Department of Clinical Oncology, The University of Hong Kong, Hong Kong
11 Hong Kong College of Radiologists, Hong Kong
12 The College of Surgeons of Hong Kong, Hong Kong
13 Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong
14 Hong Kong Cancer Registry, Hospital Authority, Hong Kong
15 Hong Kong College of Community Medicine, Hong Kong
16 The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong
17 Hospital Authority (Non-surgical), Hong Kong
18 The Hong Kong Anti-Cancer Society, Hong Kong
19 Centre for Health Protection, Department of Health, Hong Kong
 
Corresponding author: Dr Regina Ching (regina_ching@dh.gov.hk)
 
 Full paper in PDF
 
Abstract
Colorectal cancer is the commonest cancer in Hong Kong. The Cancer Expert Working Group on Cancer Prevention and Screening was established in 2002 under the Cancer Coordinating Committee to review local and international scientific evidence, assess and formulate local recommendations on cancer prevention and screening. At present, the Cancer Expert Working Group recommends that average-risk individuals aged 50 to 75 years and without significant family history consult their doctors to consider screening by: (1) annual or biennial faecal occult blood test, (2) sigmoidoscopy every 5 years, or (3) colonoscopy every 10 years. Increased-risk individuals with significant family history such as those with a first-degree relative diagnosed with colorectal cancer at age ≤60 years; those who have more than one first-degree relative diagnosed with colorectal cancer irrespective of age at diagnosis; or carriers of genetic mutations associated with familial adenomatous polyposis or Lynch syndrome should start colonoscopy screening earlier in life and repeat it at shorter intervals.
 
 
 
Introduction
In Hong Kong, the Cancer Coordinating Committee is a high-level committee chaired by the Secretary for Food and Health to steer the direction of work on prevention and control of cancer. Under the Cancer Coordinating Committee, the Cancer Expert Working Group (CEWG) on Cancer Prevention and Screening was established in 2002 to review local and international scientific evidence and practices with a view to making recommendations on cancer prevention and screening suitable for Hong Kong.
 
This article details the local burden and prevention of colorectal cancer (CRC), and explains the rationale underpinning the current CEWG recommendations on CRC screening, which were reaffirmed and updated in 2017.
 
Local epidemiology
Colorectal cancer is the commonest cancer in Hong Kong. According to the Hong Kong Cancer Registry, there were 5036 newly registered CRC cases in 2015, representing 16.6% of all new cancer cases.1 The age-standardised incidence rates were 41.5 per 100 000 population for men and 26.2 per 100 000 population for women.1 The median age at diagnosis of CRC was 68 years in men and 70 years in women.1 The age-specific incidence rates increased significantly from age 50 years. Colorectal cancer is more common in men with the male-to-female ratio of 1.3:1 for new cases in 2015.1
 
The Death Registry registered 2089 deaths caused by CRC in 2016, representing 14.7% of all cancer deaths and ranking it the second leading cause of cancer deaths in Hong Kong.2 The age-standardised mortality rates were 18.0 per 100 000 population for men and 10.5 per 100 000 population for women.2 After adjusting for the effect of population ageing, the age-standardised incidence rates for both sexes still showed an upward trend, whereas the age-standardised mortality rates for both sexes have remained stable for more than 30 years.2
 
Risk factors
Risk factors for developing CRC may be modifiable or non-modifiable. Modifiable risk factors are those that are related to lifestyle, such as physical inactivity, low fibre intake, consumption of red meat or processed meat, overweight or obesity, smoking, and alcohol use. The World Health Organization’s International Agency for Research on Cancer classifies consumption of processed meat as “carcinogenic to humans (Group I),” and consumption of red meat as “probably carcinogenic to humans (Group 2A)” and indicated that every 50-g portion of processed meat eaten daily increases the risk of CRC by about 18%.3 Conversely, the risk of CRC is inversely associated with intake of fibre.4 In addition, the International Agency for Research on Cancer considered that there is sufficient evidence to classify alcoholic beverage and tobacco smoking as carcinogenic to humans in the development of CRC.5 Separately, the World Cancer Research Fund/American Institute for Cancer Research reported that being overweight or obese can increase the risk of CRC, whereas increased physical activity is associated with reduction in risk.6
 
Non-modifiable risk factors include ageing, male gender, positive family history, history of familial adenomatous polyposis, Lynch syndrome (previously known as hereditary non-polyposis CRC), colonic polyp, and ulcerative colitis.
 
Based on local epidemiology, CRC is more common in men and its risk increases significantly from age 50 years.1 Regarding family history, according to a local study, 80% to 90% of CRC cases are sporadic, and the remaining 10% to 20% are familial cancers.7 The cancer risk of individuals with a positive family history may vary according to the age of diagnosis of CRC in the index patient and the number of affected first-degree relatives. The younger the age of diagnosis of CRC in the index patient, the higher the risk of CRC of family members would be. In a meta-analysis, the estimated relative risk of individuals with relatives diagnosed with CRC at age <50 years was 3.55, whereas that for relatives diagnosed with CRC at age ≥50 years was 2.18.8
 
Familial adenomatous polyposis is an autosomal dominant disorder caused by germline mutation of the adenomatous polyposis coli gene located on the short arm of chromosome 5 (5q21-22).9 Individuals with this mutation have a 95% chance of developing CRC by age 50 years.10 Lynch syndrome is another dominantly inherited CRC syndrome. It is caused by germline mutation in one of the genes responsible for the repair of mismatches during DNA replication. The lifetime risk of CRC for those carrying this mutation is estimated to be 50% to 80%.10
 
Ulcerative colitis has been associated with an increased risk of developing CRC, likely caused by long-standing chronic inflammation.11 Moreover, CRC arises predominantly from adenomatous polyps, which can develop into CRC after ≥10 years.12 Development of larger polyps, villous histology, and severe dysplasia are important indicators for progression into CRC.13
 
Primary prevention
Primary prevention is of utmost importance for the prevention of CRC as many of the risk factors are modifiable. For preventing CRC, the CEWG recommends:
  • increasing intake of dietary fibre (eg, fibre from at least five servings of fruits and vegetables daily);
  • decreasing consumption of red and processed meat;
  • taking part in moderate-intensity aerobic physical activities for ≥150 minutes per week;
  • maintaining a healthy body weight with body mass index between 18.5 to 22.9 and waist circumference <80 cm for women and <90 cm for men;
  • avoiding or quitting tobacco smoking; and
  • avoiding alcoholic drinks.
  •  
    Secondary prevention
    Secondary prevention involves screening individuals without symptoms in order to detect disease or identify individuals who are at increased risk of disease. Since CRC arises predominantly from precancerous adenomatous polyps developed over a long latent period, it is one of the few cancers that can be effectively prevented through organised and evidence-based screening. In general, for CRC screening, individuals can be classified into “average risk” and “increased risk” groups.
     
    According to screening recommendations made by the CEWG, increased-risk individuals are those with a significant family history, such as an immediate relative diagnosed with CRC at age ≤60 years; more than one immediate relatives diagnosed with CRC irrespective of age at diagnosis; or immediate relatives diagnosed with hereditary bowel diseases. Average-risk individuals are those aged 50 to 75 years who do not have the aforesaid family history.
     
    Screening for general population at average risk
    Since 2010, the CEWG has recommended that average-risk individuals aged 50 to 75 years should consult their doctors to consider one of the following screening methods:
  • annual or biennial faecal occult blood test (FOBT);
  • sigmoidoscopy every 5 years; and
  • colonoscopy every 10 years.
  •  
    The CEWG made the above recommendations after taking into consideration local epidemiology, research evidence, as well as international guidelines and practices.
     
    The age range recommended for CRC screening in the general population should be defined to capture the largest number of CRC cases while taking into account the efficacy and cost-effectiveness of screening tests, local epidemiology, and anticipated benefits and harms to the screened population. In Hong Kong, the risk of CRC increases significantly from age 50 years.1 Guidelines in US14 15 and Singapore16 recommend starting screening at age 50 years, whereas guidelines in the UK recommend starting screening at age >50 years.17
     
    Regarding screening modalities, FOBT, sigmoidoscopy and colonoscopy have been shown to reduce mortality from CRC. Faecal occult blood tests can decrease CRC mortality by 15% to 33%, according to findings from large-scale randomised control trials.18 19 20 A Cochrane review showed that screening by FOBT might reduce CRC mortality in the average risk population by 16%.21 Sigmoidoscopy has been shown to lead to a 28% risk reduction in overall CRC mortality and a 43% risk reduction in distal CRC mortality in a meta-analysis.22 Colonoscopy was associated with 61% reduction in CRC mortality in another meta-analysis.23
     
    International guidelines and practices for CRC screening in the general population mainly recommend annual or biennial FOBT, sigmoidoscopy once every 5 years, or colonoscopy once every 10 years.15 16
     
    To reduce the burden arising from CRC, the government launched the 3-year Colorectal Cancer Screening Pilot Programme (Pilot Programme) on 28 September 2016 to provide subsidised screening by phases to average risk Hong Kong residents born in 1946 to 1955 (aged 61-70 years in 2016). The screening workflow comprises two stages. Participants first receive a subsidised faecal immunochemical test (a new version of FOBT) from an enrolled primary care doctor. If the faecal immunochemical test result is positive, the participant receives a subsidised colonoscopy examination from a colonoscopy specialist enrolled in the Pilot Programme. In August 2018, the government regularised the programme and would progressively extend it to cover individuals aged 50 to 75 years. Details are available at http://www.colonscreen.gov.hk.
     
    Screening for increased-risk individuals
    In 2017, the CEWG updated the CRC screening recommendations for increased-risk individuals. The key change was related to the interval for colonoscopy screening among individuals with significant family history of CRC but without genetic mutations.
  • For carriers of genetic mutations associated with Lynch syndrome, the CEWG recommends screening for CRC by colonoscopy every 1 to 2 years from age 25 years.
  • For carriers of genetic mutations associated with familial adenomatous polyposis, the CEWG recommends screening by sigmoidoscopy every 2 years from age 12 years.
  • For individuals with one first-degree relative (offspring, sibling or parent) diagnosed with CRC at age ≤60 years, or more than one first-degree relative with CRC irrespective of age at diagnosis, colonoscopy should be performed every 5 years (previously the recommendation was every 3 to 5 years). Colonoscopy should begin at age 40 years or 10 years prior to the age at diagnosis of the youngest affected relative, whichever is earliest, but not earlier than age 12 years.
  •  
    For patients with CRC with identifiable genetic mutations, including Lynch syndrome and familial adenomatous polyposis, the CEWG recommends two-tier screening for their family members. Genetic testing should be conducted first, followed by endoscopic examination at specified and shorter intervals if the genetic test is positive. This reduces the number of unnecessary investigations among those with strong family history but without proven genetic mutation, decreasing the risk of potential complications arising from repeated endoscopic procedures.
     
    These recommendations were made after considering the scientific evidence and international guidelines and practices.
     
    Individuals who are carriers of genetic mutations associated with familial adenomatous polyposis or Lynch syndrome and individuals with a family history of CRC are at increased risk of CRC. Colorectal cancer in these individuals tends to be diagnosed at a younger age and progresses more aggressively than CRC in the general population.24 25
     
    International recommendations emphasise that CRC screening in increased-risk individuals needs to start earlier in their lifetime and be repeated at shorter intervals. Recommendations made by countries and by professional organisations on screening for increased-risk individuals generally suggest the use of colonoscopy and sigmoidoscopy as the screening methods.15 16 26 27 28 29 30 31 32
     
    The recommended endoscopic screening method for carriers of genetic mutations associated with Lynch syndrome is annual or biennial colonoscopy. It is recommended to start screening at age 20 to 25 years in the US15 26 27 and Singapore,16 at age 25 years in UK,28 and at age 25 years or 5 years earlier than the age at diagnosis of the youngest affected member of the family (whichever is the earliest) in Australia.29 The guidelines issued by the World Gastroenterology Organization (WGO) recommend that screening should start at age 20 to 25 years or 10 years earlier than the youngest age at CRC diagnosis in the family, whichever comes first.30
     
    The recommended endoscopic screening method for carriers of genetic mutations associated with familial adenomatous polyposis is mainly annual or biennial flexible sigmoidoscopy, or annual colonoscopy. It is recommended to start screening at age 10 to 12 years in the US15 and Singapore,16 at age 13 to 15 years in the UK,28 and at age 12 to 15 years (later age is recommended) in Australia.29 The guidelines issued by the National Comprehensive Cancer Network suggest screening should start at age 10 to 15 years,31 32 whereas the WGO recommendation is to start screening at age 10 to 12 years.30
     
    International guidelines recommend endoscopic screening for individuals who have one first-degree relative diagnosed with CRC at age 50 to 60 years.15 16 26 28 29 30 31 32 33 Individuals with more than one first-degree relative with CRC irrespective of age at diagnosis are considered at increased risk and endoscopic screening at more frequent intervals is recommended.15 16 26 28 29 30 31 32 For these individuals, the recommended endoscopic screening method is to receive colonoscopy every 5 years.15 16 26 29 30 31 32 It is recommended to start screening at age 40 to 50 years, or 10 years prior to the age at diagnosis of the youngest affected relative.15 16 26 29 30 31 32
     
    Currently, patients with CRC may be referred for genetic counselling and testing. These services are provided at centres run by non-governmental organisation, including the Hereditary Gastrointestinal Cancer Genetic Diagnosis Laboratory (http://www.patho.hku.hk/colonreg.htm); the Department of Health’s Clinical Genetic Service (http://www.dh.gov.hk); and the private sector. Although referral criteria for testing may differ among these testing services, commonly adopted criteria include strong family history, occurrence of multiple cancers in a single individual, early onset of disease, presence of pathogenic mutation in the cancer predisposition gene, and clinically suspected hereditary cancer syndrome.
     
    Emerging evidence for colorectal cancer screening
    In the past 2 years, new evidence supporting the effectiveness of CRC screening has emerged which reinforces the CEWG recommendations.
     
    A systematic review reported that sigmoidoscopy is associated with a 27% reduction in CRC-specific mortality in four randomised controlled trials and that biennial FOBT screening reduced CRC-specific mortality by 9% to 22% at 19.5 to 30 years of follow-up in five randomised controlled trials compared with no screening in the average-risk population.34 35
     
    Separately, a prospective study in Sweden found that colonoscopic surveillance for increased-risk individuals with significant family history is a cost-effective intervention to prevent CRC.36
     
    In addition, the US Preventive Services Task Force,37 the US Multi-Society Task Force on Colorectal Cancer Screening,38 and the American Cancer Society39 40 updated their recommendations for CRC screening in 2016 and 2017. All continue to recommend annual FOBT, sigmoidoscopy every 5 to 10 years, or colonoscopy every 10 years as appropriate screening modalities for average-risk individuals.
     
    Conclusion
    After considering local epidemiology, scientific evidence, and local and international screening guidelines and practices, the CEWG reaffirms in 2017 the CRC screening recommendations for average-risk individuals and updates the screening interval relating to the recommendations for increased-risk individuals with significant family history of CRC, as summarised in the Table. A leaflet and booklet on the CEWG recommendations are available (http://www.chp.gov.hk/en/content/9/25/31932.html) for downloading and dissemination to the general public to help them make informed choices. The CEWG will continue to monitor emerging local and international evidence and practice to ensure evidence-based CRC prevention and screening recommendations are up to date.
     

    Table. Recommendations on CRC screening by the CEWG
     
    Author contributions
    All authors have made substantial contributions to the concept or design; acquisition of data; analysis or interpretation of data; drafting of the article; and critical revision for important intellectual content.
     
    Declaration
    As editors of this journal, DVK Chao, HHF Loong, and MCS Wong were not involved in the peer review process of this article. All authors have no conflicts of interest to disclose. All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity. An earlier version of this article was published online on the Centre for Health Protection website (https://www.chp.gov.hk/files/pdf/cewg_crc_professional_hp.pdf).
     
    References
    1. Hong Kong Cancer Registry. Colorectal cancer in 2015. 2016. Available from: http://www3.ha.org.hk/cancereg/pdf/factsheet/2015/colorectum_2015.pdf. Accessed 31 Oct 2017.
    2. Department of Health and Census and Statistics Department, Hong Kong SAR Government. Mortality Statistics; 2016.
    3. World Health Organization. Q&A on the carcinogenicity of the consumption of red meat and processed meat. 2015. Available from: http://www.who.int/features/qa/cancerred-meat/en/. Accessed 6 Sep 2017.
    4. Bradbury KE, Appleby PN, Key TJ. Fruit, vegetable, and fiber intake in relation to cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Clin Nutr 2014;100(Suppl l):394S-398S. Crossref
    5. International Agency for Research on Cancer, World Health Organization. List of classifications by cancer sites with sufficient or limited evidence in humans, Vol 1 to 121. 2018. Available from: https://monographs.iarc.fr/ENG/Classification/Table4.pdf. Accessed 6 Sep 2017.
    6. World Cancer Research Fund and American Institute for Cancer Research. Diet, Nutrition, Physical Activity and Colorectal Cancer. World Cancer Research Fund International; 2017.
    7. Ho JW, Yuen ST, Lam TH. A case-control study on environmental and familial risk factors for colorectal cancer in Hong Kong: chronic illnesses, medication and family history. Hong Kong Med J 2006;12(Suppl 1):S14-6.
    8. Butterworth AS, Higgins JP, Pharoah P. Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. Eur J Cancer 2006;42:216-27. Crossref
    9. Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. Orphanet J Rare Dis 2009;4:22. Crossref
    10. Samadder NJ, Jasperson K, Burt RW. Hereditary and common familial colorectal cancer: evidence for colorectal screening. Dig Dis Sci 2015;60:734-47. Crossref
    11. Castaño-Milla C, Chaparro M, Gisbert JP. Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther 2014;39:645-59. Crossref
    12. Winawer SJ. Natural history of colorectal cancer. Am J Med 1999;106:3S-6S. Crossref
    13. Terry MB, Neugut AI, Bostick RM, et al. Risk factors for advanced colorectal adenomas: a pooled analysis. Cancer Epidemiol Biomarkers Prev 2002;11:622-9.
    14. Agency for Healthcare Research and Quality, Department of Health & Human Services, US Government. US Preventive Services Task Force. Screening for Colorectal Cancer: Summary of Recommendations. October 2008. Available from: http://www.ahrq.gov/clinic/uspstf/uspscolo.htm. Accessed 8 Oct 2008.
    15. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008;58:130-60. Crossref
    16. Ministry of Health, Singapore Government. Cancer Screening: MOH Clinical Practice Guidelines 1/2010, February 2010.
    17. The UK NSC recommendation on bowel cancer screening. Available from: https://legacyscreening.phe.org.uk/bowelcancer. Accessed 10 Sep 2018.
    18. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7. Crossref
    19. Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-71. Crossref
    20. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota colon cancer control study. N Engl J Med 1993;328:1365-71. Crossref
    21. Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev 2007;(1):CD001216.
    22. Shroff J, Thosani N, Bartra S, Singh H, Guha S. Reduced incidence and mortality from colorectal cancer with flexible-sigmoidoscopy screening: a meta-analysis. World J Gastroenterol 2014;20:18466-76. Crossref
    23. Pan J, Xin L, Ma YF, Hu LH, Li ZS. Colonoscopy reduces colorectal cancer incidence and mortality in patients with non-malignant findings: a meta-analysis. Am J Gastroenterol 2016;111:355-65. Crossref
    24. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997;112:594-642. Crossref
    25. Rose P, Dunlop M, Burton H, Haites N. Screening for late onset genetic disorders colorectal cancer. The UK National Screening Committee; October 2000.
    26. Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. American J Gastroenterol 2009;104:739-50. Crossref
    27. Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol 2014;109:1159-79. Crossref
    28. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010;59:666-89. Crossref
    29. National Health and Medical Research Council, Australia Government. Clinical Practice Guidelines: The Prevention, Early Detection and Management of Colorectal Cancer; December 2005.
    30. Winawer S, Classen M, Lambert R, et al. World Gastroenterology Organisation/International Digestive Cancer Alliance Practice Guidelines: Colorectal Cancer Screening. South African Gastroenterology Review 2008;6.
    31. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer Version 2; 2016.
    32. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer Version 1; 2017.
    33. Sung JJ, Ng SC, Chan FK, et al. An updated Asia Pacific consensus recommendations on colorectal cancer screening. Gut 2015;64:121-32. Crossref
    34. Lin JS, Piper MA, Perdue LA, et al. Screening for colorectal cancer: updated evidence report and systematic review for the US preventive services task force. JAMA 2016;315:2576-94. Crossref
    35. Lin JS, Piper MA, Perdue LA, et al. Screening for colorectal cancer: a systematic review for the US preventive services task force. Evidence synthesis No. 135. Agency for Healthcare Research and Quality; 2016.
    36. Sjöström O, Lindholm L, Melin B. Colonoscopic surveillance—a cost-effective method to prevent hereditary and familial colorectal cancer. Scand J Gastroenterol 2017;52:1002-7. Crossref
    37. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Screening for colorectal cancer: US preventive services task force recommendation statement. JAMA 2016;315:2564-75. Crossref
    38. Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the US multi-society task force on colorectal cancer. Gastroenterology 2017;153:307-23. Crossref
    39. American Cancer Society. American Cancer Society recommendations for colorectal cancer early detection. July 2017. Available from: https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/acsrecommendations.html. Accessed 6 Sep 2017.
    40. Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2017: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2017;67:100-21. Crossref

    Joint recommendations on management of anaemia in patients with gastrointestinal bleeding in Hong Kong

    DOI: 10.12809/hkmj187348
    © Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
     
    MEDICAL PRACTICE  CME
    Joint recommendations on management of anaemia in patients with gastrointestinal bleeding in Hong Kong
    LY Mak, MB, BS1,2; CW Lau, MB, BS3; YT Hui, MB, BS2; C Ng, MB, BS2; E Shan, MB, BS2; Michael KK Li, MB, BS2; James YW Lau, MD4; Philip WY Chiu, MD4; HT Leong, MB, BS4; J Ho, MD1; Justin CY Wu, MD1; CK Lee, MB, BS3; WK Leung, MD1,2
    1 Hong Kong Society of Gastroenterology
    2 Hong Kong IBD Society
    3 Hong Kong Red Cross Blood Transfusion Service
    4 Hong Kong Society of Digestive Endoscopy
     
    Corresponding author: Prof WK Leung (waikleung@hku.hk)
     
     Full paper in PDF
     
    Abstract
    The demand for blood products continues to grow in an unsustainable manner in Hong Kong. While anaemia associated with gastrointestinal bleeding (GIB) is the leading indication for transfusion, there is no local recommendation regarding best practices for transfusion. We aimed to provide evidence-based recommendations regarding management of anaemia in patients with acute and chronic GIB. We reviewed all original papers, meta-analyses, systematic reviews, or guidelines that were available in PubMed. For acute GIB, a restrictive transfusion strategy, targeting a haemoglobin threshold of 7 to 8 g/dL, should be adopted because overtransfusion is associated with significantly higher all-cause mortality and re-bleeding. A liberal transfusion strategy should only be considered in patients with co-existing symptomatic coronary artery disease, targeting a haemoglobin threshold of 9 to 10 g/dL. When acute GIB settles, patients should be prescribed iron supplements if iron deficiency is present. For chronic GIB, iron stores should be replenished aggressively via iron supplementation before consideration of blood transfusion, except in patients with symptoms of severe anaemia. Oral iron replacement is the preferred first-line therapy, while intravenous iron is indicated for patients with inflammatory bowel disease, poor response or poor tolerability to oral iron, and in whom a rapid correction of iron deficit is preferred. Intravenous iron is underutilised and the risk of anaphylactic reaction to current preparations is extremely low. These recommendations are provided to local clinicians to facilitate judicious and appropriate use of red cell products and iron replacement therapy in patients with GIB.
     
     
     
    Introduction
    Gastrointestinal bleeding (GIB) is a leading indication for blood transfusion in Hong Kong. In a recent report issued by The Hong Kong Red Cross Blood Transfusion Service, 242 379 units of red cells (RBCs) were issued in 2016, an increase of 34% from 2006. More than 90% of blood products were used by patients in public hospitals; more than 70% of RBCs were utilised in medical/geriatric and surgery departments.1 Blood demand is expected to continue rising because of the ageing population, in whom the highest amount of blood was used, compared with younger age-groups. The respective units of blood use per 1000 person-years were: 0 to 14 years (8.0), 15 to 64 years (17.5), 65 to 74 years (58.4), 75 to 84 years (117.7) and ≥85 years (209.3).1 Importantly, compared with many western countries, Hong Kong is using more RBCs per population. In 2016, Hong Kong used 33.0 units of RBCs per 1000 population, compared with 20.7 in Singapore, 25.3 in Japan, 19.0 in Western Australia, 23.5 in New Zealand, 28.5 in England and North Wales, and 20.8 in Canada (unpublished data from Hong Kong Red Cross Blood Transfusion Service). Possible explanations for lower usages in other nations include the adoption of restrictive transfusion practices and more frequent utilisation of iron replacement therapy. With the continuously rising demand for blood products in Hong Kong, unmatched by a corresponding increase in blood donors, there is a pressing need to institute sustainable transfusion practices, such that blood products can be used appropriately.
     
    In addition to the inadequate supply of blood products, transfusion is not without risks. Approximate risks per unit of RBC transfusion are 1:60 for febrile reaction, 1:100 for transfusion-associated circulatory overload, 1:250 for allergic reaction, and 1:12 000 for transfusion-related acute lung injury. In Hong Kong, the most recent estimated risks for transmission of hepatitis B virus (1:58 000), hepatitis C virus (1:8 000 000), and human immunodeficiency virus (1:2 400 000) are not negligible.2 3 4 5 6 7 8 9 10 There are additional risks of overtransfusion. Hence, blood transfusion should be instituted appropriately with good indications which should outweigh the potential risks.
     
    Because of these issues and the lack of standardisation of local clinical practices for blood transfusion, the aim of this joint recommendation paper by the Hong Kong Society of Gastroenterology, the Hong Kong IBD Society, the Hong Kong Society of Digestive Endoscopy, and the Hong Kong Red Cross Blood Transfusion Service was to provide evidence-based recommendations for the management of anaemia in patients with acute and chronic GIB; this will facilitate more judicious and appropriate use of RBC products, as well as other alternative measures to control anaemia resulting from GIB.
     
    Types of gastrointestinal bleeding
    Gastrointestinal bleeding can be classified on the basis of the speed of blood loss, site of bleeding (upper or lower GIB), or aetiology of bleeding. For the purpose of this recommendation paper, only the speed of blood loss (ie, acute or chronic) is considered. Acute GIB, also known as overt GIB, is defined as frank bleeding from the gastrointestinal tract, with or without iron deficiency. Clinically visible bleeding typically presents as haematemesis, coffee-ground vomiting, melena or haematochezia. Conversely, chronic GIB, also known as occult bleeding, is defined as guaiac positive stool accompanying iron deficiency.11 12 13 In this group of patients, blood is not visible macroscopically; they are typically managed in an out-patient setting. Iron deficiency is inevitable in this context of blood loss, because every 1 mL of blood contains 0.5 mg of elemental iron; a decrease of 1 g/dL haemoglobin results in approximately 200 mg elemental iron loss.
     
    Some patients present with acute massive exsanguinating GIB, where life-saving blood transfusion is essential. There are no universally accepted definitions for massive exsanguinating GIB. Some trials have defined it as the need for transfusion of at least 4 units of blood during a period of 24 hours in-hospital, or hypotension with systolic blood pressure <90 mm Hg.14 In the acute care setting, massive bleeding is defined as 50% blood volume loss within 3 hours, or a rate of 150 mL per minute. In patients with haemodynamic instability, initial resuscitation is the primary goal and blood transfusion is often dictated by haemodynamic status, including the degree of depletion of intravascular volume and clinical signs of organ hypoperfusion. Thus, these patients are excluded from clinical trials of transfusion strategies, as discussed in the following sections, and should be managed accordingly.
     
    Acute gastrointestinal bleeding
    Transfusion strategies
    The haemoglobin threshold below which RBC transfusion should be given has been controversial. Older observational studies and smaller controlled trials suggested that transfusion may be harmful for patients with hypovolemic anaemia due to GIB.15 16 17 18 19 Recently, increasing evidence from randomised controlled trials has suggested that a restrictive transfusion strategy is preferred in patients with acute GIB.2 3 20 In most trials, a restrictive transfusion strategy has referred to a haemoglobin threshold of 7 to 8 g/dL, whereas a threshold of 9 to 10 g/dL is used in liberal transfusion strategy. A restrictive transfusion strategy has been associated with significantly lower short-term mortality. In a study by Villanueva et al,3 the hazard ratio (HR) for death at 6 weeks was lower in the restrictive strategy group than in the liberal strategy group (HR=0.55; 95% confidence interval [CI]=0.33-0.92; P=0.002). Moreover, re-bleeding risk was significantly lower for the restrictive transfusion group than the liberal transfusion group (10% vs 16%, respectively; P=0.01; HR=0.68; 95% CI=0.47-0.98).3 In a subgroup of patients with cirrhosis, the survival advantage conferred by a restrictive transfusion strategy remained for those with Child-Pugh class A or B disease (HR=0.30; 95% CI=0.11-0.85). Additionally, a restrictive transfusion strategy is not associated with harm in terms of risks of myocardial infarction, pulmonary oedema, stroke, pneumonia, or thromboembolism. In a meta-analysis of four randomised controlled trials that examined this issue, restrictive transfusion was associated with a lower risk of all-cause mortality (relative risk [RR]=0.65, 95% CI=0.44-0.97; P=0.03) and a lower overall re-bleeding rate (RR=0.58, 95% CI=0.40-0.80; P=0.004).21 It has become clear that a restrictive transfusion strategy should be adopted for acute GIB; this is currently recommended in many international guidelines.22 23 24 25
     
    The above recommendation includes exceptions where a more liberal transfusion strategy should be adopted. This is particularly true for patients with concurrent symptomatic coronary artery disease. It is estimated that up to 14% of patients with acute upper GIB exhibit coexisting coronary artery disease.26 In a prior analysis, these patients showed greater risk of death, myocardial infarction or unscheduled revascularisation at 30 days if a restrictive transfusion strategy (haemoglobin threshold of 8 g/dL) was adopted, compared with a liberal transfusion strategy (haemoglobin threshold of 10 g/dL) [25.5% vs 10.9%, respectively, risk difference=15%, 95% CI=0.7-29.3%; P=0.054].27
     
    Haemostasis
    Ongoing bleeding should be controlled whenever possible, including endoscopic, radiographic or surgical interventions to reduce the blood loss and hence, transfusion requirement.22 23 Correction of coagulopathy and use of antifibrinolytic agents should be considered in appropriate cases. For patients who are using antithrombotic or anticoagulant therapies, specific reversal agents can be considered. Ideally, a multidisciplinary team including a haematologist, cardiologist, neurologist, and gastroenterologist or surgeon should be involved to ensure the best decision regarding discontinuation of medications or the use of reversal agents after balancing risk of bleeding versus risk of thromboembolic events.22
     
    Iron therapy after initial haemostasis
    Patients with acute GIB typically exhibit iron-deficiency anaemia. Although haemoglobin <10 g/dL was associated with doubling of short-term mortality,28 iron replacement therapy should be considered in stable patients with borderline low haemoglobin, rather than blood transfusion. In a randomised controlled trial, oral or intravenous iron supplementation significantly reduced the proportion of patients with anaemia at 3 months after acute GIB.29 Unfortunately, this was often underutilised and only 16% of patients with acute GIB were prescribed with iron supplements upon discharge.30
     
    Chronic gastrointestinal bleeding
    Replenishing the iron store
    Iron deficiency should always be corrected by iron replacement before consideration of blood transfusion in the context of chronic GIB. Adults typically have approximately 50 mg/kg of total bodily elemental iron; two thirds is stored in haem and one third is stored in the form of ferritin or haemosiderin. Approximately 20 mg of iron is recycled daily in the bone marrow and spleen to maintain haem synthesis, and approximately 1 to 2 mg/day of additional dietary iron is needed to balance losses in urine, sweat, and stool. Assuming absorption of 10% of iron in the medicinal form, the daily elemental iron requirement is approximately 10 mg; this requirement is higher for menstruating women and pregnant mothers.31 32 Dietary iron is present in two main forms. Haem iron is found in meat-based foods and fish. Absorption of haem iron is independent of body iron status. Non-haem iron is found in plant-based foods, cereals, or egg yolks. Absorption of non-haem iron, in contrast to haem iron, is enhanced if the body’s iron store declines. It is absorbed in its ferrous form in the duodenum and proximal jejunum; therefore, an acidic environment favours iron absorption. Another important molecular mechanism of iron absorption involves hepcidin, which regulates ferroportin-mediated release of iron from enterocytes and macrophages. In a chronic inflammatory state, hepcidin is increased and negatively regulates iron homeostasis.33
     
    In patients with iron-deficiency anaemia, the daily recommended iron requirement substantially increases to 150 to 200 mg elemental iron per day to replenish the deficit; approximately 4 weeks are needed to fully correct the iron deficit.32 Iron replacement therapy is indicated in these patients, because dietary iron intake alone is unlikely to replace this deficit. The Ganzoni equation is used in some studies to estimate the iron deficit as follows: iron deficit (mg) = body weight (kg) × [target haemoglobin (g/dL) − actual haemoglobin (g/dL)] × 2.4 + 500 mg.34 However, many clinicians view this formula as inconvenient and may underestimate iron deficit35; therefore, it is not widely used in clinical practice. A simplified fixed-dose regimen, as used for treatment of patients with inflammatory bowel disease (IBD), may be considered for iron replacement (Table 1).36
     

    Table 1. Simplified scheme for estimation of total iron requirements based on body weight and haemoglobin level36
     
    Route and dosing of iron replacement therapy
    Iron replacement can be administered in either oral or intravenous form. In most cases, the oral route remains first-line treatment because of its convenience, low cost and avoidance of hospitalisation, as well as the potential risks of anaphylactic reaction with intravenous iron. However, gastrointestinal upset, such as nausea and constipation, is very common with oral iron replacement, which decreases patient compliance. Additionally, this method requires a few weeks or months to replenish depleted iron stores in the body. To further complicate treatment, oral iron therapy is ineffective in a few clinical situations. First, in patients with chronic inflammation, hepcidin is upregulated and exerts a negative effect on intestinal iron absorption. Second, in patients with achlorhydria (eg, those undergoing long-term treatment with proton pump inhibitors), or a history of vagotomy or gastric bypass, the acidic gastric environment that maintains the ferrous state of iron is lost; thus, absorption is largely impaired. Other causes of poor response to oral iron replacement include small bowel malabsorption (eg, IBD, prior small bowel resection, or celiac disease) and co-administration of iron with coffee or tea. In particular, IBD patients with iron-deficiency irondeficiency anaemia are recommended to receive intravenous iron as first-line therapy, because of its greater effectiveness than oral iron.37 The “Day-14 haemoglobin”, ie, increase in haemoglobin by ≥1 g/dL on day 14 after oral iron therapy, is a useful tool to determine whether and when to transit from oral to intravenous iron.
     
    Because of the above caveats related to oral iron replacement, intravenous iron replacement can be considered as an alternative. Intravenous iron may also be considered in accordance with patient preference, as some patients cannot tolerate the adverse effects of oral iron or prefer rapid correction of iron deficiency. An older preparation of intravenous iron, in the form of high-molecular-weight iron dextran, was underutilised in the past because of potential anaphylactic reactions. However, this preparation has been removed from the US and Europe. In recent years, the safety of intravenous iron has been vastly improved by newer well-tolerated preparations, such as iron sucrose and iron isomaltoside. According to the US Food and Drug Administration, the cumulative rate of serious adverse reactions is <1:200 000 with different intravenous compounds (iron sucrose, ferric gluconate and low-molecular-weight iron dextran).38 39 Intravenous iron is now generally considered safe and more effective than oral preparations.40 41 42
     
    Table 2 shows the recommended dosing of commonly used preparations of oral and intravenous iron replacement available in Hong Kong.43 A 300-mg iron sulphate tablet contains 20% to 30% elemental iron. Typical dosing of an oral iron sulphate tablet would be 300 mg administered twice daily, which would supply approximately 120 to 180 mg of elemental iron to the patient. However, the recommended dosing for patients with IBD might be lower. According to the European Crohn’s and Colitis Organisation Consensus, no more than 100 mg elemental iron per day should be administered to patients with IBD, as a result of a few preclinical or early reports of the adverse effects of oral iron on exacerbation of disease activity, carcinogenesis, and alteration of intestinal microbiota.37 The benefits of lower iron dosing are not limited to IBD patients. A recent randomised unblinded trial showed that alternate daily dosing of iron is superior to daily dosing of iron in terms of efficacy (specifically related to hepcidin regulation) and tolerability.44 Most oral preparations of iron replacement therapy are equally effective, as long as compliance is ensured. Liquid preparations may minimise gastrointestinal upset and avoid the risk of iron tablet–induced gastric erosion.45 46 Co-administration of oral iron with ascorbic acid is advocated by some experts because of the theoretical enhancement of iron absorption by reduction of ferric iron to the ferrous form.47 Indeed, oral ascorbic acid administration was associated with a dose-dependent increase of oral iron absorption in healthy volunteers.48 Although large-scale studies of patients with iron-deficiency anaemia are lacking, oral ascorbic acid is well tolerated and may be considered for concomitant administration with oral iron.
     

    Table 2. Recommended dosing of oral and intravenous iron replacement therapies commonly used in Hong Kong
     
    Intravenous iron can be considered as first choice in patients with a high probability of non-compliance, small bowel malabsorption, severe anaemia, or multiple co-morbidities that affect hepcidin-regulated iron absorption. There are two preparations of intravenous iron commonly available in Hong Kong: iron sucrose (Venofer®, American Regent, Inc, New York, US) and iron isomaltoside (Monofer®, Pharmacosmos, Denmark). Monofer® can be administered at a maximum of 20 mg/kg or 1000 mg per single dose weekly. Premedication to prevent anaphylaxis is not routinely needed, but patients should be monitored for at least 30 minutes after drug administration.
     
    Blood transfusions should not be routinely used in chronic GIB and are reserved for patients with severe anaemic symptoms, where blood transfusion would provide rapid relief of the symptoms. Typically, 1 unit of RBC provides approximately 200 mg elemental iron, which would increase haemoglobin by 1 g/dL.
     
    Further management
    Whenever possible, the source of bleeding should be identified, with haemostasis secured to prevent continuous blood loss. It may remain difficult in some cases of obscure bleeding, or with multiple sites of bleeding (eg, multiple small bowel angiodysplasia). Clinicians should always maintain awareness of other potential causes of anaemia in these patients, including malabsorption, chronic inflammation, erythropoietin deficiency and other concurrent nutritional deficiencies, such as vitamin B12 and folate; these must be corrected to optimise the haemoglobin level.
     
    Recommendations
     
    1. In massive exsanguinating GIB, blood transfusion for life-saving purposes should be administered on the basis of haemodynamic status and response to fluid resuscitation.
    2. In acute GIB:
  • A restrictive transfusion strategy should be adopted, which involves a haemoglobin threshold of 7 to 8 g/dL; below this threshold, RBC transfusion should be administered.
  • Overtransfusion is associated with higher all-cause mortality and re-bleeding.
  • A less restrictive transfusion strategy, targeting a haemoglobin level of 9 to 10 g/dL, is only preferred in patients with coexisting symptomatic coronary artery disease.
  • After acute GIB settles, patients should be prescribed iron supplements. The duration of this supplementation is not yet defined, but should be titrated in accordance with haemoglobin and iron status.
  • 3. In chronic GIB:
  • Iron stores should be replenished aggressively via iron supplementation.
  • Blood transfusion should not be routinely used and is reserved for patients with severe anaemic symptoms.
  • Oral iron replacement is the first-line therapy, whereas intravenous iron is indicated in patients with IBD, poor response or poor tolerability to oral iron, and in whom a rapid correction of iron deficit is preferred.
  • Oral iron can be given at alternate daily dosing to improve effectiveness and tolerability.
  • Co-administration of ascorbic acid with oral iron may be considered.
  • Intravenous iron is underutilised. The risk of anaphylactic reaction to current preparations of intravenous iron is extremely low.
  •  
    Author contributions
    This is a Joint Position Statement issued by the three professional gastrointestinal societies (Hong Kong Society of Gastroenterology, Hong Kong Society of Digestive Endoscopy, Hong Kong IBD Society) and the Hong Kong Red Cross Blood Transfusion Service. All authors were involved in the preparation, drafting, and critical review of this article.
     
    Funding/support
    This article received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
     
    Declaration
    All authors have disclosed no conflicts of interest. All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
     
    References
    1. Fact sheet on blood collection and use. Hong Kong Red Cross Blood Transfusion Service. Apr 2017.
    2. Carson JL, Guyatt G, Heddle NM, et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA 2016;316:2025-35. Crossref
    3. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013;368:11-21. Crossref
    4. The Sanguis Study Group. Use of blood products for elective surgery in 43 European hospitals. Transfus Med 1994;4:251-68. Crossref
    5. Clifford L, Jia Q, Yadav H, et al. Characterizing the epidemiology of perioperative transfusion-associated circulatory overload. Anesthesiology 2015;122:21-8. Crossref
    6. DeBaun MR, Gordon M, McKinstry RC, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med 2014;371:699-710. Crossref
    7. Federowicz I, Barrett BB, Andersen JW, Urashima M, Popovsky MA, Anderson KC. Characterization of reactions after transfusion of cellular blood components that are white cell reduced before storage. Transfusion 1996;36:21-8. Crossref
    8. Popovsky MA, Audet AM, Andrzejewski C Jr. Transfusion-associated circulatory overload in orthopedic surgery patients: a multi-institutional study. Immunohematology 1996;12:87-9.
    9. Stramer SL, Notari EP, Krysztof DE, Dodd RY. Hepatitis B virus testing by minipool nucleic acid testing: does it improve blood safety? Transfusion 2013;53:2449-58. Crossref
    10. Zou S, Dorsey KA, Notari EP, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010;50:1495-504. Crossref
    11. Raju GS, Gerson L, Das A, Lewis B, American Gastroenterological Association. American Gastroenterological Association (AGA) Institute technical review on obscure gastrointestinal bleeding. Gastroenterology 2007;133:1697-717. Crossref
    12. Raju GS, Gerson L, Das A, Lewis B, American Gastroenterological Association. American Gastroenterological Association (AGA) Institute medical position statement on obscure gastrointestinal bleeding. Gastroenterology 2007;133:1694-6. Crossref
    13. Gerson LB, Fidler JL, Cave DR, Leighton JA. ACG clinical guideline: diagnosis and management of small bowel bleeding. Am J Gastroenterol 2015;110:1265-87. Crossref
    14. Yoon W, Jeong YY, Shin SS, et al. Acute massive gastrointestinal bleeding: detection and localization with arterial phase multi-detector row helical CT. Radiology 2006;239:160-7. Crossref
    15. Blair SD, Janvrin SB, McCollum CN, Greenhalgh RM. Effect of early blood transfusion on gastrointestinal haemorrhage. Br J Surg 1986;73:783-5. Crossref
    16. Halland M, Young M, Fitzgerald MN, Inder K, Duggan JM, Duggan A. Characteristics and outcomes of upper gastrointestinal hemorrhage in a tertiary referral hospital. Dig Dis Sci 2010;55:3430-5. Crossref
    17. Hearnshaw SA, Logan RF, Palmer KR, Card TR, Travis SP, Murphy MF. Outcomes following early red blood cell transfusion in acute upper gastrointestinal bleeding. Aliment Pharmacol Ther 2010;32:215-24. Crossref
    18. Kravetz D, Sikuler E, Groszmann RJ. Splanchnic and systemic hemodynamics in portal hypertensive rats during hemorrhage and blood volume restitution. Gastroenterology 1986;90:1232-40. Crossref
    19. Villarejo F, Rizzolo M, Lópéz E, Domeniconi G, Arto G, Apezteguia C. Acute anemia in high digestive hemorrhage. Margins of security for their handling without transfusion of red globules [in Spanish]. Acta Gastroenterol Latinoam 1999;29:261-70.
    20. Jairath V, Kahan BC, Gray A, et al. Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. Lancet 2015;386:137-44. Crossref
    21. Odutayo A, Desborough MJ, Trivella M, et al. Restrictive versus liberal blood transfusion for gastrointestinal bleeding: a systematic review and meta-analysis of randomised controlled trials. Lancet Gastroenterol Hepatol 2017;2:354-360. Crossref
    22. Strate LL, Gralnek IM. ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. Am J Gastroenterol 2016;111:459-74. Crossref
    23. Gralnek IM, Dumonceau JM, Kuipers EJ, et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015;47:a1-46. Crossref
    24. Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol 2012;107:345-60. Crossref
    25. Jalan R, Hayes PC. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. Br Soc Gastroenterol Gut 2000;46:III1-15. Crossref
    26. Crooks CJ, West J, Card TR. Comorbidities affect risk of nonvariceal upper gastrointestinal bleeding. Gastroenterology 2013;144:1384-93.e2. Crossref
    27. Carson JL, Brooks MM, Abbott JD, et al. Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. Am Heart J 2013;165:964-71.e1. Crossref
    28. Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996;38:316-21. Crossref
    29. Bager P, Dahlerup JF. Randomised clinical trial: oral vs. intravenous iron after upper gastrointestinal haemorrhage—a placebo-controlled study. Aliment Pharmacol Ther 2014;39:176-87. Crossref
    30. Bager P, Dahlerup JF. Lack of follow-up of anaemia after discharge from an upper gastrointestinal bleeding centre. Dan Med J 2013;60:A4583.
    31. Office of Dietary Supplements. National Institutes of Health. US Government. Iron: dietary supplement fact sheet. Last updated Mar 2018. Available from: https://ods.od.nih.gov/factsheets/Iron-HealthProfessional/. Accessed Apr 2018.
    32. Alleyne M, Horne MK, Miller JL. Individualized treatment for iron-deficiency anemia in adults. Am J Med 2008;121:943-8. Crossref
    33. Olsson KS, Norrby A. Comment to: Hepcidin: from discovery to differential diagnosis. Haematologica 2008;93:90-7. Haematologica 2008;93:e51. Crossref
    34. Ganzoni AM. Intravenous iron-dextran: therapeutic and experimental possibilities [in German]. Schweiz Med Wochenschr 1970;100:301-3.
    35. Koch TA, Myers J, Goodnough LT. Intravenous iron therapy in patients with iron deficiency anemia: dosing considerations. Anemia 2015;2015:763576. Crossref
    36. Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol 2010;7:599-610. Crossref
    37. Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 2015;9:211-22. Crossref
    38. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006;21:378-82. Crossref
    39. Yessayan L, Sandhu A, Besarab A, et al. Intravenous iron dextran as a component of anemia management in chronic kidney disease: a report of safety and efficacy. Int J Nephrol 2013;2013:703038. Crossref
    40. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008;103:1182-92. Crossref
    41. Johnson-Wimbley TD, Graham DY. Diagnosis and management of iron deficiency anemia in the 21st century. Therap Adv Gastroenterol 2011;4:177-84. Crossref
    42. Koduru P, Abraham BP. The role of ferric carboxymaltose in the treatment of iron deficiency anemia in patients with gastrointestinal disease. Therap Adv Gastroenterol 2016;9:76-85. Crossref
    43. Camaschella C. Iron-deficiency anemia. N Engl J Med 2015;372:1832-43. Crossref
    44. Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol 2017;4:e524-33. Crossref
    45. Meliţ LE, Mărginean CO, Mocanu S, Mărginean MO. A rare case of iron-pill induced gastritis in a female teenager: A case report and a review of the literature. Medicine (Baltimore) 2017;96:e7550. Crossref
    46. Hashash JG, Proksell S, Kuan SF, Behari J. Iron pill-induced gastritis. ACG Case Rep J 2013;1:13-5. Crossref
    47. Atanassova BD, Tzatchev KN. Ascorbic acid—important for iron metabolism. Folia Med (Plovdiv) 2008;50:11-6.
    48. Brise H, Hallberg L. Effect of ascorbic acid on iron absorption. Acta Med Scand Suppl 1962;376:51-8. Crossref

    Guidance on the management of familial hypercholesterolaemia in Hong Kong: an expert panel consensus viewpoint

    DOI: 10.12809/hkmj187215
    © Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
     
    MEDICAL PRACTICE  CME
    Guidance on the management of familial hypercholesterolaemia in Hong Kong: an expert panel consensus viewpoint
    Brian Tomlinson, MB, BS, MD1; Juliana CN Chan, MB, ChB, MD1; WB Chan, MB, ChB, FHKAM (Medicine)2; Walter WC Chen, MD, FACC3; Francis CC Chow, MB, BS1; SK Li, FRCP (Lond), FACC4; Alice PS Kong, FRCP, MD1; Ronald CW Ma, FHKCP, FHKAM (Medicine)1; David CW Siu, MB, BS, MD5; Kathryn CB Tan, MBBCH, MD5; Lawrence KS Wong, FRCP (Lond), MD1; Vincent TF Yeung, FHKAM (Medicine), MD6; Betty WM But, MB, BS, FHKAM (Paediatrics)7; PT Cheung, FRCP (Edin), FHKCPaed8; CC Fu, MB, ChB, FHKAM (Paediatrics)9; Joanna YL Tung, MB, BS, FHKAM (Paediatrics)10; WC Wong, FHKAM (Paediatrics), FHKCPaed11; HC Yau, FHKCPaed, FHKAM (Paediatrics)12
    1 Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong
    2 Qualigenics Diabetes Centre, Hong Kong
    3 The Heart Clinic, Hong Kong
    4 Premier Medical Center, Hong Kong
    5 Department of Medicine, The University of Hong Kong, Pokfulam, Hong Kong
    6 Department of Medicine and Geriatrics, Our Lady of Maryknoll Hospital, Wong Tai Sin, Hong Kong
    7 Department of Paediatrics, Queen Elizabeth Hospital, Jordan, Hong Kong
    8 Town Health International Health Management Centre, Hong Kong
    9 Department of Paediatrics and Adolescent Medicine, Princess Margaret Hospital, Laichikok, Hong Kong
    10 Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Pokfulam, Hong Kong
    11 Department of Paediatrics and Adolescent Medicine, Alice Ho Miu Ling Nethersole Hospital, Tai Po, Hong Kong
    12 Department of Paediatrics, Prince of Wales Hospital, Shatin, Hong Kong
     
    Corresponding author: Prof Brian Tomlinson (btomlinson@cuhk.edu.hk)
     
     Full paper in PDF
     
    Abstract
    In 2016, meetings of groups of physicians and paediatricians with a special interest in lipid disorders and familial hypercholesterolaemia were held to discuss several domains of management of familial hypercholesterolaemia in adults and children in Hong Kong. After reviewing the evidence and guidelines for the diagnosis, screening, and management of familial hypercholesterolaemia, consensus was reached on the following aspects: clinical features, diagnostic criteria, screening in adults, screening in children, management in relation to target plasma low-density lipoprotein cholesterol levels, detection of atherosclerosis, lifestyle and behaviour modification, and pharmacotherapy.
     
     
     
    Introduction
    Familial hypercholesterolaemia (FH), an autosomal codominant inherited disorder of lipoprotein metabolism, is characterised by markedly elevated plasma low-density lipoprotein cholesterol (LDL-C) levels and increased risk of premature atherosclerotic cardiovascular disease (CVD), particularly coronary heart disease (CHD).1 2 3 Familial hypercholesterolaemia is generally caused by mutations in the genes related to the LDL receptor (LDLR) pathway (eg, loss-of-function mutations in the LDLR or apolipoprotein B (apoB) gene (APOB) or gain-of-function mutations in the proprotein convertase subtilisin-kexin type 9 [PCSK9] gene) resulting in marked elevation of plasma LDL-C levels from birth.
     
    Heterozygous (He) FH is one of the most common human genetic disorders. It affects 1 in 200 to 300 individuals in unselected general populations. The prevalence of homozygous (Ho) FH has been estimated at 1 in 1 000 000, based on a frequency of 1 in 500 for HeFH, but it is likely to be more common.1 4 Familial hypercholesterolaemia is associated with considerable morbidity and mortality because of CHD. If left untreated, men and women with HeFH typically develop CHD before the ages of 55 and 60 years, respectively; 50% of men and 15% of women die before these ages, whereas those with HoFH may develop CHD very early in life.1
     
    Early identification and optimal treatment of patients with FH are crucial for the prevention of atherosclerosis progression and coronary complications. Although FH is a very common genetic disorder, it remains largely undetected and undertreated.1 Recent guidelines and consensus statements in Europe and in some Asia-Pacific countries highlight the need for the early identification of FH to improve the awareness and management of this condition.1 4 5 6 7
     
    As in most other countries,8 there are significant gaps in the awareness and management of FH among physicians and the general public in Hong Kong. There is no clear management guideline or consensus statement for FH in Hong Kong. On 22 February 2016, 12 experts on lipid disorders in Hong Kong convened for the local Advisory Board Meeting on the Management of Familial Hypercholesterolaemia in Hong Kong; and on 14 December 2016, 10 experts convened for a second meeting specifically regarding the management of paediatric patients with FH in Hong Kong. The principal objectives were to discuss the evidence for diagnosis, screening, and management of FH, in order to develop a consensus statement relevant to Hong Kong. The panel reviewed both international guidelines and those for individual Asia-Pacific countries, then developed a consensus treatment matrix/guide regarding the diagnosis, screening, and management of FH. The expert panel discussed each issue until they had attained a unanimous consensus.
     
    Clinical features of familial hypercholesterolaemia in Hong Kong
    Plasma LDL-C levels in the Hong Kong general population are comparable to those of some Western countries.9 10 According to the experts’ clinical experience, patients with FH in Hong Kong, especially older adults, tend to exhibit CVD later in life (approximately 70 years of age), compared with patients in Western countries. Many older patients with FH in Hong Kong are free of cardiovascular events in their 70s or 80s; this may be related to their previously healthy lifestyle (eg, substantial physical activity with a healthy diet). However, young patients with FH tend to develop CVD at an earlier age than older patients within the same families. More recently, cardiovascular events have been observed in patients who are in their mid-20s. The increased risk in these young patients is likely due to lifestyle changes in the younger generations. Stroke remains uncommon in patients with FH in Hong Kong, presumably because elevated LDL-C levels are not a strong risk factor for cerebrovascular diseases.11
     
    Clinical characteristics have been reported for 252 Hong Kong Chinese patients from 87 pedigrees who were clinically diagnosed with FH during 1990-2000 (mean [standard deviation] age 37 [17] years, including 43 patients aged <18 years).10 The mean plasma LDL-C level was 7.2 (1.5) mmol/L.10 Tendon xanthomata was present in 40.6% of males and 54.8% of females. The prevalence of known CHD was relatively low: 9.9% in males and 8.5% in females.10
     
    Diagnostic criteria of familial hypercholesterolaemia
    Although FH is generally considered to be a monogenic condition, it is typically diagnosed on the basis of clinical features and family history, rather than a genetic test. There are several sets of clinical criteria for diagnosing FH (Table 17 12 13 14 15), including the Simon Broome Register diagnostic criteria,12 the Make Early Diagnosis to Prevent Early Deaths (MEDPED) criteria,13 and the Dutch Lipid Clinic Network Diagnostic Criteria14 (DLCNC; online supplementary Appendix); however, none of these are universally accepted as the best approach. More recently, Japanese experts have developed specific criteria for the diagnosis of FH in Japan.7
     

    Table 1. Comparison of diagnostic criteria for familial hypercholesterolaemia7 12 13 14 15
     
    The DLCNC14 use a point system to assess the following characteristics: family history of FH, history of premature CVD, physical examination of tendinous xanthomata and premature arcus cornealis, LDL-C levels, and DNA analysis. There is a point score for each item; a total point score of >8 is regarded as definite FH, 6 to 8 as probable FH, 3 to 5 as possible FH, and <3 as unlikely FH. Similar to the DLCNC, the Simon Broome criteria12 use family history of FH, physical signs (excluding arcus cornealis), LDL-C levels, and genetic tests to predict the probability of the diagnosis of FH. The MEDPED criteria13 rely on plasma total cholesterol and LDL-C levels in the probands and their family members, without consideration of other phenotypes. The MEDPED criteria have a higher sensitivity, but lower specificity than the Dutch and Simon Broome diagnostic criteria. The Japanese FH criteria,16 which are similar to the Simon Broome criteria, use a population-specific LDL-C level >4.7 mmol/L for adults and >3.6 mmol/L for children as a criterion for the diagnosis of FH.
     
    The Dutch criteria were developed from patients who had been genotyped; thus, these comprise the only set of criteria validated by genetic tests. The panel agreed to apply the Dutch criteria for the diagnosis of FH adults in Hong Kong; however, because of lower reported LDL-C levels in local patients with FH, the panel recommended a lower threshold for LDL-C levels indicative of definite FH, probable FH, possible FH, and unlikely FH.10 Secondary causes of increased LDL-C levels, such as hypothyroidism and nephrotic syndrome, should be excluded before considering a diagnosis of FH.
     
    Screening for familial hypercholesterolaemia in adults in Hong Kong
    Universal screening for FH in adults is not practicable in Hong Kong or in most other countries. General screening for FH as primary prevention in Hong Kong can be challenging, as it is difficult to convince asymptomatic patients to participate in the screening programme. A regular body check, including measurement of the plasma lipid profile, is becoming more popular in Hong Kong. The panel recommended that greater attention should be given to the cholesterol profile as a routine body check item, together with documentation of family history of FH and premature CHD; this approach may increase the likelihood of identifying potential index FH cases. The risk of cardiovascular events in patients with FH largely depends on the plasma LDL-C level; however, other risk factors, such as smoking, hypertension, diabetes, and elevated levels of lipoprotein(a) [Lp(a)], are also important. Targeted LDL-C screening in high-risk patients, especially younger patients with premature CHD, is encouraged.
     
    The panel recommended that adults with a plasma LDL-C level >5 mmol/L should be regarded as potential probands. For patients at high risk of FH, such as patients with a family history of FH or premature CHD, the LDL-C level threshold could be 4.5 mmol/L. Tendon xanthomata, arcus cornealis, and tuberous xanthoma or xanthelasma are typically observed in patients with FH who exhibit very high LDL-C levels. Xanthelasma and arcus cornealis are not specific clinical signs for FH. Tendon xanthomas are more specific for FH and occur in patients with markedly elevated LDL-C levels (typically >7.0 mmol/L); these are rarely present before adulthood in patients with HeFH. They can also occur in patients with sitosterolaemia and cerebrotendinous xanthomatosis.
     
    Cascade screening for relatives of patients with FH is recommended in both the private and public sectors. Although this may be challenging in the private sector due to financial constraints, cascade screening is the most cost-effective approach for the identification of new patients with FH; moreover, it is recommended by international and national bodies, such as the European Atherosclerosis Society and the American Heart Association.1 5 The relatives of patients with FH can be screened with a combination of plasma lipid profiles and genetic testing. If the causative mutation is unknown or genetic testing is unavailable, screening can be performed by using plasma lipid profiles alone. Currently, a potential patient with FH must wait several months for counselling and genetic testing in the public sector (ie, the Hong Kong Department of Health Clinical Genetic Service) and the cost of genetic testing may not be covered by the public health care system.
     
    Genetic testing may not always be necessary or cost-effective. Patients with high LDL-C levels typically must be treated, regardless of the genetic test results; notably, these test results may not substantially alter treatment strategies. Although there may not be great advantages to genetic testing, there are potential benefits in genotyping.17 For similar LDL-C levels, the risk of cardiovascular events is greater in patients with FH than in those without, due to their lifelong exposure to high LDL-C levels since birth. Treatment may not be necessary in patients with FH who have mildly elevated LDL-C levels. In contrast, long-term follow-up is necessary in patients with FH who have similar LDL-C levels. With the increasing affordability of genetic testing, the resulting genetic information will help improve the precision of diagnosis and management of FH.
     
    Screening for familial hypercholesterolaemia in children in Hong Kong
    Universal screening of plasma cholesterol levels in children has been proposed in some Western countries, including Australia18 and the US.19 20 Early diagnosis can lead to effective treatment with lifestyle modification and pharmacotherapy, as appropriate. By reducing the lifetime exposure to LDL-C from an early age, these patients experience substantial benefits in terms of CVD prevention. Thus, universal cholesterol screening in children is more cost-effective than identical screening in younger or older adults. Although it is expensive, universal cholesterol screening in childhood may offer the best and most effective strategy for diagnosing FH.18 The paediatric panel agreed that universal screening should target all citizens below 20 years of age, ideally before puberty; moreover, it should identify potential cases of FH based on age- and gender-specific plasma LDL-C levels.
     
    Cascade screening is highly recommended in children with elevated LDL-C levels and in children with relatives who exhibit FH phenotypes. Children with a relevant family history and an LDL-C level >3.6 mmol/L are likely to have FH. In a local survey of Chinese adolescents in Hong Kong (median [interquartile range] age, 16 [14-17] years), the mean (standard deviation) LDL-C level was 2.15 (0.60) mmol/L in boys and 2.24 (0.61) mmol/L in girls; thus, the 95th percentile would be approximately 3.4 mmol/L.21 In children with a plasma LDL-C level >4.9 mmol/L and/or physical signs (eg, xanthomata), FH is likely; these children should be screened at any age, as soon as they are identified. Because FH and sitosterolaemia share several clinical characteristics, sitosterolaemia should also be considered in these patients, especially if both parents appear to exhibit normal lipid levels. Sitosterolaemia can be identified by measuring the plasma levels of plant sterols; the genetic defect can be detected by sequencing the genes for the ABCG5 and ABCG8 transporters.22 After consideration of international recommendations and the increasingly early age of acquisition of other risk factors, including obesity and diabetes, in our local population, the paediatric panel suggested a screening age of 5 to 10 years to identify FH; moreover, the panel suggested that a lower threshold for LDL-C levels should be used in children, relative to that used in adults. The paediatric panel also agreed that genetic testing, if available, should be provided for all children who are suspected to have FH, after counselling. Genetic testing would be particularly useful in children whose LDL-C levels are not sufficiently high to make a definite diagnosis of FH when a mutation has been detected in an affected parent or sibling. Genetic counselling should be provided to the family before undergoing genetic testing to ensure a clear understanding of the implications of such tests.
     
    Despite these recommendations, the panel emphasised that additional surveys are required regarding the distribution of plasma cholesterol levels among local children, in order to improve the screening strategy for FH in children.
     
    Management of familial hypercholesterolaemia
    Target plasma low-density lipoprotein cholesterol levels
    The prognosis of FH largely depends on the plasma LDL-C levels; these should be maintained as low as possible. The panel suggested that, for primary prevention of CHD, the target LDL-C level for Hong Kong Chinese patients with FH should be <2.5 mmol/L. The panel agreed that patients with established atherosclerotic CVD or other cardiovascular risk factors, such as diabetes, elevated Lp(a) level ≥50 mg/dL, pretreatment LDL-C level ≥6.72 mmol/L, family history of premature CHD, or advanced age, should be considered as very high risk. For very-high-risk patients, the target LDL-C level should be <1.8 mmol/L; for paediatric patients (>10 years of age) with FH, the panel recommended that the target LDL-C level should be <3.4 mmol/L.
     
    Detection of atherosclerosis
    The detection of atherosclerosis should begin by taking a complete medical history and performing a thorough physical examination. If the patient is suspected to have atherosclerotic CVD, it may be appropriate to refer them to a cardiologist or other appropriate specialist for further investigation. Computed tomographic coronary angiography is a useful and non-invasive tool to detect coronary atherosclerosis and determine CVD risk. Stress echocardiography can be used to assess myocardial functional capacity and the possibility of silent ischaemia. Carotid ultrasound imaging is non-invasive and can identify early-stage atherosclerosis; it can be used to assess carotid artery disease, predict the risk of stroke, and determine the requirement for intensive treatment in patients with FH. The ankle-brachial index is a useful diagnostic test for early peripheral arterial disease and has been shown to predict CVD and all-cause death in Chinese populations.23 24 Pulse wave velocity is a non-invasive measure of arterial stiffness which also correlates with cardiovascular events, such as the development of CHD.
     
    Lifestyle and behaviour modification
    All patients with a clinical diagnosis of FH should be counselled on lifestyle modification, particularly healthy eating, regular exercise and physical activity, weight control, and cessation of smoking.
     
    Pharmacotherapy
    First-line treatment for hypercholesterolaemia for reducing the risk of CHD involves the use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors or statins, which significantly reduce the risk of CVD and progression of atherosclerosis in FH. In a long-term cohort study involving more than 2000 patients with FH without prevalent CHD in the Netherlands, patients treated with statins showed a 76% risk reduction (hazard ratio=0.24; 95% confidence interval=0.18-0.30; P<0.001) for CHD compared with untreated patients.25 In patients with HoFH, statin-treated patients showed a 66% reduction in all-cause mortality and 51% reduction in major cardiovascular events compared with statin-naïve patients; however, the mean reduction in LDL-C level was only 26.4% with lipid-lowering therapy.26
     
    A recent Mendelian randomisation analysis revealed that prolonged exposure to lower LDL-C levels, beginning early in life, reduced the risk of CHD by three-fold, when compared with the risk reduction achieved by lowering LDL-C level with a statin started later in life.27 The European Atherosclerosis Society Consensus Panel recommended early detection (from age 5 years, or earlier if HoFH is suspected) in children; the panel suggested lifestyle modification and statin therapy for the treatment of children with FH, as early as age 8 to 10 years.6
     
    Typically, adult patients with FH should be treated with high-intensity statin therapy. Female patients should be advised that statins are contra-indicated during pregnancy and should be avoided during lactation.5 If the target LDL-C level cannot be achieved with statin monotherapy, a combination therapy with concurrent ezetimibe and/or a bile-acid sequestrant or niacin can be considered. Generally, Lp(a) levels are increased in patients with FH,28 and are considered an independent predictor of CHD in FH after adjustment for other modifiable risk factors.1 29 30 It is desirable to measure the Lp(a) level if the assay is available. Niacin can reduce plasma Lp(a) levels by 30% to 40%; notably, the LDL-C level lowering-effect of niacin is largely dependent on baseline LDL-C levels.31 32 Therefore, if available, niacin may be used in patients with FH who do not reach their target LDL-C levels with statin therapy. Lipoprotein apheresis will also reduce Lp(a) level, but is not readily available in the public hospitals in Hong Kong; however, plasmapheresis is currently used.
     
    In Hong Kong, statins are the main therapy for paediatric patients with FH. All available statins are approved for use in patients with HeFH aged ≥10 years (Table 233). However, in exceptional circumstances, such as when there is a family history of premature CHD, statins are used before age 10 years, as recommended by the guidelines from the United Kingdom National Institute for Health and Care Excellence.34 A 2017 Cochrane review analysed nine randomised controlled trials comparing the efficacy and safety of statins versus placebo in 1177 children with FH aged 6 to 18 years; the authors concluded that statins seem to be safe in the short term, but long-term safety remains unknown.35
     

    Table 2. Oral lipid-lowering drugs approved for use in children or adolescents in Hong Kong33
     
    Patients are initially treated with the lowest doses, which can be increased as necessary. Some patients are prescribed bile acid sequestrants (eg, colestyramine) as early as age 1 year, and ezetimibe at age ≥10 years (Table 233). Plasmapheresis is reserved for patients with severe disease uncontrolled by conventional therapy. It should be emphasised that lifestyle interventions should be the first-line treatment for paediatric patients with FH; they should not be disregarded, even if pharmacotherapy is used.
     
    Emerging therapies
    Monoclonal antibodies to PCSK9 have emerged as the most promising treatment option for patients with FH. This class of agents, given by subcutaneous injection once or twice monthly, reduced LDL-C levels by 50% to 70% in patients with HeFH who were treated with statins with or without ezetimibe,36 37 as well as in patients with primary hypercholesterolaemia with or without statin therapy.38 39 Two PCSK9 inhibitors, alirocumab (previously known as REGN727 and SAR236553, Sanofi and Regeneron Pharmaceuticals, Inc) and evolocumab (AMG-145, Amgen) were approved by the US Food and Drug Administration (FDA) and European Medicines Agency in 2015 for their proven efficacy in reducing LDL-C levels in patients at risk for CVD; these drugs are available in Hong Kong. By using this group of drugs, very low LDL-C levels (eg, <1.0 mmol/L) can be achieved in patients with HeFH.
     
    Mipomersen is an apoB antisense oligonucleotide which inhibits the biosynthesis of apoB, thus reducing hepatic very low–density lipoprotein cholesterol (VLDL-C) production and secretion.40 In clinical trials, subcutaneous injection of mipomersen reduced plasma LDL-C levels by 25% and 28% in patients with HoFH41 and HeFH,42 respectively. The major side-effects of mipomersen include frequent injection site reactions, short-lived fatigue and myalgia, hepatic steatosis, and elevations in plasma aminotransferases. These hepatic changes typically resolve upon drug discontinuation. Mipomersen is not available in Hong Kong.
     
    Lomitapide is an orally available microsomal triglyceride transfer protein inhibitor which decreases the hepatic production and secretion of VLDL-C. Lomitapide has been approved for the treatment of HoFH in the US and Europe as an add-on therapy. In a multi-centre study of patients with HoFH, lomitapide reduced LDL-C levels by 50%, 44%, and 38% at 26, 56, and 78 weeks, respectively.43 However, lomitapide may increase plasma aminotransferases and intrahepatic fat content. Lomitapide is not available in Hong Kong. Both mipomersen and lomitapide work via pathways independent of the LDLR and are effective in patients with HoFH who exhibit null mutations. These two drugs have been approved by the FDA for use in patients with HoFH.
     
    Conclusion
    Patients with FH remain underdiagnosed and undertreated in Hong Kong. Increased awareness, early identification, and optimal treatment are essential to reduce the risk of premature CHD, thereby restoring decades of healthy, normal life in patients with FH. Developing a model of care for FH in Hong Kong will help to bridge the gap in prevention of CVD and improve outcomes in patients with FH. Action is needed to collect more population-based data to further guide recommendations and the development of models of care for the management of FH. While these data are gathered, this consensus statement aims to serve as a guide to inform clinical practice and future research.
     
    Author contributions
    All authors have made substantial contributions to the expert panel consensus viewpoint and provided critical revision for important intellectual content. B Tomlinson is responsible for drafting of the article.
     
    Acknowledgement
    The expert panel thanks Sanofi-Aventis Hong Kong Limited for supporting the organisation of the meetings and providing editorial assistance in preparing the statement by an unrestricted educational grant.
     
    Funding/support
    The meetings during which this consensus statement was formulated and some editorial assistance in preparing the manuscript were funded by an unrestricted educational grant from Sanofi-Aventis Hong Kong Limited. The funder had no role in determining the content of the expert panel consensus statement.
     
    Declaration
    All authors have disclosed no conflicts of interest. All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
     
    References
    1. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013;34:3478-90a. Crossref
    2. Hovingh GK, Davidson MH, Kastelein JJ, O’Connor AM. Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J 2013;34:962-71. Crossref
    3. Reiner Ž. Management of patients with familial hypercholesterolaemia. Nat Rev Cardiol 2015;12:565-75. Crossref
    4. Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014;35:2146-57. Crossref
    5. Gidding SS, Champagne MA, de Ferranti SD, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation 2015;132:2167-92. Crossref
    6. Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015;36:2425-37. Crossref
    7. Harada-Shiba M, Arai H, Oikawa S, et al. Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb 2012;19:1043-60. Crossref
    8. Pang J, Sullivan DR, Harada-Shiba M, et al. Significant gaps in awareness of familial hypercholesterolemia among physicians in selected Asia-Pacific countries: a pilot study. J Clin Lipidol 2015;9:42-8. Crossref
    9. Pang RW, Tam S, Janus ED, et al. Plasma lipid, lipoprotein and apolipoprotein levels in a random population sample of 2875 Hong Kong Chinese adults and their implications (NCEP ATP-III, 2001 guidelines) on cardiovascular risk assessment. Atherosclerosis 2006;184:438-45. Crossref
    10. Hu M, Lan W, Lam CW, Mak YT, Pang CP, Tomlinson B. Heterozygous familial hypercholesterolemia in Hong Kong Chinese. Study of 252 cases. Int J Cardiol 2013;167:762-7. Crossref
    11. O’Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010;376:112-23. Crossref
    12. Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991;303:893-6. Crossref
    13. Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993;72:171-6. Crossref
    14. Civeira F, International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004;173:55-68. Crossref
    15. Damgaard D, Larsen ML, Nissen PH, et al. The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis 2005;180:155-60. Crossref
    16. Harada-Shiba M, Arai H, Okamura T, et al. Multicenter study to determine the diagnosis criteria of heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb 2012;19:1019-26. Crossref
    17. Nordestgaard BG, Benn M. Genetic testing for familial hypercholesterolaemia is essential in individuals with high LDL cholesterol: who does it in the world? Eur Heart J 2017;38:1580-3. Crossref
    18. Pang J, Martin AC, Mori TA, Beilin LJ, Watts GF. Prevalence of familial hypercholesterolemia in adolescents: potential value of universal screening? J Pediatr 2016;170:315-6. Crossref
    19. Kwiterovich PO, Gidding SS. Universal screening of cholesterol in children. Clin Cardiol 2012;35:662-4. Crossref
    20. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011;128(Suppl 5):S213-56. Crossref
    21. Kong AP, Choi KC, Ko GT, et al. Associations of overweight with insulin resistance, beta-cell function and inflammatory markers in Chinese adolescents. Pediatr Diabetes 2008;9:488-95. Crossref
    22. Hu M, Yuen YP, Kwok JS, Griffith JF, Tomlinson B. Potential effects of NPC1L1 polymorphisms in protecting against clinical disease in a Chinese family with sitosterolaemia. J Atheroscler Thromb 2014;21:989-95. Crossref
    23. Hong Kong Diabetes Registry, Yang X, So WY, et al. Development and validation of an all-cause mortality risk score in type 2 diabetes. Arch Intern Med 2008;168:451-7. Crossref
    24. Luo YY, Li J, Xin Y, Zheng LQ, Yu JM, Hu DY. Risk factors of peripheral arterial disease and relationship between low ankle brachial index and mortality from all-cause and cardiovascular disease in Chinese patients with hypertension. J Hum Hypertens 2007;21:461-6. Crossref
    25. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008;337:a2423. Crossref
    26. Raal FJ, Pilcher GJ, Panz VR, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011;124:2202-7. Crossref
    27. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol 2012;60:2631-9. Crossref
    28. Langsted A, Kamstrup PR, Benn M, Tybjærg-Hansen A, Nordestgaard BG. High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study. Lancet Diabetes Endocrinol 2016;4:577-87. Crossref
    29. Alonso R, Andres E, Mata N, et al. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol 2014;63:1982-9. Crossref
    30. Chan DC, Pang J, Hooper AJ, et al. Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia. Int J Cardiol 2015;201:633-8. Crossref
    31. Hu M, Tomlinson B. Niacin for reduction of cardiovascular risk. N Engl J Med 2014;371:1941-2. Crossref
    32. Hu M, Yang YL, Ng CF, et al. Effects of phenotypic and genotypic factors on the lipid responses to niacin in Chinese patients with dyslipidemia. Medicine (Baltimore) 2015;94:e881. Crossref
    33. Monthly Index of Medical Specialities. Available from: http://www.mims.com/hongkong. Accessed 1 Aug 2017.
    34. National Institute for Health and Clinical Excellence. Familial hypercholesterolaemia: identification and management. 2008. Available from: https://www.nice.org .uk/guidance/cg71/resources/familial-hypercholesterolaemia-identification-and-management-pdf- 975623384005. Accessed 1 Feb 2016.
    35. Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev 2017;(7):CD006401. Crossref
    36. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012;380:29-36. Crossref
    37. Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 2013;128:2113-20. Crossref
    38. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012;59:2344-53. Crossref
    39. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012;366:1108-18. Crossref
    40. Visser ME, Witztum JL, Stroes ES, Kastelein JJ. Antisense oligonucleotides for the treatment of dyslipidaemia. Eur Heart J 2012;33:1451-8. Crossref
    41. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:998-1006. Crossref
    42. Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012;126:2283-92. Crossref
    43. Cuchel M, Blom DJ, Averna MR. Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia. Atheroscler Suppl 2014;15:33-45. Crossref

    Recommendations on prevention and screening for breast cancer in Hong Kong

    DOI: 10.12809/hkmj177037
    © Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
     
    MEDICAL PRACTICE
    Recommendations on prevention and screening for breast cancer in Hong Kong
    Cancer Expert Working Group on Cancer Prevention and Screening (August 2016 to July 2018)
    TH Lam, MD1; KH Wong, MB, BS, FHKAM (Medicine)2; Karen KL Chan, MBBChir, FHKAM (Obstetrics and Gynaecology)3; Miranda CM Chan, MB, BS, FHKAM (Surgery)4; David VK Chao, FRCGP, FHKAM (Family Medicine)5; Annie NY Cheung, MD, FHKAM (Pathology)6; Cecilia YM Fan, MB, BS, FHKAM (Family Medicine)7; Judy Ho, MB, BS, FHKAM (Surgery)8; EP Hui, MD (CUHK), FHKAM (Medicine)9; KO Lam, MB, BS, FHKAM (Radiology)10; CK Law, FHKCR, FHKAM (Radiology)11; WL Law, MS, FHKAM (Surgery)12; Herbert HF Loong, MB, BS, FHKAM (Medicine)13; Roger KC Ngan, FRCR, FHKAM (Radiology)14; Thomas HF Tsang, MB, BS, FHKAM (Community Medicine)15; Martin CS Wong, MD, FHKAM (Family Medicine)16; Rebecca MW Yeung, MD, FHKAM (Radiology)17; Anthony CH Ying, MB, BS, FHKAM (Radiology)18; Regina Ching, MB, BS, FHKAM (Community Medicine)19
    1 School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong
    2 Department of Health, Hong Kong
    3 The Hong Kong College of Obstetricians and Gynaecologists, Hong Kong
    4 Hospital Authority (Surgical), Hong Kong
    5 The Hong Kong College of Family Physicians, Hong Kong
    6 The Hong Kong College of Pathologists, Hong Kong
    7 Professional Development and Quality Assurance, Department of Health, Hong Kong
    8 World Cancer Research Fund Hong Kong, Hong Kong
    9 Hong Kong College of Physicians, Hong Kong
    10 Department of Clinical Oncology, The University of Hong Kong, Hong Kong
    11 Hong Kong College of Radiologists, Hong Kong
    12 The College of Surgeons of Hong Kong, Hong Kong
    13 Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong
    14 Hong Kong Cancer Registry, Hospital Authority, Hong Kong
    15 Hong Kong College of Community Medicine, Hong Kong
    16 The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong
    17 Hospital Authority (Non-surgical), Hong Kong
    18 The Hong Kong Anti-Cancer Society, Hong Kong
    19 Centre for Health Protection, Department of Health, Hong Kong
     
    Corresponding author: Dr Regina Ching (regina_ching@dh.gov.hk)
     
     Full paper in PDF
     
    Abstract
    In Hong Kong, breast cancer is the most common cancer among women and poses a significant health care burden. The Cancer Expert Working Group on Cancer Prevention and Screening (CEWG) was set up in 2002 by the Cancer Coordinating Committee to review and assess local and international scientific evidence, and to formulate recommendations for cancer prevention and screening. After considering the local epidemiology, emerging scientific evidence, and local and overseas screening practices, the CEWG concluded that it was unclear whether population-based breast cancer screening did more harm than good in local asymptomatic women at average risk. The CEWG considers that there is insufficient evidence to recommend for or against population-based mammography screening for such individuals. Women who consider breast cancer screening should be adequately informed about the benefits and harms. The CEWG recommends that all women adopt primary preventive measures, be breast aware, and seek timely medical attention for suspicious symptoms. For women at high risk of breast cancer, such as carriers of confirmed BRCA1/2 deleterious mutations and those with a family history of breast cancer, the CEWG recommends that they seek doctor’s advice for annual mammography screening and the age at which the process should commence. Additional annual screening by magnetic resonance imaging is recommended for confirmed BRCA1/2 mutation carriers or women who have undergone radiation therapy to the chest between the age of 10 and 30 years. Women at moderate risk of breast cancer should discuss with doctors the pros and cons of breast cancer screening before making an informed decision about mammography screening every 2 to 3 years.
     
     
     
    Introduction
    In Hong Kong, the Cancer Coordinating Committee (CCC) is a high-level committee chaired by the Secretary for Food and Health to steer the direction of work and advice on local strategies for cancer prevention and control. Under the auspices of the CCC, the Cancer Expert Working Group on Cancer Prevention and Screening (CEWG) was set up in 2002 to review local and international scientific evidence, and to assess and formulate local recommendations.
     
    This article describes the local breast cancer burden, preventive measures, as well as the rationale that underlies screening recommendations made by the CEWG that were reaffirmed in September 2017.
     
    Local epidemiology of female breast cancer
    Since the early 1990s, breast cancer has become the most common cancer among women in Hong Kong. According to the Hong Kong Cancer Registry,1 there were 3900 newly registered female breast cancer cases in 2015, accounting for 26.1% of all new cancer cases among women. The median age at diagnosis was 56 years. The age-standardised incidence rate (ASIR) of female breast cancer was 58.8 per 100 000 standard population. In addition, 575 new cases of carcinoma in situ of breast cancer (also known as ductal carcinoma in situ [DCIS]) were reported in 2015, and the highest age-specific incidence rate was 33.8 per 100 000 female population at age 70 to 74 years. More than half (66%) of DCIS cases were diagnosed in females aged ≥50 years.
     
    There were 702 registered deaths due to breast cancer in 2016, representing 12.2% of and the third leading cause of female cancer deaths.2 The age-standardised mortality rate (ASMR) of female breast cancer was 10.2 per 100 000 standard population. There has been a rising trend of new cases and deaths of female breast cancer over the past three decades. After adjusting for population ageing, the ASIR has maintained an increasing trend while the ASMR has remained relatively stable. Although the ASIR of female breast cancer has been increasing in Hong Kong, it remained lower than the West (eg, UK or Australia) and some Asian countries (eg, Singapore) in 2012 (Fig3 4 5).
     

    Figure. Comparison of estimated age-standardised incidence and mortality rates of female breast cancer in Hong Kong and other countries3, in 2012
     
    Risk factors for female breast cancer
    A range of factors account for woman’s risk of breast cancer, of which family history being a strong known one. Risk increases with degree of relatedness of affected relatives, number of affected relatives, and their age at diagnosis.6 7 8 Having one first-degree relative with breast cancer doubles a woman’s risk while having an affected second-degree relative increases risk by 50%.6 The risk increases especially when the relative has been diagnosed before the age of 50.7
     
    Women with certain deleterious gene mutations are at higher risk of breast cancer. Germline mutations in BRCA1/2 genes are associated with 40% to 90% lifetime risk of breast cancer and are the most common cause of hereditary breast cancer. Other less common gene mutations (eg, TP53, PTEN) are also associated with an increased risk.8 9 10 11 It has been estimated that BRCA1/2 mutations contribute to 5% to 10% of breast cancer cases in western countries.8 10 There are limited data on the prevalence of BRCA mutations in the general population of Hong Kong. Latest findings (as of September 2017) from the Hong Kong Hereditary Breast Cancer Family Registry of 2549 clinically high-risk breast or ovarian cancer patients revealed that BRCA mutation was found in 9.6% of patients, among whom 45.1% were BRCA1 and 54.9% were BRCA2.12 This is noticeably different from patients in western countries where the majority of mutations are of BRCA1. In 2011, the Registry started to employ a four-gene panel including TP53 and PTEN.10 13 Since then, 15 (0.6%) and two (0.08%) patients carrying TP53 and PTEN mutations have been identified, respectively.12
     
    Additional established risk factors for female breast cancer include a history of receiving radiation therapy at a young age, history of breast cancer, ovarian cancer or endometrial cancer, history of benign breast disease (eg, atypical hyperplasia), exposure to exogenous hormones (eg, combined oral contraceptives or hormone replacement therapy), reproductive factors (eg, early menarche or late menopause, nulliparity, late first live birth), alcohol consumption, obesity after menopause, and increasing age.6 8 14 15 16 17 18 19 20 21 22 23 24 25 26 A summary of these risk factors for breast cancer and the magnitude of risk is presented in Table 1.6 11 16 17 18 19 20 21 22 23 24 25 26
     

    Table 1. Summary of risk factors for breast cancer6 11 16 17 18 19 20 21 22 23 24 25 26
     
    Primary prevention and breast awareness
    Certain breast cancer risk factors are related to personal lifestyle and behaviour. Women can lower their risk by adopting primary preventive measures such as undertaking moderate-intensity or equivalent aerobic physical activity for at least 150 minutes per week, avoidance of alcohol, maintaining a healthy body weight with body mass index between 18.5 and 22.9 and waist circumference less than 80 cm, bearing children at an earlier age and breastfeeding for a longer duration.8 14 15 17 20 Alcohol is a Group I carcinogen as classified by the International Agency for Research on Cancer (IARC), World Health Organization. There is strong evidence that alcohol can cause, inter alia, female breast cancer. With respect to cancer risk, there is no safe level of alcohol consumption. For women, drinking 10 grams of alcohol per day (eg, 250 mL of beer with 5% alcohol content, a small glass (~100 mL) of red or white wine with 12% alcohol content increases the risk of premenopausal breast cancer by 5% and postmenopausal breast cancer by 9%.20 The higher the intake, the higher the risk, not only of breast cancer but at least six or seven other cancers.14
     
    Symptoms of early breast cancer may not be easily noticed. The CEWG recommends all women to be breast aware, that is, be familiar with the normal look and feel of their breasts and visit the doctor promptly if suspicious symptoms appear, such as presence of a breast or axillary lump, change in skin texture of the breast or nipple, or nipple rash, discharge, or retraction.
     
    Screening for the general female population at average risk
    Breast self-examination, clinical breast examination, and mammography are widely used breast cancer screening modalities. The CEWG considers there is insufficient evidence to recommend regular breast self-examination as a screening tool due to its low sensitivity in detecting breast cancer, no proven benefit in reducing breast cancer mortality, and greater harm due to the increased detection of benign lesions and biopsies performed.27 The CEWG is also of the view that there is insufficient evidence to recommend clinical breast examination since its effectiveness in reducing breast cancer mortality cannot be concluded from the limited studies available.28 29 30
     
    Ultrasonography, used as an adjunct to mammography in women with radiologically dense breasts, has the potential to depict small breast cancers not visible on mammography.31 However, both the Cochrane review in 201332 and the IARC review in 20158 33 concluded that there is insufficient evidence that ultrasonography as an adjunct to mammography screening can decrease breast cancer mortality.
     
    Evidence from some western countries suggests that organised breast screening programmes using mammography are effective in the detection of tumours at an earlier stage and reduction of breast cancer mortality in their populations. Nevertheless disadvantages such as false-positive or false-negative results, overdiagnosis (the diagnosis of breast cancer, in particular of DCIS, as a result of screening that would not have been diagnosed or never have caused harm in a patient’s lifetime if screening had not taken place), overtreatment, and potential complications arising from subsequent invasive investigations or treatment may outweigh the benefits.1 34 35
     
    A Cochrane review in 2013 estimated that mammography screening resulted in a 15% reduction in breast cancer mortality and a 30% increase in overdiagnosis and overtreatment. For every 2000 women invited for mammography screening over a 10-year period, one woman would be prevented from dying of breast cancer; 10 healthy women would be treated unnecessarily; and more than 200 women would be falsely alarmed and experience significant psychological distress because of false-positive findings.36
     
    In UK, the Independent Breast Review in 2013 showed that mammography screening led to a relative risk reduction in breast cancer mortality of 20% and an estimated 11% overdiagnosis rate.37
     
    The Swiss Medical Board reported in 2013 that for every 1000 women who underwent regular mammography screening, one to two women’s lives could be saved, but around 100 women would undergo unnecessary investigations and treatment. The cost-effectiveness ratio was very unfavourable. The Board concluded that introduction of a mammography screening programme was not recommended and a time limit should be set on existing programmes. The Board further recommended that thorough medical assessment and comprehensive information about the benefits and harms of screening should be provided to women considering mammography screening.38
     
    The 25-year follow-up of the Canadian National Breast Screening Study in 2014 revealed that women aged 40 to 59 years who underwent annual mammography screening received no benefit in terms of breast cancer mortality but resulted in 22% overdiagnosis, prompting the need of policy-makers to reassess the rationale of screening.34
     
    In 2015, the IARC evaluated the cancer-preventive and adverse effects of different breast cancer screening methods. It was estimated that women aged 50 to 69 years invited for mammography screening had a 24% reduced risk of mortality from breast cancer. Notwithstanding this, the evaluation concluded sufficient evidence that mammography screening led to overdiagnosis at an average rate of 6.5% (range, 1-10%). The estimated cumulative risk of false-positive results was about 20% for a woman who had 10 screens from age 50 to 70 years, leading to short-term negative psychological consequences.8 33
     
    In some regions of Asia where organised mammography screening programmes (eg, Singapore, Korea, Taiwan) are implemented, there is a lack of published peer-reviewed articles in the public domain documenting systematic programme evaluation or modelling studies that estimate or report on the extent of overdiagnosis and the number of lives saved. At the same time, there is evidence of a generally low acceptance of mammography screening in Asian regions. Data kept by the International Cancer Screening Network39 showed that the participation rate of a breast cancer screening programme in 2010 was 19% in Japan and 39.3% in Korea. The Singapore National Health Survey of 2010 showed that 39.6% women aged 50 to 69 years reported a history of mammography according to the recommended screening interval in Singapore, which was within the 2 years preceding the survey.40 In Taiwan, the coverage of mammography screening among women aged 45 to 69 years was 36% in 2012/2013.41
     
    Furthermore, some international and local evidence suggests a reduction in breast cancer mortality could be attributable to improved survival due to treatment advances and improved health service delivery rather than screening per se.35 42 43 44
     
    In Hong Kong, the ASIR of breast cancer is relatively low when compared with that in western countries. Therefore, the positive predictive value of mammography will be lower, generating more false-positive results and ensuing unnecessary follow-up investigations, potential complications and psychological distress.45 Furthermore, local modelling studies have shown that population-based mammography screening is not a cost-effective public health intervention in Hong Kong as compared with other strategies to prevent and control breast cancer.46 47
     
    In conclusion, the CEWG considers that there is so far insufficient evidence to make a definitive recommendation for or against population-based mammography screening for asymptomatic women at average risk in Hong Kong. Individuals considering breast cancer screening should be adequately informed by doctors about the associated benefits and harms.
     
    Screening for women at increased risk
    Locally, there is lack of consensus on how to identify women at increased risk of breast cancer. The CEWG has based its conclusions on international studies and overseas practices to derive a local definition of increased risk by adopting a set of qualitative risk stratification criteria, which include BRCA1/2 deleterious mutation carrier status, characteristics of family history and personal risk factors. Women at increased risk are categorised as being at ‘high risk’ or ‘moderate risk’ (Table 2).
     

    Table 2. Recommendations for breast cancer screening
     
    Enhanced surveillance for early detection of breast cancer has been suggested as a secondary preventive measure for women at increased risk. Although there has been no randomised controlled trial of mammography screening specifically in women at increased risk, previous observational studies concluded that mammography screening of high-risk population could be effective despite differences in study populations, criteria for risk stratification, screening protocols, and measures of effectiveness.48 49 50 51 Having said that, mammography generally has lower sensitivity in younger women and those with a genetic predisposition to breast cancer due to increased mammographic density obscuring the radiological features of early breast cancer in premenopausal women, and a higher likelihood of benign mammographic images for BRCA-related breast cancer.52
     
    Magnetic resonance imaging has been recommended as an adjunct to routine mammography for surveillance of women at high risk. Magnetic resonance imaging is more sensitive than mammography for detection of breast cancer among BRCA1/2 mutation carriers.53 54 The IARC review found improved sensitivity (95% vs 40%) but lower specificity (80% vs 95%) of MRI plus mammography compared with mammography alone.8
     
    In this regard, several studies have reported that breast cancer screening with MRI in women at increased risk has significantly shifted the stage at diagnosis from advanced stage to earlier and pre-invasive stage, when compared with other common screening modalities such as clinical breast examination, mammography, and ultrasonography.55 56 57 A modelling study of three large BRCA1/2 screening projects in UK, Canada, and the Netherlands demonstrated that screening with mammography and MRI (combined screening) detected relatively more DCIS and smaller invasive cancers in BRCA2 mutation carriers than BRCA1 mutation carriers, resulting in larger reductions in breast cancer mortality that ranged from 41.9% (for mammography alone) to 50.1% (combined screening) for BRCA1 and from 46.8% (for mammography alone) to 61.6% (combined screening) for BRCA2.58
     
    One survival analysis among 959 UK women with high-risk genetic mutations reported that 10-year survival was significantly higher in the MRI-screened carriers of BRCA1/2 mutations (95.3%) compared with unscreened mutation carriers (73.7%). However, the analysis did not show any significant difference in 10-year survival between the combined mammography plus MRI and mammography-only groups.59 The IARC review also found variable all-cause survival results among the reviewed cohort studies in women with BRCA1/2 mutation.8
     
    Notwithstanding the above, studies showed that MRI was superior to mammography in detecting hereditary breast cancer. The radiation risk and false-positive rate of different screening strategies should be considered when making individual screening decisions.60 Regarding the effectiveness of screening Chinese women at higher breast cancer risk, there is currently a lack of local studies on the role and effectiveness of MRI and/or mammography.
     
    Based on the emerging scientific evidence and international screening practices, the CEWG recommends that women at high risk of breast cancer see a doctor and undergo mammography screening every year, starting at age 35 or 10 years prior to the age at diagnosis of the youngest affected relative (for those with a family history), whichever is earlier, but not earlier than age 30. For confirmed carriers of BRCA1/2 deleterious mutations or women who have had radiation therapy to the chest between age 10 and 30 years (eg, for Hodgkin’s disease), the CEWG recommends that they consider additional annual screening by MRI.
     
    Women who have any first-degree female relative with confirmed BRCA1/2 deleterious mutations should be offered genetic testing to confirm or refute their carrier status. Apart from this, for women at high risk due to other types of family history of breast/ovarian cancer (Table 2) who wish to clarify their genetic risk or that of their family, referral to a specialist cancer clinic for advice, counselling and management should be discussed and considered. Genetic testing should be performed by specialised cancer centres with expertise in genetic counselling that should be provided before genetic testing. Health care professionals should discuss with their clients in detail the limitations, uncertainties, and implications of test results.
     
    There exists a group of women whose risk of developing breast cancer may not be as high as those with a genetic mutation or strong family history, but who are at moderate risk due to a family history of breast cancer. The CEWG recommends that women at moderate risk discuss with their doctor the pros and cons of breast cancer screening before deciding whether to start screening by mammography every 2 to 3 years. Magnetic resonance imaging is not recommended for women at moderate risk.
     
    Table 2 summarises the current CEWG recommendations for breast cancer screening in women at average and increased risk. A set of leaflets and a booklet on breast cancer prevention and screening are available (http://www.chp.gov.hk/en/content/9/25/31932.html) to the public to empower informed decision-making.
     
    Conclusion
    After taking into consideration the local epidemiology, emerging scientific evidence, and local and overseas screening practices, the CEWG concludes that it is unclear whether breast cancer screening does more harm than good for the asymptomatic woman at average risk, and has reaffirmed that there is insufficient evidence so far to recommend population-based mammography screening for these women. Individuals considering breast cancer screening should discuss the matter with their doctors and be adequately informed about the benefits and harms. Primary prevention, breast awareness, and timely medical attention for suspicious symptoms are recommended for women of any age. The CEWG recommends that women at high risk seek medical advice and counselling about breast cancer screening.
     
    The CEWG will continue to review emerging evidence for or against breast cancer screening and prevention, including the outcome of research commissioned by the Research Office of the Food and Health Bureau at a local institution to develop a validated risk prediction tool for the local population. The findings will facilitate formulation by the CEWG of evidence-based recommendations of criteria for breast cancer screening, especially for those at higher risk.
     
    Declaration
    As editors of this journal, DVK Chao, HHF Loong, and MCS Wong were not involved in the peer review process of this article. All other authors have no conflicts of interest to disclose. All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity. An earlier version of this article was published online in the Centre for Health Protection website, September 2017.
     
    References
    1. Hong Kong Cancer Registry, Hospital Authority. Female Breast Cancer in 2015. Available from: http://www3.ha.org.hk/cancereg/pdf/factsheet/2015/breast_2015.pdf. Accessed 21 Dec 2017.
    2. Department of Health, Census and Statistics Department, Hong Kong SAR Government. Mortality statistics in 2016. Available from: https://www.chp.gov.hk/en/healthtopics/content/25/53.html. Accessed 21 Dec 2017.
    3. Ervik M, Lam F, Ferlay J, Mery L, Soerjomataram I, Bray F. Cancer today. Lyon, France: International Agency for Research on Cancer. Cancer Today. Available from: http://gco.iarc.fr/today. Accessed 19 Sep 2017.
    4. Doll R, Payne P, Waterhouse J. Cancer Incidence in Five Continents: A Technical Report. Berlin: Springer Verlag; 1966.
    5. Segi M. Cancer Mortality for Selected Sites in 24 Countries (1950-57). Sendai: Tohoku University School of Public Health; 1960.
    6. Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer 1997;71:800-9. Crossref
    7. Kharazmi E, Chen T, Narod S, Sundquist K, Hemminki K. Effect of multiplicity, laterality, and age at onset of breast cancer on familial risk of breast cancer: a nationwide prospective cohort study. Breast Cancer Res Treat 2014;144:185-92. Crossref
    8. International Agency for Research on Cancer. IARC Handbooks of Cancer Prevention. Volume 15: Breast Cancer Screening. France: World Health Organization; 2016.
    9. Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol 2015;26:1291-9. Crossref
    10. Kwong A, Chen JW, Shin VY. A new paradigm of genetic testing for hereditary breast/ovarian cancer. Hong Kong Med J 2016;22:171-7. Crossref
    11. Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006;98:1694-706. Crossref
    12. Hong Kong Hereditary Breast Cancer Registry. Our Statistics: Analysis of participants recruited into research study till September 2017. Available from: http://www.asiabreastregistry.com/en/hereditary-cancers/our-statistics.Accessed 21 Dec 2017.
    13. Kwong A, Shin VY, Au CH, et al. Detection of germline mutation in hereditary breast and/or ovarian cancers by next-generation sequencing on a four-gene panel. J Mol Diagn 2016;18:580-94. Crossref
    14. World Cancer Research Fund. American Institute for Cancer Research. Breast Cancer 2010 Report: Food, nutrition, physical activity, and the prevention of breast cancer. 2010. Available from: http://www.wcrf.org/sites/default/files/Breast-Cancer-2010-Report.pdf. Accessed 19 Sep 2017.
    15. International Agency for Research on Cancer, World Health Organization. List of classifications by cancer sites with sufficient or limited evidence in humans. Vol 1-117. Available from: http://monographs.iarc.fr/ENG/Classification/Table4.pdf. Accessed 19 Sep 2017.
    16. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 2012;13:1141-51. Crossref
    17. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50 302 women with breast cancer and 96 973 women without the disease. Lancet 2002;360:187-95. Crossref
    18. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-27. Crossref
    19. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59. Crossref
    20. World Cancer Research Fund. American Institute for Cancer Research. Continuous update project. Analysing research on cancer prevention and survival. Diet, nutrition, physical activity and breast cancer. 2017. Available from: https://wcrf.org/sites/default/files/Breast-Cancer-2017-Report.pdf. Accessed 19 Sep 2017.
    21. Anderson WF, Pfeiffer RM, Dores GM, Sherman ME. Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 2006;15:1899-905. Crossref
    22. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med 2005;353:229-37. Crossref
    23. Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003;290:465-75. Crossref
    24. Singletary SE. Rating the risk factors for breast cancer. Ann Surg 2003;237:474-82. Crossref
    25. Brinton LA, Hoover R, Fraumeni JF, Jr. Reproductive factors in the aetiology of breast cancer. Br J Cancer 1983;47:757-62.
    26. Robinson D, Holmberg L, Møller H. The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ. Br J Cancer 2008;99:611-5. Crossref
    27. Kösters JP, Gøtzsche PC. Regular self-examination or clinical examination for early detection of breast cancer. Cochrane Database Syst Rev 2003;(2):CD003373. Crossref
    28. Mittra I, Mishra GA, Singh S, et al. A cluster randomized, controlled trial of breast and cervix cancer screening in Mumbai, India: methodology and interim results after three rounds of screening. Int J Cancer 2010;126:976-84. Crossref
    29. Pisani P, Parkin DM, Ngelangel C, et al. Outcome of screening by clinical examination of the breast in a trial in the Philippines. Int J Cancer 2006;118:149-54. Crossref
    30. Sankaranarayanan R, Ramadas K, Thara S, et al. Clinical breast examination: preliminary results from a cluster randomized controlled trial in India. J Natl Cancer Inst 2011;103:1476-80. Crossref
    31. Ohuchi N, Suzuki A, Sobue T, et al. Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): a randomised controlled trial. Lancet 2016;387:341-8. Crossref
    32. Gartlehner G, Thaler K, Chapman A, et al. Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk. Cochrane Database Syst Rev 2013;(4):CD009632. Crossref
    33. Lauby-Secretan B, Scoccianti C, Loomis D, et al. Breast-cancer screening—viewpoint of the IARC Working Group. N Engl J Med 2015;372:2353-8. Crossref
    34. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ 2014;348:g366. Crossref
    35. Autier P, Boniol M, Gavin A, Vatten LJ. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ 2011;343:d4411. Crossref
    36. Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2013;(6):CD001877. Crossref
    37. Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer 2013;108:2205-40. Crossref
    38. Swiss Medical Board. Systematic mammography screening. December 2013. Available from: http://www.medical-board.ch/fileadmin/docs/public/mb/fachberichte/2013-12-15_bericht_mammographie_final_kurzfassung_e.pdf. Accessed 19 Sep 2017.
    39. National Cancer Institute. International Cancer Screening Network. Breast cancer screening programs in 26 ICSN Countries, 2012: organization, policies, and program reach. December 2016. Available from: https://healthcaredelivery.cancer.gov/icsn/breast/screening.html. Accessed 31 Jan 2018.
    40. Epidemiology and Disease Control Division. Singapore Ministry of Health. National Health Survey 2010. Available from: https://www.moh.gov.sg/content/dam/moh_web/Publications/Reports/2011/NHS2010%20-%20low%20res.pdf. Accessed 31 Jan 2018.
    41. Health Promotion Administration, Taiwan Ministry of Health and Welfare. Breast cancer screening rate: Percentage of women aged 45-69 reporting a mammography in the past 2 years. Available from: http://210.71.254.151/dataset/143070580718. Accessed 31 Jan 2018.
    42. Jørgensen KJ, Zahl PH, Gøtzsche PC. Breast cancer mortality in organised mammography screening in Denmark: comparative study. BMJ 2010;340:c1241. Crossref
    43. Wong IO, Schooling CM, Cowling BJ, Leung GM. Breast cancer incidence and mortality in a transitioning Chinese population: current and future trends. Br J Cancer 2015;112:167-70. Crossref
    44. Kalager M, Zelen M, Langmark F, Adami HO. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med 2010;363:1203-10. Crossref
    45. Lui CY, Lam HS, Chan LK, et al. Opportunistic breast cancer screening in Hong Kong; a revisit of the Kwong Wah Hospital experience. Hong Kong Med J 2007;13:106-13.
    46. Wong IO, Kuntz KM, Cowling BJ, Lam CL, Leung GM. Cost-effectiveness analysis of mammography screening in Hong Kong Chinese using state-transition Markov modelling. Hong Kong Med J 2010;16 Suppl 3:38-41.
    47. Wong IO, Tsang JW, Cowling BJ, Leung GM. Optimizing resource allocation for breast cancer prevention and care among Hong Kong Chinese women. Cancer 2012;118:4394-403. Crossref
    48. Maurice A, Evans DG, Shenton A, et al. Screening younger women with a family history of breast cancer—does early detection improve outcome? Eur J Cancer 2006;42:1385-90. Crossref
    49. Kerlikowske K, Carney PA, Geller B, et al. Performance of screening mammography among women with and without a first-degree relative with breast cancer. Ann Intern Med 2000;133:855-63. Crossref
    50. Gui GP, Kadayaprath G, Darhouse N, et al. Clinical outcome and service implications of screening women at increased breast cancer risk from a family history. Eur J Surg Oncol 2006;32:719-24. Crossref
    51. Cortesi L, Turchetti D, Marchi I, et al. Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience. BMC Cancer 2006;6:210. Crossref
    52. Lord SJ, Lei W, Craft P, et al. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer 2007;43:1905-17. Crossref
    53. Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 2008;148:671-9. Crossref
    54. Passaperuma K, Warner E, Causer PA, et al. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer 2012;107:24-30. Crossref
    55. Kuhl C, Weigel S, Schrading S, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol 2010;28:1450-7. Crossref
    56. Sardanelli F, Podo F, Santoro F, et al. Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): final results. Invest Radiol 2011;46:94-105. Crossref
    57. Warner E, Hill K, Causer P, et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 2011;29:1664-9. Crossref
    58. Heijnsdijk EA, Warner E, Gilbert FJ, et al. Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined. Cancer Epidemiol Biomarkers Prev 2012;21:1458-68. Crossref
    59. Evans DG, Kesavan N, Lim Y, et al. MRI breast screening in high-risk women: cancer detection and survival analysis. Breast Cancer Res Treat 2014;145:663-72. Crossref
    60. Lowry KP, Lee JM, Kong CY, et al. Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis. Cancer 2012;118:2021-30. Crossref

    A paradigm shift in the provision of improved critical care in the emergency department

    DOI: 10.12809/hkmj176902
    © Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
     
    MEDICAL PRACTICE
    A paradigm shift in the provision of improved critical care in the emergency department
    KM Yim, MB, ChB, FHKCEM1,2; HF Ko, MB, BS, FHKCEM1; Marc LC Yang, MB, ChB, FHKCEM1; TY Li, MB, BS, FHKCEM1; S Ip, APN1; J Tsui, APN1
    1 Accident and Emergency Department, Queen Elizabeth Hospital, Jordan, Hong Kong
    2 Intensive Care Unit, Queen Elizabeth Hospital, Jordan, Hong Kong
     
    Corresponding author: Dr KM Yim (anferneeyim@gmail.com)
     
     Full paper in PDF
     
    Abstract
    With Hong Kong’s ageing population, advancement of medical technologies and hospital congestion, it is not uncommon for emergency physicians to encounter complicated critically ill patients in daily practice. It becomes a fundamental role of emergency physicians to initiate timely diagnostic and therapeutic interventions to save a patient’s life and improve their prognosis. It is the reason a critical care service has been developed in emergency departments worldwide over the last decade. This article shares how emergency department intensivists can contribute to this novel model of care with some illustrative cases. Advanced airway and peri-intubation management, difficult mechanical ventilation, treatment of shock, circulatory arrest, and metabolic disturbances can be safely and efficiently handled in the current emergency department setting. Obstacles, barriers, and the road ahead will be discussed.
     
     
     
    Introduction
    The provision of a critical care service in the emergency department (ED) was once considered synonymous with an intensive care unit (ICU). Nonetheless with more and more critically ill patients presenting to the ED, it is not uncommon for them to remain there for the first 1 to 2 hours of treatment. Examples include patients with out-of-hospital cardiac arrest and post-arrest care, septic shock, and status asthmaticus. In addition, ICU overcrowding results in some patients with relatively less critical disease entities such as diabetic ketoacidosis or hypokalaemia being triaged out from ICU admission. Nonetheless these patients still require close monitoring and intervention that are beyond the capacity of a general medical ward. It would be ideal for this group of patients to receive the same evidence-based aggressive intensive care measures regardless of their location within the hospital. An emergency department intensivist (EDI) can provide such care. Emergency department intensivist refers to a dually qualified emergency medicine (EM) and intensive care fellows who practises ED critical care as part of their clinical role.1
     
    The development of an intensive care subspecialty under the umbrella of emergency medicine is increasing rapidly around the world. For example, such combined training is provided by the Australian College of Emergency Medicine and College of Intensive Care Medicine of Australia, the Royal College of Emergency Medicine and the Faculty of Intensive Care Medicine in the United Kingdom, as well as the American Board of Internal Medicine, American Board of Emergency Medicine, and American Board of Medical Specialties in the United States. In our region, emergency physicians in mainland China, Taiwan, Singapore, Japan, and Macau are providing a critical care service in their EDs and some are even running their separate Emergency-ICU as well. As one of the preeminent medical hubs in Asia, we followed the trend several years ago. We have a well-established training pathway in Hong Kong for those wishing to attain dual fellowship qualification in EM and intensive care medicine (ICM). A memorandum of understanding was signed between the Hong Kong College of Anaesthesiologists and the Hong Kong College of Emergency Medicine in 2012. In order to become a dually qualified EDI, an Emergency Medicine fellow is required to complete a 2-year rotation in an accredited ICU and 1 year in an accredited anaesthesia training centre. The trainee should fulfil the training requirements of the ICM programme including regular tutorials, research projects, and success in a final examination to obtain the dual qualification.
     
    By bringing intensive care monitoring and therapies to the ED, EDI may provide timely, life-saving treatment to critically ill patients and mitigate the negative effect of ICU overcrowding by reducing the number of patients who progress to multi-organ dysfunction and reducing the need for ICU admission.2 3 Nonetheless international studies have emphasised that most EDs have not been designed or staffed to provide care beyond the initial resuscitation period in the first 20 to 60 minutes.4 5 Our ED has been transformed over the last few years to overcome such limitations. Examples include an expanded and dedicated resuscitation area in the ED; provision of the ability to perform basic hemodynamic monitoring, including measurements of arterial blood pressure, non-invasive cardiac output monitoring device, echocardiogram machines; mechanical ventilation capability, including high flow nasal cannula and conventional ICU ventilator; and an exchange programme for ED nursing staff so that they may develop proficiency in haemodynamic monitoring and mechanical ventilation.
     
    Hybrid and resource intensivist models
    There are two models of practice of EDI worldwide: the resource intensivist model and the hybrid model. In the former, the EDI plays a standard clinical role in the specialist roster of ED. Whenever a critically ill patient presents to the department, the EDI can provide additional expertise either as the primary physician or as an adviser. This has the benefit of exposing all clinical team members to the same level of care. It is similar to the toxicology model in the ED wherein the toxicologist can improve an entire department’s care of poisoned patients. The presence of EDIs may lead to similarly improved management. In the hybrid model, the ED resuscitation area is transformed to act as an ED-ICU. In this model, the EDI can easily shift the abilities of this resuscitation area to allow for the care of critically ill patients beyond the first hour and provide a similar intensity of care to that available in the ICU.1
     
    Our department adopts a mixed resource intensivist and hybrid model of care. Three of the four qualified EDIs in Hong Kong work in the department and act as resource intensivists. From November 2016, our department commenced provision of an ED specialist-led service specifically for all critically ill patients who presented to our resuscitation room between 08:00 and 18:00 on weekdays. About one third of such duties were assumed by the three EDIs, providing other clinical team members with opportunities to keep up-to-date with their skills, knowledge, and practice of managing critically ill patients. Physically, we have an expanded and dedicated area (Fig) that can care for up to six critically ill patients at any one time. Emergency department intensivists may decide the level of care required and this will depend on the clinical situation of the patient and review of the available resources and administrative considerations. At other times, EDIs are assigned duties in the normal EP roster. Emergency department intensivists can also provide on-site advice to emergency physicians upon request. The critical care team endeavours to incorporate critical care skills into routine ED practice, such that manpower utilisation is optimised and patient workflow is not altered. The team can function as a bridge that enables better communication between the ED and the ICU. Quality assurance is achieved by regular critical care audits, research, and sharing of local and international experience.
     

    Figure. Extended resuscitation area for patients requiring intensive care in the emergency department of Queen Elizabeth Hospital
     
    Extended triage and advanced resuscitation strategy
    We aimed to adopt an extended triage strategy. This involves the targeting of critically ill patients who require close monitoring with timely initiation of resuscitative and therapeutic measures in the presence of a readily reversible condition. Examples include metabolic diseases such as diabetic ketoacidosis and severely poisoned patients. The primary goal is to institute early aggressive therapy and monitoring. The patient can either be escalated to care in the ICU if a suboptimal response to therapy is evident, or admitted to a general ward if they show signs of recovery. Overseas study has quoted a 11.1% reduction in ICU admissions (patients were instead admitted to the general ward) after therapy was administered in the ED. It proved a preventive role of the ED in disease progression and ICU resource utilisation.6
     
    The increasing complexity of critically ill patients demands sophisticated skills and knowledge, both in the early diagnostic process and initial management. Examples include refractory septic shock, acute respiratory distress syndrome, and refractory cardiac arrest. Emergency department intensivists can provide advanced resuscitation to those patients in the ED who are awaiting ICU admission. It is well established that more rapid and aggressive treatment of sepsis and septic shock patients can reduce in-hospital mortality.7 The objective of advanced resuscitation is to stabilise acute physiological derangement, working up the underlying causes of acute deterioration, and initiating timely life-sustaining therapies. The following clinical case of septic shock illustrates how the EDI can integrate critical care into ED practice.
     
    We were referred a 40-year-old female with multi-lobar pneumonia and septic shock from a nearby private hospital in February 2017. Intensive care unit staff were immediately consulted and agreed to take the patient. Since an isolation facility was not immediately available within the ICU, it was expected that the patient would remain in the ED for at least 2 hours. On presentation, her saturation was 85% in a non-rebreathing mask, respiratory rate was 40/min, and she was in distress. Her blood pressure was 80/50 mm Hg and heart rate 130/min. Chest X-ray showed diffuse bilateral infiltration. After performing rapid sequence intubation with adequate pre-oxygenation, she remained in profound septic shock. The EDI managed her according to the latest Surviving Sepsis Campaign Guideline.8 The management strategy in the first 3 hours of presentation included adequate fluid resuscitation, lactate measurement, blood culture, and administration of a broad-spectrum antibiotic. Fluid responsiveness was frequently assessed by bedside echocardiography. Despite these measures that also included 2 litres of crystalloid, the patient remained hypotensive. Non-invasive blood pressure monitoring may not be optimal in this setting. Once thought to be within the ICU domain, arterial blood pressure monitoring is now readily available in ED. An arterial line can provide continuous blood pressure readings for vasopressor titration as well as enable the EDI to obtain valuable information about fluid responsiveness and perform frequent blood sampling. An arterial line and a central venous catheter were inserted into the patient using an aseptic technique and ultrasound guidance in accordance to international guidelines.9 Noradrenaline was the vasopressor of choice and the dose was titrated to maintain mean arterial pressure above 65 mm/Hg. Ceftriaxone was administered at a door-to-needle time of 30 minutes after blood culture. The first point-of-care lactate level was 6 mmol/L. After nearly 2 hours of aggressive resuscitation, the patient was transferred to ICU for further management. The lactate level on arrival was 3 mmol/L, demonstrating a significant improvement in perfusion. Urine pneumococcal antigen was positive. She was weaned off the vasopressor on day 2, and she was extubated and discharged to the general ward on day 3.
     
    We have also encountered other clinical cases where the extended triage and advanced resuscitation approach were adopted. A brief period of intensive therapy in the ED can alter the clinical trajectory with improved outcome and reduced resource utilisation for many crashing patients in the ED who have readily reversible conditions, eg, acute pulmonary oedema, diabetic ketoacidosis, and hypokalaemic periodic paralysis. Emergency physicians possess the skills required for airway management in the majority of patients and an EDI can lend additional support. This is especially true for those patients with a difficult airway, as well as hypoxic and hypotensive patients.10 11 12 13 14 15 16 Use of ventilation strategies in patients with respiratory failure are also within the realm of the EDI, eg, intubated asthmatic patients with high airway pressure connected to an ICU ventilator.17 18
     
    Extracorporeal cardiopulmonary resuscitation (ECPR) describes the application of percutaneous extracorporeal life support to the arresting patient, and aims to improve the survival to hospital discharge rate in cardiac arrest.19 Over the past decade, it has emerged as a salvage therapy in patients with refractory cardiac arrest. An algorithm has been described that involves screening of patients by an emergency physician for their suitability for ECPR, rapid access to the femoral vessels, and initiation of bypass in appropriate cases, without interruption of optimal traditional resuscitative efforts.20 The role of EDIs in this critical moment cannot be overemphasised. Since all EDIs have received extracorporeal life support (ECLS) training during their pursuit of ICU fellowship, they can liaise with intensivists in the identification of suitable candidate patients following application of strict inclusion/exclusion criteria, supervise ongoing resuscitation, as well as perform vascular cannulation. We recently initiated ECPR on a 40-year-old male in January 2016, with a history of diabetes and hypertension and witnessed cardiac arrest in the ED. The time to ECPR activation was 20 minutes from cardiac arrest. The time to establishment of an ECLS circuit was 50 minutes. Although the patient succumbed 3 days later due to advanced triple vessel disease not amenable to percutaneous coronary intervention or surgery, this case illustrates how the EDI can contribute to this novel therapeutic option in selected patients.
     
    The obstacles that we are facing
    Providing critical care in the ED is a paradigm shift in the local ED setting. There remains much to be learned.
     
    Emergency department overcrowding and staff shortages are the main obstacles to the provision of a critical care service in the ED. Many will argue that stabilising the critically ill patient in ED will slow their transfer to ICU. Resources may be directed to these patients while the care of non–critically ill patients will be compromised. Departmental leaders are reluctant to place an additional burden on staff who already have an overwhelming workload, especially during admission blocks and long waiting time. A separate medical and nursing staff roster for critically ill patients may alleviate the problem. Others may argue that critical care in the ED should be provided by in-patient intensivists who come down to the ED. Nonetheless with a scarcity of intensivists throughout the territory as well as a tremendous workload, this may not be possible.
     
    Leaders’ initiatives, colleagues’ acceptance, and devotion of emergency physicians are the keys to success. Even with adequate staffing, the meticulous management requirements in the care of critically ill patients do not appeal to some emergency physicians.2 In addition to regular departmental case conferences and in-house training, a course on emergency care of critically ill patients will be organised on a regular basis by the Hong Kong College of Emergency Medicine for doctors and nurses who work in the ED. The course will be tailor-made to suit the unique Hong Kong ED environment. Emergency care of critically ill patients focuses on initial stabilisation and advanced resuscitation techniques with lectures, simulations, and hands-on workshops. Through education and experience sharing, more and more emergency physicians may choose to join us to provide evidence-based aggressive care for critically ill patients in their own ED.
     
    Conclusion
    The benefits of providing critical care in the ED in reducing ICU length of stay and reducing ICU admission have been illustrated by studies in the United States.3 6 Nonetheless local data are lacking. There is a need to conduct research in order to convince administrators that more proximal delivery of critical care in the ED, before ICU admission, may decrease downstream ICU costs and yield significant system savings.
     
    We established a critical care registry in January 2017 for critically ill patients who present to our ED. A total of 100 cases were seen in 6 months. The outcome can be quantified by measuring patient improvement in physiological parameters using Acute Physiology and Chronic Health Evaluation II, Simplified Acute Physiology Score II, and Multiple Organ Dysfunction Score during their ED stay.3 Intensive care unit length of stay and mortality can be evaluated in future cost-effectiveness analyses.21 22 Hopefully, as data accrue, many of the perceived advantages of early critical care in the ED will be proven and accepted.
     
    Declaration
    All authors have no conflicts of interest to disclose. All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
     
    References
    1. Weingart SD, Sherwin RL, Emlet LL, Tawil I, Mayglothling J, Rittenberger JC. ED intensivists and ED intensive care units. Am J Emerg Med 2013;31:617-20. Crossref
    2. Gupta R, Butler RH. Fellowship training in critical care may not be helpful for emergency physicians. Ann Emerg Med 2004;43:420-1. Crossref
    3. Nguyen HB, Rivers EP, Havstad S, et al. Critical care in the emergency department: a physiologic assessment and outcome evaluation. Acad Emerg Med 2000;7:1354-61. Crossref
    4. Gill FJ, Leslie GD, Grech C, Latour JM. A review of critical care nursing staffing, education and practice standards. Aust Crit Care 2012;25:224-37. Crossref
    5. Goldstein RS. Management of the critically ill patient in the emergency department: focus on safety issues. Crit Care Clin 2005;21:81-9. Crossref
    6. Rivers EP, Nguyen HB, Huang DT, Donnino MW. Critical care and emergency medicine. Curr Opin Crit Care 2002;8:600-6. Crossref
    7. Seymour CW, Gesten F, Prescott HC, et al. Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med 2017;376:2235-44. Crossref
    8. Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 2017;43:304-77. Crossref
    9. American Society of Anesthesiologists Task Force on Central Venous Access, Rupp SM, Apfelbaum JL, et al. Practice guidelines for central venous access: a report by the American Society of Anesthesiologists task force on Central Venous Access. Anesthesiology 2012;116:539-73. Crossref
    10. Heffner AC, Swords DS, Nussbaum ML, Kline JA, Jones AE. Predictors of the complication of postintubation hypotension during emergency airway management. J Crit Care 2012;27:587-93. Crossref
    11. Heffner AC, Swords DS, Neale MN, Jones AE. Incidence and factors associated with cardiac arrest complicating emergency airway management. Resuscitation 2013;84:1500-4. Crossref
    12. Ramkumar V, Umesh G, Philip FA. Preoxygenation with 20° head-up tilt provides longer duration of non-hypoxic apnea than conventional preoxygenation in non-obese healthy adults. J Anesth 2011;25:189-94. Crossref
    13. Weingart SD, Levitan RM. Preoxygenation and prevention of desaturation during emergency airway management. Ann Emerg Med 2012;59:165-75.e1. Crossref
    14. Baillard C, Fosse JP, Sebbane M, et al. Noninvasive ventilation improves preoxygenation before intubation of hypoxic patients. Am J Respir Crit Care Med 2006;174:171-7. Crossref
    15. Wimalasena Y, Burns B, Reid C, Ware S, Habig K. Apneic oxygenation was associated with decreased desaturation rates during rapid sequence intubation by an Australian helicopter emergency medicine service. Ann Emerg Med 2015;65:371-6. Crossref
    16. Sakles JC, Mosier JM, Patanwala AE, Arcaris B, Dicken JM. First pass success without hypoxemia is increased with the use of apneic oxygenation during rapid sequence intubation in the emergency department. Acad Emerg Med 2016;23:703-10. Crossref
    17. Mannam P, Siegel MD. Analytic review: management of life-threatening asthma in adults. J Intensive Care Med 2010;25:3-15. Crossref
    18. Leatherman JW, McArthur C, Shapiro RS. Effect of prolongation of expiratory time on dynamic hyperinflation in mechanically ventilated patients with severe asthma. Crit Care Med 2004;32:1542-5. Crossref
    19. Ortega-Deballon I, Hornby L, Shemie SD, Bhanji F, Guadagno E. Extracorporeal resuscitation for refractory out-of-hospital cardiac arrest in adults: a systematic review of international practices and outcomes. Resuscitation 2016;101:12-20. Crossref
    20. Bellezzo JM, Shinar Z, Davis DP, et al. Emergency physician-initiated extracorporeal cardiopulmonary resuscitation. Resuscitation 2012;83:966-70. Crossref
    21. Cowan RM, Trzeciak S. Clinical review: emergency department overcrowding and the potential impact on the critically ill. Crit Care 2005;9:291-5. Crossref
    22. Huang DT. Clinical review: impact of emergency department care on intensive care unit costs. Crit Care 2004;8:498-502. Crossref

    Complexity of syncope in elderly people: a comprehensive geriatric approach

    DOI: 10.12809/hkmj176945
    © Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
     
    MEDICAL PRACTICE  CME
    Complexity of syncope in elderly people: a comprehensive geriatric approach
    CW Wong, FHKAM (Medicine), FHKCP
    Department of Medicine and Geriatrics, Caritas Medical Centre, Shamshuipo, Kowloon, Hong Kong
     
    Corresponding author: Dr CW Wong (chitwaiwong@hotmail.com)
     
     Full paper in PDF
     
    Abstract
    Syncope is a prevalent health problem among elderly people. It may be neurally mediated or caused by conditions such as orthostatic hypotension, postprandial hypotension, and cardiac disorders. A combination of different aetiologies is not uncommon in the elderly people. Many pathophysiological processes, including age-related physiological changes, co-morbidities, concomitant medication use, and prolonged bedrest, coexist and predispose elderly people to syncope; advanced age and cardiac syncope are associated with increased mortality. Recurrent syncope and its co-morbidities, such as fall-related physical injury, negative psychological impact, and functional decline, may increase the dependency of elderly patients. Furthermore, the overlap between falls and syncope, and the interaction between syncope and frailty complicate management. Available clinical guidelines for the management of syncope that focus on diagnosis, investigation, and treatment are therefore insufficient to address syncope in elderly patients. A comprehensive geriatric approach that considers an individual’s functional and cognitive capacities, as well as medical and psychosocial aspects, would be more appropriate.
     
     
     
    Introduction
    Syncope is a transient loss of consciousness (LOC) and postural tone resulting from global cerebral hypoperfusion, followed by spontaneous and complete recovery and no neurological sequelae.1 This pathophysiology distinguishes syncope from other causes of transient LOC, including metabolic disorder, epileptic seizure, and transient ischaemic attack.
     
    Syncope is prevalent in elderly populations. After a peak in younger populations (age, 10-30 years), the incidence of syncope increases sharply from 5.4 events per 1000 person-years in people aged 60 to 69 years to 11.1 events per 1000 person-years in those aged 70 to 79 years, and reaching 19.5 events per 1000 person-years in those aged 80 years or older.2 The incidence is similar for men and women but tends to increase in women of advanced age. The prevalence of syncope is high for the institutionalised elderly, at 23%.3 Syncope in elderly patients often presents atypically, such as with falls. Elderly patients may also have difficulty in recalling events. Therefore, the true incidence and prevalence of syncope are expected to be higher than those estimated in some previous studies.
     
    Syncope is typically an isolated disease in young people. However, it is usually multifactorial and associated with many predisposing factors in the elderly people; thus, its management is challenging. In this article, the aetiology of syncope in the elderly people, pathophysiological factors that impair haemodynamic homeostasis, consequences of syncope, and relationships between syncope and falls and between syncope and frailty are discussed. Finally, a comprehensive approach for the management of syncope in elderly patients is recommended.
     
    Causes of syncope in the elderly people
    The causes of syncope are highly age-dependent.4 Reflex or neurally mediated syncope is the most common cause, particularly in younger patients. With increasing age, orthostatic hypotension (OH) and cardiac syncope occur more frequently.
     
    Reflex or neurally mediated syncope
    Reflex syncope is a heterogeneous group of conditions, including vasovagal syncope, situational syncope, and carotid sinus syndrome, and is the most frequent cause of syncope in the elderly people (44% of cases).5 In reflex syncope, the cardiovascular reflexes that normally help control the circulation become intermittently inappropriate (eg, inappropriate vasodilation or bradycardia) in response to a trigger (eg, emotion or orthostatic stress).
     
    Vasovagal syncope is the most common form of reflex syncope and is mediated by the vasovagal reflex. The most common triggers in elderly people are prolonged standing or sitting and use of vasodilator drugs. The classic prodromal features (pallor, diaphoresis, nausea, and warmth) are less prominent in elderly people.
     
    Situational syncope occurs in conditions that trigger the Valsalva manoeuvre, such as urination, defaecation, coughing, and swallowing.
     
    Syncope exacerbated by the carotid sinus reflex response is referred to as carotid sinus syndrome (CSS). It is related to underlying carotid sinus hypersensitivity, which is diagnosed when carotid sinus massage (CSM) produces asystole longer than 3 seconds (cardioinhibitory CSS) or a reduction in systolic blood pressure (SBP) by more than 50 mm Hg (vasodepressor CSS). Carotid sinus syndrome typically occurs in adults older than 50 years and is predominant in men. There is usually no identifiable trigger, but CSS may be precipitated by sudden head turning and wearing tight clothing around the neck.6 Carotid sinus syndrome is regarded as a significant cause of syncope and unexplained falls in the elderly people; as many as 45% of elderly patients presenting with syncope or unexplained falls demonstrate carotid sinus hypersensitivity.7 8
     
    Orthostatic hypotension
    Orthostatic hypotension (OH) is prevalent in elderly people and in those who are frail, affecting up to 18% of people aged 65 years or older9 and up to 52% of institutionalised elderly patients.10 It also accounts for 30% of cases of syncope in patients aged 75 years or older.5 Orthostatic hypotension is defined as a sustained reduction in systolic blood pressure of at least 20 mm Hg or in diastolic blood pressure of 10 mm Hg, within 3 minutes of standing.11 Because elderly patients may present beyond 3 minutes of standing and OH may not always be reproducible in elderly people, repeated measurement—preferably in the morning—may be required. Among factors that precipitate OH are age-related changes in the blood pressure regulatory mechanism, disease-related autonomic dysfunction, and numerous other factors that decrease cardiac output or total peripheral vascular resistance (Table). Occurrence of OH is significantly related to the number of co-morbidities and to potentially causative medications.12 13 However, supine systolic hypertension is often also present in elderly people with OH and further complicates management of OH.
     

    Table. Aetiology and precipitating factors of syncope
     
    Postprandial hypotension
    Postprandial hypotension (PPH) is also common in the elderly people, with a prevalence reaching 59% in older Chinese men, especially in those older than 80 years.14 It is often under-recognised as a potential cause of syncope and is seldom mentioned in published clinical guidelines on syncope. In one study, PPH accounted for 8% of syncopal episodes.15 Postprandial hypotension is defined as a decline in systolic blood pressure of 20 mm Hg or more, or to lower than 90 mm Hg, within 2 hours of starting a meal.16 Similar to OH, PPH is more likely to occur in the morning. Consuming a meal that is large or rich in carbohydrates also increases the risk of PPH. The condition is caused by the pooling of blood in the splanchnic vascular bed. Although PPH occurs frequently with OH, the pathophysiological mechanisms of OH and PPH may be different.17 Postprandial hypotension is more likely to occur if patients have diabetes mellitus, hypertension, or Parkinson’s disease, or if they take multiple concurrent medications, particularly diuretics.18 19
     
    Cardiac syncope
    Cardiac syncope accounts for up to 15% of cases of syncope in the elderly people.5 20 It is caused by impaired cardiac output due to arrhythmia or structural heart disease in which left ventricular blood flow is obstructed. Arrhythmia—either bradyarrhythmia or tachyarrhythmia—is the most common cause of cardiac syncope. Calcific degenerative aortic stenosis is the most common valvular lesion in the elderly people and also the most common structural cardiovascular cause of syncope.21 In general, cardiac syncope is associated with a high mortality rate.2
     
    Unexplained syncope
    The prevalence of unexplained syncope has decreased as the use of diagnostic techniques, such as the tilt-table test and CSM, has increased. These techniques can identify reflex syncope and CSS in the elderly people. The reported proportion of elderly patients with unexplained syncope decreased from 40% in 198622 to 10% in 2006.5 For elderly patients with syncope in whom the aetiology remains undetermined after extensive evaluation, it is important to look for a cardiac cause. In a study using an implantable loop recorder, arrhythmia accounted for 59% of all recurrences of syncope that would previously have been regarded as unexplained.23
     
    Multiple causes of syncope
    There are commonly multiple potential causes of syncope in elderly patients: in 23.5% of those aged 65 or older and in 13.4% of those younger than 65 years.24 Apart from older age, patients with atrial fibrillation or symptomatic heart failure, or those receiving drug therapy for cardiac conditions are more likely than others to have multiple causes of syncope. The presence of multiple causes also correlates with poor survival.
     
    Multiple risk factors in the elderly people
    Maintaining blood pressure at a constant level during a wide range of daily activities or conditions requires an intact cardiovascular system, baroreflex function, autonomic nervous system, and humoural regulatory mechanism. Age-related change in the blood pressure regulatory mechanism increases the susceptibility to syncope in elderly people. Baroreflex sensitivity is blunted by ageing, resulting in reduced heart rate and reduced vasoconstriction response to hypotensive stimuli.25 Furthermore, elderly people are prone to dehydration and reduced blood volume owing to reduced thirst sensation, reduction in renin–aldosterone activity, and elevation of atrial natriuretic peptide, which decreases the kidneys’ capacity to conserve salt and water.26 27 The blunted baroreflex response and contracted blood volume, together with age-related diastolic dysfunction, can lead to low cardiac output and thus low cerebral blood flow. The latter predisposes elderly people to syncope under conditions causing hypotensive stress.
     
    Co-morbidities and concomitant medication use can impair the adaptive response to hypotensive stress. Any conditions that contribute to haemodynamic stress or impair the blood pressure regulation mechanism, leading to decreased cardiac output or total peripheral vascular resistance (vasodilation), predispose the elderly people to reflex syncope and OH. Syncope can be induced by acute conditions, such as sepsis, myocardial infarction, cardiac arrhythmia, heart failure, haemorrhage, and dehydration. It can also be induced by chronic conditions such as chronic adrenal suppression from steroid use (which can produce hypovolaemia), as well as untreated or uncontrolled hypertension and coronary heart disease. Untreated or uncontrolled hypertension can increase the risk of OH by reducing baroreflex sensitivity and shifting the threshold for cerebral autoregulation to a higher blood pressure,28 29 whereas coronary heart disease is associated with carotid sinus hypersensitivity.30 In addition, patients presenting with OH may have autonomic insufficiency, which can be secondary to peripheral nervous system diseases, such as diabetes mellitus, alcoholism, chronic kidney disease, vitamin B12 deficiency, and paraneoplastic disease. Autonomic insufficiency may also be due to central nervous system diseases, such as multiple system atrophy, dementia with Lewy bodies, and Parkinson’s disease.
     
    The Table lists the medications that may precipitate syncope. Although antihypertensive drugs are commonly thought to increase the risk of postural blood pressure drop and thus OH, clinical trials have shown inconsistent results.31 On the contrary, the reduction or normalisation of blood pressure by antihypertensive agents may even improve OH in elderly patients with hypertension.32 However, excessive blood pressure reduction and concurrent use of three or more antihypertensive drugs is independently associated with OH.12 13 Diuretics, nitrates, antipsychotics, tricyclic antidepressants, and levodopa can also induce OH. Drugs that can induce QT prolongation and torsades de pointes include antiarrhythmics and antipsychotics.33 Drugs that can cause bradyarrhythmia include amiodarone, beta-blockers, calcium channel blockers, and digoxin. Because of age-related changes in pharmacokinetics and pharmacodynamics, the adverse effects and interactions of these drugs are further exacerbated in the elderly people.
     
    Bedrest is common in patients with acute illness or in those who are frail or chronically ill. After prolonged bedrest, however, elderly patients can develop syncope when sitting up. Prolonged bedrest can cause deconditioning in the musculoskeletal and cardiovascular system, as well as pressure natriuresis, which in turn induces blood volume contraction. These conditions can aggravate OH, syncope, and fall.34
     
    All of the above pathophysiological processes can act together to impair cardiovascular compensation for haemodynamic stress in elderly people and thereby complicate the management of syncope.
     
    Consequences of syncope
    Whether syncope independently increases the risk of overall or cardiac mortality remains controversial. Nonetheless, among patients with syncope, mortality generally tends to increase with advancing age and in those with cardiac syncope and OH.35 36 37 38 39 A 2-year study found that the overall mortality rate was 0% in patients aged 65 to 69 years, increasing to 14%, 22%, and 43% in patients aged 70 to 79 years, 80 to 89 years, and ≥90 years, respectively.37 Syncope of cardiac cause was noted to have higher 5-year mortality (51%) than non-cardiac (30%) or unknown-cause (24%) mortality.38 Orthostatic hypotension is associated with a significantly increased risk of death for patients younger than 65 years (relative risk = 1.78; 95% confidence interval = 1.25-2.52) but not for older patients.39 Overall prognosis is worse in patients with an underlying cardiac disease such as myocardial infarction, arrhythmia, structural cardiac defect, cardiomyopathy, or congestive heart failure, regardless of the occurrence or aetiology of syncope.36 40 41 The presence of multiple potential causes of syncope also predicts a lower survival rate as compared with a single cause of syncope (73% vs 89% at 4 years).24 In contrast, patients with non-cardiac co-morbidities or no underlying heart disease are at low risk.
     
    Patients with a history of syncope have an increased risk of recurrence. Patients with syncope have a 20% recurrence rate at 1 year, compared with a 2% rate of syncope in patients without prior syncope.40 The recurrence rate is even higher in the institutionalised elderly, at 30%.3 Syncope recurs more frequently in older patients at 2 years, with a rate of 28% in patients aged 65 to 79 years, 37% in those aged 80 to 89 years, and 43% in those older than 90 years.37 Other factors predicting recurrence include the concurrent use of multiple medications with known adverse effects of OH or syncope and cardiac co-morbidities, particularly atrial fibrillation, atrioventricular or left bundle branch block, or aortic valve stenosis.42 Recurrence may not be related to the aetiology of syncope, although a higher recurrence in patients affected by reflex and unexplained syncope has been reported.36
     
    Besides physical injuries and disabilities due to syncope-related falls, depression and fear of falling after syncope may reduce elderly patients’ functional capacity and mobility, and can result in institutionalisation. Furthermore, syncope can negatively affect quality of life,43 particularly in patients who are older, have multiple co-morbidities, and experience recurrent episodes of syncope.44
     
    Syncope and falls
    There is an overlap between syncope and falls in the elderly people; syncope causes falls and some falls are due to syncope. Although taking an accurate history of an event allows the differentiation between syncope and fall, the history is often unreliable in the elderly people because of poor recall and lack of witnesses. Many elderly patients will only recall the fall but not realise they fainted; amnesia is common (up to 42%) for witnessed syncope, even in cognitively normal elderly patients.6 7 8 45 This is particularly the case for CSS: in one study, 21% of patients with CSS presented with falls alone and 27% failed to recall the syncope event.6 Furthermore, frequently reported reasons for falls in the elderly people, such as muscle weakness, arthritis, gait and balance problems, visual impairment, functional decline, depression, cognitive impairment, polypharmacy, and environmental factors,46 47 may distract clinicians from searching for syncope.
     
    Nonetheless, multiple co-morbidities and polypharmacy associated with advancing age predispose elderly people to both falls and syncope. Moderate haemodynamic changes that are insufficient to cause syncope may cause falls in elderly patients with gait balance instability or slow protective reflexes.48 Such falls may be indistinguishable from syncope in elderly patients. Considering that syncope may be a component of fall in elderly patients, especially in those with unwitnessed or recurrent unexplained fall, assessment of cardiovascular status and postural blood pressure, as well as further investigation for accurate diagnosis and treatment, are recommended.47
     
    Syncope and frailty
    Frailty that leads to diminished functional reserve and adverse health outcomes is defined as the presence of three of more of the following criteria: unintentional weight loss (10 lbs [~4.5 kg] in the past year), self-reported exhaustion, weakness (grip strength), slow walking speed, and low physical activity.49 The relationship between frailty and syncope is not well described in the literature. However, there is an interaction between ageing, co-morbidities, and the development of frailty (Fig 1). Co-morbidities are common among the elderly people. As many as 82% of people aged 65 years or older have one or more chronic conditions.50 Advancing age and co-morbidities, in turn, increase the likelihood of being frail. Conversely, frail people are likely to have more co-morbidities.51 Age-related physiological changes and co-morbidities also increase the risk of syncope and falls. Thus, an episode of syncope with a fall may act as an acute stressor in the elderly people. The decreased physiological reserve in frail elderly patients inhibits their response to acute stressors. This inhibited response leads to rapid functional decline and results in hospitalisation, dependency, and institutionalisation (Fig 1).
     

    Figure 1. Interaction between syncope, age, frailty, and co-morbidities
     
    Comprehensive geriatric approach
    According to clinical guidelines,1 52 initial evaluation for syncope starts with careful recording of the patient’s history, physical examination (including orthostatic blood pressure measurement), and electrocardiography (ECG). On the basis of these findings, additional examinations such as Holter monitoring, CSM, tilt-table test, echocardiography, and blood tests may be performed. The purpose of the initial evaluation is to differentiate syncopal from non-syncopal conditions, to determine the cause of syncope, and to stratify the risk of major cardiovascular events or death. Predictors of high cardiovascular risk are the presence of structural heart disease or coronary artery disease (eg, heart failure, low left ventricular ejection fraction, and previous myocardial infarction), palpitation before syncope, syncope during exertion or in the supine position, and ECG features suggesting arrhythmic disturbance. Initial evaluations can identify a certain or highly likely cause of syncope in 63% of patients.53 If the cause remains uncertain, further investigation is indicated. The subsequent tests are based on the findings of the initial evaluation and suspected aetiology: tilt-table test for reflex syncope or OH; CSM for elderly people with unexplained falls; Holter monitoring or external/implantable loop recording to detect arrhythmia in recurrent unpredictable syncope; echocardiography for structural heart disease and cardiac function, especially in the presence of abnormal findings of ECG or cardiovascular examination or suspicion from history; or neurological evaluation for autonomic failure or neurological conditions that are difficult to differentiate from syncope. Treatment depends on the underlying causes and usually includes the following:
  • Patient education to avoid triggers (prolonged standing or extreme environments), to recognise prodromal symptoms, and to perform manoeuvres to abort episodes of syncope
  • Review and adjustment of the patient’s medication
  • Non-pharmacotherapies for OH, including increasing fluid and salt intake, eating frequent small meals and low-carbohydrate meals, raising the head of the bed when sleeping, slowly rising from the supine position, wearing compression stockings or an abdominal binder (compression belt), and exercising
  • Pharmacotherapies for OH, including fludrocortisone, midodrine, and octreotide
  • Cardiac interventions for cardiac syncope or CSS with cardioinhibitory response, including cardiac pacing or an implantable cardiac defibrillator
  •  
    However, as outlined in this article, syncope in elderly people has certain complexities—namely, (1) there is a marked overlap between syncope, fall, and dizzy spell, and atypical presentations make diagnosis difficult; (2) the syncope event is often multifactorial, with many predisposing factors; and (3) management is often complicated by underlying co-morbidities, concomitant medication use, cognitive and functional decline, and declined psychosocial support. Therefore, the above standard structural approach is insufficient to address syncope in elderly patients. Comprehensive geriatric assessment, “a multidimensional interdisciplinary diagnostic process focused on determining a frail elderly person’s medical, psychological and functional capacity in order to develop a coordinated and integrated plan for treatment and long term follow up”, is recommended.54 This comprehensive approach is both a diagnostic and a therapeutic process and involves a multidisciplinary team (physician, nurse, physiotherapist, occupational therapist, and social worker) with the collective goal of improving care outcomes and quality of life for elderly people. When an elderly patient is referred for syncope, an unexplained fall, or dizziness, comprehensive geriatric assessment is applied to obtain a thorough history and physical examination, together with assessments for co-morbidities, frailty, cognitive and functional status, psychological and social variables, and medication review (Fig 2). After extensive evaluation, a problem list is generated with details of the identified syncope event and its cause or predisposing factors, whether the patient is at high risk of cardiovascular event or death, and any cognitive or functional impairments or psychosocial problems. Then, multidisciplinary interventions are integrated with the patient’s or caregiver’s preferences, so as to conserve the patient’s health status, improve psychosocial support, and maintain the patient’s independence and community living situation. The following should be considered in the management of syncope:
  • Because of the overlap between syncope and falls, comprehensive geriatric assessment for syncope should be applied to include elderly people with falls, especially unexplained falls.
  • Although the tilt-table test and CSM are regarded as safe in elderly people, the patient’s tolerance to such tests should be considered, especially in frail patients.
  • The extent of investigations depends on the patient’s risk of cardiovascular events or death, and the severity of the symptoms and the frequency of recurrence. For example, for patients with a single episode who are at low risk of cardiac syncope, a test to confirm reflex syncope may be unnecessary.
  • Stepped management starts with non-pharmacotherapy (such as education, medication adjustment, and physical manoeuvres), then pharmacotherapy if the patient’s condition does not improve.
  •  

    Figure 2. Comprehensive geriatric assessment for syncope in elderly patients
     
    An example of comprehensive geriatric assessment for elderly people referred for syncope is presented in the following case scenario. A 75-year-old woman was admitted to hospital after an episode of transient LOC. She reported walking down the street then feeling dizzy, passing out, and falling on the ground. There were no eyewitnesses. The patient recovered spontaneously but could not recall the duration of LOC. She denied any preceding events such as palpitation or chest discomfort, except dizziness. The patient reported having experienced similar episodes twice in the previous 2 years, once while standing and once while walking. Her medical history included hypertension, type 2 diabetes mellitus, ischaemic heart disease, and knee osteoarthritis, for which she was taking ramipril, metformin, metoprolol, amlodipine, isosorbide mononitrate, and amitriptyline. The patient lived alone, walked unaided, and went out shopping daily. She expressed concerned about recurrent dizziness and falls, which had restrained her social activities. Physical examination revealed postural blood pressure drop from 110/60 to 90/50 mm Hg within 3 minutes of standing, normal heart sound, varus deformities in both knees due to osteoarthritis, and lower-limb weakness with muscle power grade 4/5. Laboratory studies revealed a haemoglobin level of 100 g/L with a mean corpuscular volume of 98 fL; serum vitamin B12, 120 pmol/L; random serum glucose, 6 mmol/L; and haemoglobin A1c, 5.8%. Results of renal and liver function tests and ECG were normal. A nurse, a physiotherapist, and an occupational therapist also assessed the patient.
     
    Relevant problems included the following:
  • Causes and predisposing factors for syncope: OH, vitamin B12 deficiency (probably related to long-term metformin intake), antihypertensive agent use, and amitriptyline use
  • Fair drug compliance: sometimes forgot to take drugs or increased amitriptyline dosage because of pain
  • Good diabetic control with haemoglobin A1c of 5.8%; possible risk of hypoglycaemia
  • Varus deformity due to osteoarthritis of the knee; lower limb weakness, with risk of falls
  • Living environment: no lift; needed to climb 2 flights of stairs
  • Anxiety about recurrent dizziness and falls; poor psychosocial support because there were no close relatives in Hong Kong
  •  
    Interventions implemented in this case were as follows:
  • Physician: discontinued metformin therapy and arranged patient blood glucose monitoring, decreased amlodipine dosage and arranged blood pressure monitoring, initiated vitamin B12 replacement, discontinued amitriptyline, added paracetamol for pain relief with dosage titration and monitored response, and arranged regular follow-up
  • Community nurse service: arranged home visits to monitor blood pressure and blood glucose, provide education on manoeuvres to minimise postural dizziness, and administer and supervise drugs intake
  • Physiotherapist and occupational therapist: referred the patient to geriatric day hospital for muscle strengthening and mobility and activities of daily life training, and prescribed walking aids
  • Social worker: arranged home support services such as meal delivery, household cleaning, and personal assistant service.
  •  
    Conclusions
    In younger patients, vasovagal syncope is the predominant aetiology of syncope. In contrast, CSS, OH, PPH, and cardiac syncope become more prevalent with advancing age. Multiple aetiologies are frequently observed in elderly patients. Interactions among age-related physiological changes, co-morbidities, and concomitant medication use impair haemodynamic homeostasis and predispose elderly people to syncope. These factors, together with cognitive impairment, functional decline, and frailty associated with advanced age, make the management of syncope in elderly patients complex. Structured clinical guidelines are insufficient to manage syncope in elderly patients. Use of a comprehensive geriatric approach to integrate an individual’s co-morbidities, cognitive and functional capacities, and medical and psychosocial aspects is more appropriate and beneficial for elderly patients so as to maintain functional state and quality of life.
     
    Declaration
    The author has no conflicts of interest to disclose.
     
    References
    1. Task Force for the Diagnosis and Management of Syncope; European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA); Heart Failure Association (HFA); Heart Rhythm Society (HRS), Moya A, Sutton R, Ammirati F, et al. Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J 2009;30:2631-71. Crossref
    2. Soteriades ES, Evans JC, Larson MG, et al. Incidence and prognosis of syncope. N Engl J Med 2002;347:878-85. Crossref
    3. Lipsitz LA, Wei JY, Rowe JW. Syncope in an elderly, institutionalised population: prevalence, incidence, and associated risk. Q J Med 1985;55:45-54.
    4. Strickberger SA, Benson DW, Blaggioni L, et al. AHA/ACCF scientific statement on the evaluation of syncope: from the American Heart Association Councils on Clinical Cardiology, Cardiovascular Nursing, Cardiovascular Disease in the Young, and Stroke, and the Quality of Care and Outcomes Research Interdisciplinary Working Group; and the American College of Cardiology Foundation in Collaboration with the Heart Rhythm Society. J Am Coll Cardiol 2006;47:473-84. Crossref
    5. Ungar A, Mussi C, Del Rosso A, et al. Diagnosis and characteristics of syncope in older patients referred to geriatric departments. J Am Geriatr Soc 2006;54:1531-6. Crossref
    6. Kenny RA, Traynor G. Carotid sinus syndrome—clinical characteristics in elderly patients. Age Ageing 1991;20:449-54. Crossref
    7. McIntosh SJ, Lawson J, Kenny RA. Clinical characteristics of vasodepressor, cardioinhibitory, and mixed carotid sinus syndrome in the elderly. Am J Med 1993;95:203-8. Crossref
    8. Davies AJ, Steen N, Kenny RA. Carotid sinus hypersensitivity is common in older patients presenting to an accident and emergency department with unexplained fall. Age Ageing 2001;30:289-93. Crossref
    9. Rutan GH, Hermanson B, Bild DE, Kittner SJ, LaBaw F, Tell GS. Orthostatic hypotension in older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. Hypertension 1992;19(6 Pt 1):508-19. Crossref
    10. Ooi WL, Barrett S, Hossain M, Kelley-Gagnon M, Lipsitz LA. Patterns of orthostatic blood pressure change and their clinical correlates in a frail, elderly population. JAMA 1997;277:1299-304. Crossref
    11. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neutrally mediated syncope and the postural tachycardia syndrome. Auton Neurosci 2011;161:46-8. Crossref
    12. Kamaruzzaman S, Watt H, Carson C, Ebrahim S. The association between orthostatic hypotension and medication use in British women’s heart and health study. Age Ageing 2010;39:51-6. Crossref
    13. Poon IO, Braun U. High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther 2005;30:173-8. Crossref
    14. Zou X, Cao J, Li JH, et al. Prevalence of and risk factors for postprandial hypotension in older Chinese men. J Geriatr Cardiol 2015;12:600-4.
    15. Lipsitz LA, Pluchino FC, Wie JY, Rowe JW. Syncope in institutionalized elderly: the impact of multiple pathological conditions and situational stress. J Chronic Dis 1986;39:619-30. Crossref
    16. Jansen RW, Lipsitz LA. Postprandial hypotension: epidemiology, pathophysiology, and clinical management. Ann Intern Med 1995;122:286-95. Crossref
    17. Vloet LC, Pel-Little RE, Jansen PA, Jansen RW. High prevalence of postprandial and orthostatic hypotension among geriatric patients admitted to Dutch hospitals. J Gerontol A Biol Sci Med Sci 2005;60:1271-7. Crossref
    18. Puisieux F, Bulckaen H, Fauchais AL, Drumez S, Salomez-Granier F, Dewailly P. Ambulatory blood pressure monitoring and postprandial hypotension in elderly persons with falls or syncopes. J Gerontol A Biol Sci Med Sci 2000;55:M535-40. Crossref
    19. Luciano GL, Brennan MJ, Rothberg MB. Postprandial hypotension. Am J Med 2010;123:281.e1-6. Crossref
    20. Galizia G, Abete P, Mussi C, et al. Role of early symptoms in assessment of syncope in elderly people: results from the Italian group for the study of syncope in the elderly. J Am Geraitr Soc 2009;57:18-23. Crossref
    21. Iivanainen AM, Lindroos M, Tilvis R, Heikklä J, Kupari M. Natural history of aortic valve stenosis of varying severity in the elderly. Am J Cardiol 1996;78:97-101. Crossref
    22. Kapoor W, Snustad D, Peterson J, Wieand HS, Cha R, Karpf M. Syncope in the elderly. Am J Med 1986;80:419-28. Crossref
    23. Edvardsson N, Frykman V, van Mechelen R, et al. Use of an implantable loop recorder to increase the diagnostic yield in unexplained syncope: results from the PICTURE registry. Europace 2011;13:262-9. Crossref
    24. Chen LY, Gersh BJ, Hodge DO, Wieling W, Hammill SC, Shen WK. Prevalence and clinical outcomes of patients with multiple potential causes of syncope. Mayo Clin Proc 2003;78:414-20. Crossref
    25. Lipsitz LA. Altered blood pressure homeostasis in advancing age: clinical and research implications. J Gerontol 1989;44:M179-83. Crossref
    26. Bauer JH. Age-related changes in the renin-aldosterone system, Physiological effect and clinical implication. Drugs Aging 1993;3:238-45. Crossref
    27. Davis KM, Fush LC, Minaker KL, Elahi D. Atrial natriuretic peptide levels in the elderly: differentiating normal aging changes from disease. J Gerontol A Biol Sci Med Sci 1996;51:M95-101. Crossref
    28. Bristow JD, Honour AJ, Pickering GW, Sleight P, Smith HS. Diminished baroreflex sensitivity in high blood pressure. Circulation 1969;39:48-54. Crossref
    29. Strandgaard S. Autoregulation of cerebral blood flow in hypertensive patients. The modifying influence of prolonged antihypertensive treatment on the tolerance to acute, drug-induced hypotension. Circulation 1976;53:720-7. Crossref
    30. Brown KA, Maloney JD, Smith CH, Haritzler GO, Ilstrup DM. Carotid sinus reflex in patients undergoing coronary angiography: relationship of degree and location of coronary artery disease to response to carotid sinus massage. Circulation 1980;62:697-703. Crossref
    31. Hajjar I. Postural blood pressure changes and orthostatic hypotension in the elderly patient: impact of antihypertensive medications. Drugs Aging 2005;22:55-68. Crossref
    32. Masuo K, Mikami H, Ogihara T, Tuck ML. Changes in frequency of orthostatic hypotension in elderly hypertensive patients under medications. Am J Hypertens 1996;9:263-8. Crossref
    33. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003;89:1363-72. Crossref
    34. Stuempfle KJ, Drury DG. The physiological consequences of bed rest. J Exerc Physiol Online 2007;10:32-41.
    35. Alshekhlee A, Shen WK, Mackall J, Chelimsky TC. Incidence and mortality rates of syncope in the United States. Am J Med 2009;122:181-8. Crossref
    36. Racco F, Sconocchini C, Alesi C, Zappelli L, Pratillo G. Long-term follow-up after syncope. A group of 183 patients observed for 5 years [in English, Italian]. Minerva Cardioangiol 2000;48:69-78.
    37. Ungar A, Galizia G, Morrione A, et al. Two-year morbidity and mortality in elderly patients with syncope. Age Ageing 2011;40:696-702. Crossref
    38. Kapoor WN. Evaluation and outcome of patients with syncope. Medicine (Baltimore) 1990;69:160-75. Crossref
    39. Ricci F, Fedorowski A, Radico F, et al. Cardiovascular morbidity and mortality related to orthostatic hypotension: a meta-analysis of prospective observational studies. Eur Heart J 2015;36:1609-17. Crossref
    40. Kapoor WN, Hanusa BH. Is syncope a risk factor for poor outcomes? Comparison of patients with and without syncope. Am J Med 1996;100:646-55. Crossref
    41. Middlekauff HR, Stevenson WG, Stevenson LW, Saxon LA. Syncope in advanced heart failure: high risk of sudden death regardless of origin of syncope. J Am Coll Cardiol 1993;21:110-6. Crossref
    42. Ruwald MH, Hansen ML, Lamberts M, et al. Comparison of incidence, predictors, and the impact of co-morbidity and polypharmacy on the risk of recurrent syncope in patients <85 years versus ≥85 years of age. Am J Cardiol 2013;112:1610-5. Crossref
    43. Kenny RA, Bhangu J, King-Kallimanis BL. Epidemiology of syncope/collapse in younger and older Western patient populations. Prog Cardiovasc Dis 2013;55:357-63. Crossref
    44. van Dijk N, Sprangers MA, Boer KR, Colman N, Wieling W, Linzer M. Quality of life within one year following presentation after transient loss of consciousness. Am J Cardiol 2007;100:672-6. Crossref
    45. O’Dwyer C, Bennett K, Langan Y, Fan CW, Kenny RA. Amnesia for loss of consciousness is common in vasovagal syncope. Europace 2011;13:1040-5. Crossref
    46. Rubenstein LZ, Josephson KR. The epidemiology of falls and syncope. Clin Geriatr Med 2002;18:141-58. Crossref
    47. Guideline for the prevention of falls in older persons. American Geriatric Society, British Geriatrics Society, and American Academy of Orthopaedic Surgeons Panel on Falls Prevention. J Am Geriatr Soc 2001;49:664-72.
    48. Kenny RA, Parry SW. Syncope-related falls in the elderly. J Geriatr Cardiol 2005;2:74-83.
    49. Fried LP, Tang CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146-56. Crossref
    50. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complication of multiple chronic conditions in the elderly. Arch Intern Med 2002;162:2269-76. Crossref
    51. Wong CH, Weiss D, Sourial N, et al. Frailty and its association with disability and comorbidity in a community-dwelling sample of seniors in Montreal: a cross-sectional study. Aging Clin Exp Res 2010;22:54-62. Crossref
    52. Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2017;70:e39-110. Crossref
    53. van Dijk N, Boer KR, Colman N, et al. High diagnostic yield and accuracy of history, physical examination, and ECG in patients with transient loss of consciousness in FAST: the Fainting Assessment study. J Cardiovasc Electophysiol 2008;19:48-55.
    54. Rubenstein LZ, Struck AE, Siu AL, Wieland D. Impacts of geriatric evaluation and management programs on defined outcomes: overview of the evidence. J Am Geriatr Soc 1991;39(9 Pt 2):8S-16S. Crossref

    Hyperbaric oxygen therapy: its use in medical emergencies and its development in Hong Kong

    DOI: 10.12809/hkmj176875
    © Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
     
    MEDICAL PRACTICE
    Hyperbaric oxygen therapy: its use in medical emergencies and its development in Hong Kong
    Joe KS Leung, MHM (UNSW), FHKAM (Emergency Medicine)1; Rex PK Lam, MPH, FHKAM (Emergency Medicine)2
    1 Accident and Emergency Department, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong
    2 Emergency Medicine Unit, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong
     
    Corresponding author: Dr Joe KS Leung (leungksj@ha.org.hk)
     
     Full paper in PDF
     
    Abstract
    Hyperbaric oxygen therapy is widely accepted as life-saving treatment for decompression illness. Yet its use in acute carbon monoxide poisoning has remained controversial because of inconsistent findings in clinical trials. Hyperbaric oxygen therapy has an adjunctive role in managing gas gangrene, necrotising soft-tissue infection, and crush injury, as supported by case series. Several cases have been reported in the literature detailing the use of hyperbaric oxygen therapy in patients with severe anaemia in whom blood transfusion is not possible. Today, use of hyperbaric oxygen therapy in Hong Kong is limited by low awareness among physicians and patients, a lack of service access, and inadequate hospital and critical care support for the existing non-hospital facility. The recent introduction of a hospital-based facility is expected to benefit more patients for whom hyperbaric oxygen therapy is appropriate. This article reviews the mechanistic basis of and emerging scientific evidence to support the use of hyperbaric oxygen therapy in a number of acute medical emergencies, as well as the past and future development of hyperbaric oxygen therapy in Hong Kong.
     
     
     
    Introduction
    Hyperbaric oxygen therapy (HBOT) is not a new treatment modality. Medical use of alterations in ambient pressure can be traced back to 1662, when Henshaw built the first hyperbaric chamber (Domicilium), a century before the discovery of oxygen.1 The beneficial effects of increased pressure as therapy for decompression illness (DCI) became evident more than 100 years ago, leading subsequently to the discovery of a synergy between pressure and high oxygen levels that provides the physical and biological basis of what is now known as ‘hyperbaric oxygen therapy’. This therapy is now used in a wide range of medical conditions and hyperbaric medicine has emerged as a clinical discipline in many countries. Today, the use of HBOT in Hong Kong is still limited because of low awareness among physicians and patients, and lack of access to an HBOT facility, especially in the hospital setting. In this article, we review the mechanistic basis of and evidence supporting the use of HBOT in five selected medical emergencies, as well as the past and future development of HBOT service in Hong Kong.
     
    Clinical use of hyperbaric oxygen therapy
    Defined by the Undersea and Hyperbaric Medical Society (UHMS), HBOT is “an intervention in which an individual breathes near 100% oxygen intermittently while inside a hyperbaric chamber that is pressurised to greater than sea level pressure (1 atmosphere absolute, 1 ATA)”.2 The pressure must exceed 1.4 ATA for clinical purposes and its application must be systemic to the patient’s body—that is, topical application is not considered HBOT. Hyperbaric chambers are classified according to occupancy. Monoplace chambers are designed for a single person and generally pressurised with 100% oxygen. Multiplace chambers are intended for concurrent use by more than one patient and are pressurised with air, with oxygen given via a face-mask, hood tent, or endotracheal tube.
     
    Whereas pressure per se has some therapeutic effect in bubble-related diseases, the biological essence of HBOT is extreme hyperoxia, enabled via increased pressure. Under pressure, the physical behaviour of gases is governed by gas laws; those that are fundamental to understanding HBOT are summarised in Table 1.3 Of note, HBOT has complex biological effects that extend beyond increasing the amount of dissolved oxygen. Over the years, different additional mechanisms and applications have been reported in the literature.
     

    Table 1. Gas laws and their implications for hyperbaric oxygen therapy3
     
    At present, the UHMS approves 14 clinical indications for HBOT (Box).2 Different treatment protocols (known as treatment tables), consisting of different combinations of pressure and durations of oxygen and air breathing, have been devised for different conditions. The incidence of adverse effects is reported to be between 5 and 50 per 1000 HBOT exposures, depending on the indication, clinical setting, treatment protocol, and patient’s conditon.4 The adverse effects of and contra-indications to HBOT are summarised in Tables 2 and 3, respectively. Because of limited space, this article focuses on five acute medical conditions encountered in the emergency setting: DCI, carbon monoxide (CO) poisoning, acute infections, acute crush injuries, and severe anaemia. Readers are advised to refer to the relevant literature for clinical indications not covered in this article.
     

    Box. Indications for hyperbaric oxygen therapy approved by the Undersea and Hyperbaric Medical Society2
     

    Table 2. Adverse effects of hyperbaric oxygen therapy
     

    Table 3. Contra-indications to hyperbaric oxygen therapy
     
    Decompression illness
    Decompression illness is caused by an acute reduction in ambient pressure leading to formation of intravascular or extravascular gas bubbles. Gas embolism and decompression sickness (DCS) are the two major forms.
     
    Gas embolism occurs when gas enters the arterial (arterial gas embolism [AGE]) or venous (venous gas embolism [VGE]) circulation. Diving and iatrogenic gas embolism are the two main causes.5 Diving embolism is precipitated by rapid ascent, breath-holding, or the presence of pre-existing lung pathology. Overexpansion of the lung during ascent causes barotrauma, alveolar or small airway rupture, and air entry into the pulmonary veins followed by air transit to the arterial circulation. Iatrogenic gas embolism can occur as a complication of a variety of invasive medical procedures, including central line placement, cardiopulmonary bypass, laparoscopic surgery, and a range of open surgical procedures.6 In general, VGE is relatively better tolerated because gas in the venous system is filtered by the pulmonary vessels. Venous gas, however, can migrate to the arterial system when there is right-to-left shunting (eg, through a patent foramen ovale) or pulmonary filtration overload (large amount of bubbles), causing ‘paradoxical embolism’.7
     
    In AGE, the gas bubbles can occlude any end artery, directly inducing distal tissue ischaemia. However, most AGE pathology probably accrues from damage to the endothelium, triggering a cascade of haemostatic and inflammatory responses, endothelial leak and vasogenic oedema, and ischaemia-reperfusion injury.5 6 Clinical manifestations, usually sudden in onset (or for divers, within a few minutes of surfacing), depend on the location of the gas embolus and the quantity of gas. Of note, AGE can result in severe morbidity or even death if it involves coronary or cerebral arteries. Coronary artery emboli can lead to myocardial ischaemia, cardiac failure, dysrhythmia, or even cardiac arrest. Cerebral AGE can present as a stroke with focal neurological deficits, loss of consciousness, seizure, or even coma.
     
    Decompression sickness occurs when the rate of ambient pressure reduction exceeds that of inert gas (mainly nitrogen) washout from tissue. When a diver ascends following a period of time underwater, the partial pressure of dissolved inert gas in capillaries and tissues is greater than the ambient pressure (Henry’s Law and Dalton’s Law) and off-gassing occurs. If supersaturation results, bubbles form in venous blood and/or tissues. The reported threshold dive depth for DCS is about 6 m but problems arise only after very prolonged times at such shallow pressures.8 Such sickness is very uncommon after diving to depths of less than 10 m. The risk is also affected by multiple factors such as immersion (vs dry hyperbaric chamber exposure), exercise, and temperature. In DCS, extravascular (autochthonous) bubbles cause mechanical distortion of tissues, leading to pain or dysfunction, depending on the tissue involved; intravascular bubbles cause a VGE that can arterialise.9 Decompression sickness has a wide range of potential manifestations that begin minutes to days after surfacing, including constitutional symptoms such as malaise; joint pain that commonly involves the knees and characteristically improves on local tissue pressure; mild neurological symptoms, such as numbness or paraesthesias; and skin rash (livedo reticularis). Severe cases can present with cardiopulmonary collapse, loss of consciousness, incomplete or complete spinal cord paresis, or severe vestibular dysfunction.
     
    Diagnosis of DCI is primarily based on clinical findings. Clinicians should be aware of the possibility of AGE or DCS when patients present with compatible symptoms and a history of recent diving. The possibility of AGE should be considered in any case of sudden-onset clinical deterioration after high-risk medical procedures. Differentiation between AGE and DCS in divers may be difficult but is not necessary when selecting patients for recompression therapy.9
     
    Supportive treatment is the mainstay of pre-hospital and initial emergency treatment for DCI. High-flow oxygen is used to correct hypoxia and to create a diffusion gradient from tissue to alveolar gas for the egress of nitrogen and other gases from the bubbles. For both AGE and DCS, recompression with HBOT is widely accepted as the definitive and potentially life-saving treatment despite a lack of randomised controlled trials (RCTs) in humans. Its use is supported by more than 100 years of clinical experience, rigorous mechanistic and outcomes-based research in animal models and human volunteers. The initial response to therapeutic pressurisation is in accordance with Boyle’s Law—at 2.8 ATA pressure; bubble volume is immediately reduced by two-thirds.10 Hyperoxia corrects tissue hypoxia and, by minimising blood nitrogen, maximises the diffusion gradient from the embolised gas to circulating plasma, thus optimising off-gassing. Furthermore, HBOT has anti-oedema and anti-inflammatory effects in acute injury, in particular inhibiting neutrophil adhesion to blood vessels, thus reducing reperfusion injury. The therapy is associated with significant improvement in the majority of patients with AGE.9 11 12 Of note, HBOT should be initiated early once the patient is stabilised—the UHMS recommends 100% oxygen at 2.8 ATA, with treatment repeated until symptoms completely resolve or there is no further improvement, typically after no more than five to ten treatments.2 13
     
    Acute carbon monoxide poisoning
    Hyperbaric oxygen therapy has been used in a variety of acute poisoning settings, including those caused by CO, methylene chloride, hydrogen sulphide, and carbon tetrachloride; gas embolism resulting from hydrogen peroxide ingestion; and methaemoglobinaemia.14 This article focuses on CO poisoning, as it remains a major cause of non-medicinal poisoning death15 and often results in persistent or delayed neurological sequelae.16
     
    The pathophysiology of CO poisoning is complex and readers are referred to excellent reviews by Weaver16 and Roderique et al17 for details. In brief, CO causes tissue hypoxia by forming carboxyhaemoglobin (COHb) and shifting the oxyhaemoglobin dissociation curve to the left. It also binds to various haem proteins, impairs mitochondrial function, causes release of nitric oxide and free radicals, and triggers inflammation through a myriad of mechanisms independent of hypoxia.16 17 18 19
     
    Oxygen therapy is the standard treatment. It works by reversing hypoxia, competing with CO for haemoglobin binding, and shortening the half-life of COHb (from 320 min in room air to about 70 min with 100% oxygen at 1 ATA); HBOT further reduces its half-life to 20 min (100% at 2.5 ATA), and increases the amount of dissolved oxygen in the plasma.20 Recent studies have shown that HBOT also restores mitochondrial function,21 reduces brain lipid peroxidation,22 and inhibits the CO-induced inflammatory response by inhibiting β2 integrin–mediated neutrophil adhesion to brain microvasculature and by inhibiting lymphocyte sensitisation to myelin basic protein.23 24 25
     
    Hyperbaric oxygen therapy was first used for CO poisoning in 196026 but has remained controversial owing to the conflicting results of RCTs of its effect on delayed neurological sequelae. These are summarised in Table 4.27 28 29 30 31 32 A Cochrane review in 2011 that involved six RCTs and 1361 participants showed that HBOT does not have a significant benefit in a pooled random-effects meta-analysis (odds ratio for neurological deficits, 0.78; 95% confidence interval, 0.54-1.12). The reviewers cautioned that the “significant methodologic and statistical heterogeneity” and “design or analysis flaws” of the included trials warrant cautious interpretation of the results.33 The American College of Emergency Physicians, on the basis of a systematic literature review, stated that “It remains unclear whether [hyperbaric oxygen therapy] is superior to normobaric oxygen therapy for improving long-term neurocognitive outcomes” in CO-poisoned patients.34 Nonetheless, a recent population-based retrospective cohort study in Taiwan involving 7278 patients showed that HBOT was associated with reduced mortality in patients with CO poisoning after adjusting for covariates, especially in those who were younger than 20 years and those with acute respiratory failure.35 These findings add weight to the argument in support of HBOT use in CO poisoning.
     

    Table 4. Summary of randomised controlled trials comparing hyperbaric oxygen and normobaric oxygen for carbon monoxide poisoning
     
    Yet, the threshold for HBOT use for CO poisoning varies across different centres36 and uncertainties exist regarding the optimal chamber pressure, number and frequency of sessions, and time window after CO poisoning. In particular, pregnant women pose special challenges as they are at high risk of adverse effects from both CO and HBOT, although information is lacking because they are excluded from most prospective trials. In view of the devastating fetal outcomes of maternal CO poisoning, such as stillbirth and damage to and anatomic malformation of the fetal central nervous system, COHb thresholds for HBOT are often set lower for pregnant patients (COHb, 15%-20%) and HBOT is often considered indicated when there is evidence of fetal distress.14 Clinical experience in Russia supports the contention that HBOT is safe during pregnancy,37 38 but its benefit in averting CO-related adverse fetal outcomes is unclear.14 In CO-poisoned children, indications for HBOT are similar to those for adults, although they have not been evaluated systematically.39 Studies have reported that HBOT has been used safely in paediatric patients39 40 but there are special paediatric considerations. Readers are referred to the review by Liebelt41 for further information.
     
    Before more convincing evidence is available, clinicians are advised to weigh the benefits, risks, and costs of HBOT carefully on a case-by-case basis when making a decision about HBOT for CO-poisoned patients. It is commonly suggested that HBOT should be reserved for (1) situations where there are indicators of higher-severity CO poisoning, such as loss of consciousness, abnormal neurological signs, cardiovascular dysfunction, or severe acidosis; (2) patients older than 35 years; (3) prolonged exposure (eg, >24 hours) or high COHb level (eg, ≥25%16). The most recent UHMS guidelines nevertheless recommend that HBOT be considered for all cases of acute symptomatic CO poisoning, given the lack of predictive factors for poor long-term outcomes or for which patients might receive the greatest benefit from HBOT.2
     
    Acute infections
    Hyperbaric oxygen therapy is directly bactericidal and/or bacteriostatic to anaerobes, facultative anaerobes, and many aerobes as a result of bacterial intolerance of the excess oxygen radicals induced by HBOT. The therapy improves tissue oxygenation, maximises oxygen-dependent phagocytic function, reduces tissue oedema, and potentiates uptake and/or action of various antimicrobial drugs, including the aminoglycosides, fluoroquinolones, and vancomycin.42 The therapy has been used as an adjunct in a variety of life-threatening bacterial infections—in particular, those with associated tissue necrosis such as gas gangrene, necrotising fasciitis, and other necrotising soft tissue infections (NSTIs).
     
    Gas gangrene is a rare but fulminant infection that is most commonly caused by Clostridium perfringens and germinates in devitalised and hypoxic tissue. The lethal α-toxin produced by the organism causes rapidly progressing liquefactive myonecrosis. Hyperbaric oxygen therapy is bactericidal to C perfringens43 and inhibits toxin production.44 Experimental studies and case series support the use of HBOT as an adjunct to surgery and antibiotic therapy for gas gangrene.42 Three sessions of HBOT at 3 ATA for 90 min should be given in the first 24 h, followed by twice-daily treatments for the next 2 to 5 days, until infection control is achieved.2 45
     
    Other forms of NSTI, often polymicrobial, are often both life- and limb-threatening. Early HBOT adjunctive to surgery and antibiotic therapy has been associated with improved survival and limb salvage,46 47 48 although several other small case series have suggested no benefit.49 50 In a large case series that involved 1583 NSTI cases in 14 US centres with their own facilities, HBOT was associated with increased survival and fewer complications in the sickest group of patients.51 In heterogeneous, high-acuity, and relatively uncommon conditions like NSTI, where there is no RCT support for any particular therapeutic strategy and none is likely, clinicians must base their decision-making on evidence from observational studies supported by interpretation of known pathophysiology and therapeutic mechanisms, as well as from any relevant animal data.52 Hyperbaric oxygen therapy is mechanistically attractive and supported by what appear to be good outcomes from experienced centres that routinely use HBOT. It should be considered in patients with serious NSTI, provided that referral for such treatment does not defer aggressive surgery and antibiotic therapy. The recommended hyperbaric oxygen protocol is 2.0 to 2.5 ATA for 90 min twice daily until the infection is controlled.2 45
     
    In addition to necrotising bacterial infections, there are reports supporting HBOT use in treating intracranial abscess, actinomycosis, and mucormycosis in immunocompromised patients.45 Diabetic foot infections, refractory osteomyelitis, and certain implant infections are also important indications for HBOT, but they are outside the scope of this article.
     
    Acute crush injuries and severe anaemia
    Crush injury is a spectrum of injury ranging from minor contusions to limb-threatening damage. The energy of trauma can cause damage to multiple tissues. Damage to the microvasculature causes self-perpetuating fluid transudation, tissue oedema, interstitial bleeding, stasis, tissue hypoperfusion, and hypoxia. Compartment syndrome occurs when the tissue fluid pressure within a skeletal muscle compartment exceeds the capillary perfusion pressure to the muscle and nerves in the compartment. Hyperbaric oxygen therapy works by interrupting the oedema-ischaemia vicious cycle. It induces inflow vasoconstriction and reduces tissue oedema, thus improving microcirculatory blood flow. It also improves tissue oxygen delivery, which is essential in multiple oxygen-dependent host responses to trauma and infection, mitigates reperfusion injury, and enhances wound healing.53
     
    The use of HBOT in crush injury is supported by one small RCT that showed the effectiveness of HBOT in improving wound healing and reducing repetitive surgery, especially in older patients with Gustillo grade III soft-tissue injuries.54 A systematic review of nine studies involving 150 patients with crush injury showed that HBOT is likely to be beneficial if administered early.55 A larger and more rigorous RCT on open tibial fractures with severe associated soft-tissue injury will be published in the near future.56 For compartment syndrome, no RCT has been published, but the use of HBOT is supported by animal studies and small case series.53 The treatment regimen varies depending on the type of injury, ranging from 2 to 2.4 ATA for 90 min for two or more treatments a day to 120 min for a single daily treatment.2 53
     
    There are situations in which blood transfusion is not possible for major blood loss owing to religious or practical reasons. Hyperbaric oxygen therapy can compensate for haemoglobin deficiency by increasing the amount of dissolved oxygen in the plasma to a level sufficient to maintain tissue oxygen delivery, even in the total absence of red blood cells. Prolonged, continuous HBOT cannot, however, be used to maintain life for the multiple days necessary for autologous replacement of red blood cells, as pulmonary oxygen toxicity becomes an intolerable and eventually fatal side-effect. Literature reports suggest the potential to use intermittent HBOT as a short-term measure to relieve hypoxic symptoms in patients with otherwise intolerably low haemoglobin levels while waiting for red blood cells to regenerate or in patients with limited compatible donor options while waiting for compatible blood products to be delivered.57 58 59 60
     
    Past and future development of a hyperbaric oxygen therapy service in Hong Kong
    The year 1994 witnessed a major development of HBOT in Hong Kong. Previously, HBOT was provided by the British Royal Navy at the HMS Tamar base and was confined to diving-related conditions. The Recompression Treatment Centre was commissioned in 1994 by the Hong Kong Government on Stonecutters Island and has become the major HBOT provider since then. The facility, comprising a three-compartment multiplace chamber, is managed by the Fire Services Department under the medical supervision of the Occupational Medicine Division of the Department of Health. Nonetheless, it is primarily used during diver training by the Fire Services Department. Medical use is mainly for emergency DCI treatment and CO poisoning cases referred from public hospitals, and many elective sessions are devoted to radionecrosis treatment.61 Its remote location and lack of back-up critical care facilities, however, render it unsuitable for critically ill patients because of the risks inherent in patient transportation. Furthermore, lack of properly trained local hyperbaric physicians and expertise as well as a lack of human resources and training opportunities hinder the development of HBOT in Hong Kong. Low awareness among physicians and patients makes the referral for this treatment even less frequent. Although HBOT is also provided by a private centre in Hong Kong, patient access remains very limited.
     
    One of the most important questions to address in developing an HBOT service in Hong Kong is its service need in our locality. Current data from the Recompression Treatment Centre (200-300 sessions for 20-30 patients per year) offer limited insight since access to the service is limited. To assess the need accurately, it would be necessary to estimate the number of patients in Hong Kong in whom HBOT is indicated and the proportion of persons with each condition who might benefit from HBOT. Doing so would depend on multiple factors including considering alternative treatments available for each condition, cost and financing, and doctor and patient beliefs and acceptance. Unfortunately, treatment thresholds for each of the many possible indications are not widely agreed on, or even researched, and the appropriate criteria for referral vary widely in practice, between nations and even between locations within nations. It must also be acknowledged that the referral rates for HBOT are strongly influenced by its availability, integration into the health care system, and the reputation of individual facilities and their clinical leaders.
     
    One way of estimating the need for HBOT service is to study the data at health system level on the number of chambers and activity level in other countries. Internationally, Australia offers a good example. There, the eight major HBOT facilities are evenly distributed, with one major government hospital-based facility in each of its seven states and territory capital cities, excluding Canberra, plus one in Townsville, the major infrastructure city serving North Queensland and the Great Barrier Reef tourism zone. In addition, there are four active private facilities and several more being planned. Each of the major hospital-based facilities operates a large multiplace chamber, most commonly of ‘triple lock’ (three compartment) design, that can be configured to provide critical care as well as ambulatory care. Most facilities also operate one or more monoplace chambers to provide flexibility and allow efficient staff utilisation.
     
    All government hospital-based facilities in Australia are integrated with major academic tertiary hospitals. The indications and thresholds for HBOT in Australia are conservative by international standards and can therefore be seen as a good guide to what would be a reasonable aim for Hong Kong. With 12 facilities serving a population of approximately 24 million in Australia, each facility provides 2000 to 5000 treatment sessions every year. While emergency patients receive one to several treatment sessions, non-emergency patients typically receive 20 to 40 treatment sessions spanning 4 to 8 weeks. The workload is in the range of 2000 to 5000 HBOT sessions for 100 to 350 patients per centre per year, with two to three scheduled 2-h sessions per day and six to ten non-emergency patients per scheduled session.
     
    Hong Kong has a population of 7 million and there exists a need for at least one HBOT hospital-based facility, especially for critically ill patients. In 2010, a task force was set up in the Hospital Authority to review the development of HBOT. Approval was finally given in 2014 to establish the first hospital-based HBOT centre at the Pamela Youde Nethersole Eastern Hospital. This new centre will be managed by the Accident and Emergency Department in collaboration with the Intensive Care Unit. The facility has been designed to be close to the resuscitation room of the Accident and Emergency Department and the service will be operationally supported by the Intensive Care Unit. With the establishment of the first public hospital-based HBOT, it is expected that it will be possible to offer additional treatment options for conditions where HBOT is indicated. For instance, DCI and CO-poisoned patients can be referred to the Pamela Youde Nethersole Eastern Hospital for screening for suitability for HBOT and management. Life-threatening infections, such as gas gangrene and NSTI, and limb-threatening crush injuries can be managed with HBOT as an adjunct to conventional therapy. It is also expected that HBOT will be made available to many patients with chronic conditions such as non-healing diabetic wounds, compromised skin flaps and grafts, and radionecrosis in the out-patient setting. The hospital-based HBOT centre will also provide more opportunity for local training and research.
     
    Conclusion
    With the opening of the first hospital-based HBOT centre in Hong Kong in 2018, management of conditions such as DCI, CO poisoning, NSTI, and acute crush injuries may change dramatically, in terms of treatment choices as well as the logistics of patient transfer between hospitals. Involvement of emergency physicians as facilitators, modulators, and coordinators in this treatment will also widen the scope of HBOT application and strengthen collaboration with other disciplines.
     
    Declaration
    The authors have no conflicts of interest to disclose.
     
    References
    1. Clarke D. History of hyperbaric therapy. In: Neuman TS, Thom SR, editors. Physiology and Medicine of Hyperbaric Oxygen. Philadelphia: Saunders; 2008: 3-23.
    2. Weaver LK, editor. Hyperbaric Oxygen Therapy Indications. 13th ed. North Palm Beach, FL: Best Publishing Company; 2014.
    3. Hardy K. The physics of hyperbaric oxygen therapy. In: Neuman TS, Thom SR, editors. Physiology and medicine of hyperbaric oxygen. Philadelphia: Saunders; 2008: 57-64.
    4. Mathieu D. Contraindications to hyperbaric oxygen therapy. In: Neuman TS, Thom SR, editors. Physiology and medicine of hyperbaric oxygen. Philadelphia: Saunders; 2008: 587-98.
    5. Fukaya E, Hopf HW. HBO and gas embolism. Neurol Res 2007;29:142-5. Crossref
    6. Muth CM, Shank ES. Gas embolism. N Engl J Med 2000;342:476-82. Crossref
    7. Gronert GA, Messick JM Jr, Cucchiara RF, Michenfelder JD. Paradoxical air embolism from a patent foramen ovale. Anesthesiology 1979;50:548-9. Crossref
    8. Van Liew HD, Flynn ET. Direct ascent from air and N2-O2 saturation dives in humans: DCS risk and evidence of a threshold. Undersea Hyperb Med 2005;32:409-19.
    9. Vann RD, Butler FK, Mitchell SJ, Moon RE. Decompression illness. Lancet 2011;377:153-64. Crossref
    10. Branger AB, Lambertsen CJ, Eckmann DM. Cerebral gas embolism absorption during hyperbaric therapy: theory. J Appl Physiol (1985) 2001;90:593-600. Crossref
    11. Trytko BE, Bennett MH. Arterial gas embolism: a review of cases at Prince of Wales Hospital, Sydney, 1996 to 2006. Anaesth Intensive Care 2008;36:60-4.
    12. Moon RE, Gorman DF. Treatment of the decompression disorders. In: Brubakk AO, Neuman TS, editors. Bennett and Elliot’s Physiology and Medicine of Diving. 5th ed. London: WB. Saunders Company Ltd; 2003: 600-50.
    13. Moon RE, Sheffield PJ. Guidelines for treatment of decompression illness. Aviat Space Environ Med 1997;68:234-43.
    14. Thom SR. Antidote in depth: hyperbaric oxygen. In: Hoffman RS, Howland MA, Lewin NA, Nelson LS, Goldfrank LR, editors. Goldfrank’s Toxicologic Emergencies. 10th ed. New York: McGraw Hill Education; 2015: 1594-601.
    15. Sircar K, Clower J, Shin MK, Bailey C, King M, Yip F. Carbon monoxide poisoning deaths in the United States, 1999 to 2012. Am J Emerg Med 2015;33:1140-5. Crossref
    16. Weaver LK. Clinical practice. Carbon monoxide poisoning. N Engl J Med 2009;360:1217-25. Crossref
    17. Roderique JD, Josef CS, Feldman MJ, Spiess BD. A modern literature review of carbon monoxide poisoning theories, therapies, and potential targets for therapy advancement. Toxicology 2015;334:45-58.
    18. Hampson NB, Piantadosi CA, Thom SR, Weaver LK. Practice recommendations in the diagnosis, management, and prevention of carbon monoxide poisoning. Am J Resp Crit Care 2012;186:1095-101. Crossref
    19. Thom SR, Fisher D, Zhang J, Bhopale VM, Cameron B, Buerk DG. Neuronal nitric oxide synthase and N-methyl-D-aspartate neurons in experimental carbon monoxide poisoning. Toxicol Appl Pharmacol 2004;194:280-95.
    20. Peterson JE, Stewart RD. Absorption and elimination of carbon monoxide by inactive young men. Arch Environ Health 1970;21:165-71. Crossref
    21. Brown SD, Piantadosi CA. Recovery of energy metabolism in rat brain after carbon monoxide hypoxia. J Clin Invest 1992;89:666-72. Crossref
    22. Thom SR. Antagonism of carbon monoxide-mediated brain lipid peroxidation by hyperbaric oxygen. Toxicol Appl Pharmacol 1990;105:340-4. Crossref
    23. Thom SR. Functional inhibition of leukocyte β2 integrins by hyperbaric oxygen in carbon monoxide-mediated brain injury in rats. Toxicol Appl Pharmacol 1993;123:248-56. Crossref
    24. Thom SR, Mendiguren I, Hardy K, et al. Inhibition of human neutrophil β2-integrin-dependent adherence by hyperbaric O2. Am J Physiol 1997;272(3 Pt 1):C770-7. Crossref
    25. Thom SR, Bhopale VM, Fisher D. Hyperbaric oxygen reduces delayed immune-mediated neuropathology in experimental carbon monoxide toxicity. Toxicol Appl Pharmacol 2006;213:152-9. Crossref
    26. Smith G, Sharp GR. Treatment of carbon-monoxide poisoning with oxygen under pressure. Lancet 1960;276:905-6. Crossref
    27. Raphael JC, Elkharrat D, Jars-Guincestre MC, et al. Trial of normobaric and hyperbaric oxygen for acute carbon monoxide intoxication. Lancet 1989;2:414-9. Crossref
    28. Thom SR, Taber RL, Mediguren II, Clark JM, Hardy KR, Fisher AB. Delayed neuropsychologic sequelae after carbon monoxide poisoning: prevention by treatment with hyperbaric oxygen. Ann Emerg Med 1995;25:474-80. Crossref
    29. Mathieu D, Wattel F, Mathieu-Nolf M, et al. Randomized prospective study comparing the effect of HBO versus 12 hours NBO in non comatose CO poisoned patients: results of the interim analysis [abstract]. Undersea Hyperb Med 1996;23:7-8.
    30. Scheinkestel CD, Bailey M, Myles PS, et al. Hyperbaric or normobaric oxygen for acute carbon monoxide poisoning: a randomised controlled clinical trial. Med J Aust 1999;170:203-10.
    31. Weaver LK, Hopkins RO, Chan KJ, et al. Hyperbaric oxygen for acute carbon monoxide poisoning. N Engl J Med 2002;347:1057-67. Crossref
    32. Annane D, Chadda K, Gajdos P, Jars-Guincestre MC, Chevret S, Raphael JC. Hyperbaric oxygen for acute domestic carbon monoxide poisoning: two randomized controlled trials. Intensive Care Med 2011;37:486-92. Crossref
    33. Buckley NA, Juurlink DN, Isbister G, Bennett MH, Lavonas EJ. Hyperbaric oxygen for carbon monoxide poisoning. Cochrane Database Syst Rev 2011;(4):CD002041. Crossref
    34. American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Carbon Monoxide Poisoning; Wolf SJ, Maloney GE, Shih RD, Shy BD, Brown MD. Clinical policy: Critical issues in the evaluation and management of adult patients presenting to the emergency department with acute carbon monoxide poisoning. Ann Emerg Med 2017;69:98-107.e6. Crossref
    35. Huang CC, Ho CH, Chen YC, et al. Hyperbaric oxygen therapy is associated with lower short- and long-term mortality in patients with carbon monoxide poisoning. Chest 2017;152:943-53. Crossref
    36. Mutluoglu M, Metin S, Ibrahim Arziman, Uzun G, Yildiz S. The use of hyperbaric oxygen therapy for carbon monoxide poisoning in Europe. Undersea Hyperb Med 2016;43:49-56.
    37. Van Hoesen KB, Camporesi EM, Moon RE, Hage ML, Piantadosi CA. Should hyperbaric oxygen be used to treat the pregnant patient for acute carbon monoxide poisoning? A case report and literature review. JAMA 1989;261:1039-43. Crossref
    38. Elkharrat D, Raphael JC, Korach JM, et al. Acute carbon monoxide intoxication and hyperbaric oxygen in pregnancy. Intensive Care Med 1991;17:289-92. Crossref
    39. Yarar C, Yahut A, Akin A, Yildiz B, Dinleyici EC. Analysis of the features of acute carbon monoxide poisoning and hyperbaric oxygen therapy in children. Turk J Pediatr 2008;50:235-41.
    40. Waisman D, Shupak A, Weisz G, Melamed Y. Hyperbaric oxygen therapy in the pediatric patient: the experience of the Israel Naval Medical Institute. Pediatrics 1998;102:E53. Crossref
    41. Liebelt EL. Hyperbaric oxygen therapy in childhood carbon monoxide poisoning. Curr Opin Pediatr 1999;11:259-64. Crossref
    42. Cimşit M, Uzun G, Yildiz S. Hyperbaric oxygen therapy as an anti-infective agent. Expert Rev Anti Infect Ther 2009;7:1015-26. Crossref
    43. Kaye D. Effect of hyperbaric oxygen on Clostridia in vitro and in vivo. Proc Soc Exp Biol Med 1967;124:360-6. Crossref
    44. Unnika V. Inhibition of toxin production in Clostridium perfringens in vitro by hyperbaric oxygen. Antonie Van Leeuwenhoek 1965;31:181-6. Crossref
    45. Jacoby I. Clostridial myositis, necrotizing fasciitis, and zygomycotic infections. In: Neuman TS, Thom SR, editors. Physiology and medicine of hyperbaric oxygen therapy. Philadelphia: Saunders Elsevier; 2008: 397-418.
    46. Wilkinson D, Doolette D. Hyperbaric oxygen treatment and survival from necrotizing soft tissue infection. Arch Surg 2004;139:1339-45. Crossref
    47. Escobar SJ, Slade JB Jr, Hunt TK, Cianci P. Adjuvant hyperbaric oxygen therapy (HBO2) for treatment of necrotizing fasciitis reduces mortality and amputation rate. Undersea Hyperb Med 2006;32:437-43.
    48. Devaney B, Frawley G, Frawley L, Pilcher DV. Necrotizing soft tissue infections: the effect of hyperbaric oxygen on mortality. Anaesth Intensive Care 2015;43:685-92.
    49. Shaw JJ, Psoinos C, Emhoff TA, Shah SA, Santry HP. Not just full of hot air: hyperbaric oxygen therapy increases survival in cases of necrotizing soft tissue infections. Surg Infect (Larchmt) 2014;15:328-35. Crossref
    50. Brown DR, Davis NL, Lepawsky M, Cunningham J, Kortbeek J. A multicenter review of the treatment of major truncal necrotizing infections with and without hyperbaric oxygen therapy. Am J Surg 1994;167:485-9. Crossref
    51. Shupak A, Shoshani O, Goldenberg I, Barzilai A, Moskuna R, Bursztein S. Necrotizing fasciitis: an indication for hyperbaric oxygenation therapy? Surgery 1995;118:873-8. Crossref
    52. Levett D, Bennett MH, Millar I. Adjunctive hyperbaric oxygen for necrotizing fasciitis. Cochrane Database Syst Rev 2015;(1):CD007937. Crossref
    53. Strauss MB. The effect of hyperbaric oxygen in crush injuries and skeletal muscle-compartment syndromes. Undersea Hyperb Med 2012;39:847-55.
    54. Bouachour G, Cronier P, Gouello JP, Toulemonde JL, Talha A, Alquier P. Hyperbaric oxygen therapy in the management of crush injuries: a randomized double-blind placebo-controlled clinical trial. J Trauma 1996;41:333-9. Crossref
    55. Garcis-Covarrubias L, McSwain NE Jr, Van Meter K, Bell RM. Adjuvant hyperbaric oxygen therapy in the management of crush injury and traumatic ischemia: an evidence-based approach. Am Surg 2005;71:144-51.
    56. Millar IL, McGinnes RA, Williamson O, et al. Hyperbaric Oxygen in Lower Limb Trauma (HOLLT); protocol for a randomised controlled trial. BMJ Open 2015;5:e008381. Crossref
    57. Hart GB. Exceptional blood loss anemia. Treatment with hyperbaric oxygen. JAMA 1974;228:1028-9. Crossref
    58. McLoughlin PL, Cope TM, Harrison JC. Hyperbaric oxygen therapy in the management of severe acute anaemia in a Jehovah’s witness. Anaesthesia 1999;54:891-5. Crossref
    59. Greensmith JE. Hyperbaric oxygen reverses organ dysfunction in severe anemia. Anesthesiology 2000;93:1149-52. Crossref
    60. Graffeo C, Dishong W. Severe blood loss anemia in a Jehovah’s Witness treated with adjunctive hyperbaric oxygen therapy. Am J Emerg Med 2013;31:756.e3-4. Crossref
    61. Ramaswami RA, Lo WK. Use of hyperbaric oxygen therapy in Hong Kong. Hong Kong Med J 2000;6:108-12.

    Pages